A study of matrix metalloproteinases in cancer and atherosclerosis by Laxton, Ross Campbell
1 
 
William Harvey Research Institute 
Barts and The London School of Medicine and Dentistry 
Queen Mary University of London 
 
 
 
A study of matrix metalloproteinases in 
cancer and atherosclerosis 
 
by 
 
Ross Campbell Laxton 
 
 
 
 
Thesis for the degree of Doctor of Philosophy 
 
2012 
  
2 
 
Abstract 
 
Background: Matrix metalloproteinases (MMPs) have been shown to be involved in 
cancers and atherosclerosis, the leading causes of present day mortality. The objectives 
of the cancer element of this project were to investigate single nucleotide 
polymorphisms (SNPs) in MMP1 and MMP8 regarding breast cancer and malignant 
melanoma, and a functional characterisation of the genetic variants, including the 
MMP1 polymorphism rs19799750, previously associated with multiple cancers. The 
objective of the second part of this project was to investigate whether MMP8 played a 
role in the development of atherosclerotic lesions and if so, the underlying mechanisms. 
 
Methods/Results: Genetic investigations found the MMP8 SNP rs11225395 to be 
associated with the occurrence of both breast cancer and malignant melanoma; 
furthermore it was also associated with reduced lymph node metastasis, reduced cancer 
relapse and greater survival. Functional luciferase assays showed that the minor allele of 
the polymorphism has higher promoter activity in breast cancer and melanoma cell 
lines. They also showed haplotypic effects on MMP1 promoter activity in several 
cancer cell lines by the 2G allele of polymorphism rs1799750 and one or more MMP1 
promoter SNPS. The second part of the study found an association between a MMP8 
SNP and the extent of coronary atherosclerosis; additionally a relationship among 
MMP8 gene variation, plasma VCAM-1 level, and atherosclerosis progression was 
observed in a prospective study. Murine studies showed reduced atherosclerosis in 
MMP8/ApoE knockout mice compared with ApoE knockout littermate controls. 
Biochemical studies confirmed that MMP8 can convert angiotensin I to angiotensin II.  
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Conclusions: The data of the first part of this project support the notion that genetic 
polymorphisms in the MMP1 and MMP8 influence the expression of these genes and 
the development and progression of cancer. The results of the second part of this project 
indicate an important role of MMP8 in the pathogenesis of atherosclerosis. 
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1.0 Introduction  
 
1.1 Matrix metalloproteinases 
 
Matrix metalloproteinases (MMPs), also known as matrixins are secreted zinc-
dependent endopeptidases. There are 24 known MMP genes in humans belonging to the 
metzincin superfamily of metallopeptidases (2, 3). Members of the metzincin 
superfamily, consisting of astacins, seralycins, ADAMs (a disintegrin and 
metalloprotease)/adamalysins, and MMPs, are characterised by their topologically 
similar and conserved zinc-binding catalytic domains (4). As a family MMPs are 
capable of degrading nearly all the constituents of the extracellular matrix (ECM) and 
consequently play a vital role in many physiological processes such as embryogenesis, 
tissue remodelling, wound healing and angiogenesis; they are also involved in many 
pathological conditions including osteoarthritis, autoimmune diseases, cardiovascular 
diseases and cancer (5). The complexity of MMPs‟ involvement in physiological 
processes and disease is underlined by the fact that they not only degrade components 
of the ECM but also act on non-structural substrates; cleaving/shedding cell bound 
growth factors and receptors, adhesion molecules, cytokines and many more bio-active 
compounds (6). 
 
1.1.1 MMP structure 
 
The classic structure of MMPs consists of a signal peptide domain, propeptide, catalytic 
domain, hinge region, and hemopexin domain; depending upon the MMP other 
domains/features may or may not be added, such as a fibronectin domain, vitronectin 
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insert, type I transmembrane domain, type II transmembrane domain, 
glycosylphosphatidylinositol (GPI) anchor, cytoplasmic domain, cysteine array region, 
IgG-like domain, or a furin cleavage site (1, 7).  
 
As mentioned earlier, the zinc-binding motif within the catalytic site of MMPs is highly 
conserved, as is the cysteine switch motif within the propeptide region. In the catalytic 
site there are three histidine (H) residues and a glutamate (E) that make up the principal 
features of the zinc-binding motif HEXXHXXGXXH (X indicates any amino acid). The 
histidine residues serve to coordinate the zinc ion, while the glutamate acts as a 
nucleophile during the hydrolysis of peptide bonds.  There is also a highly conserved 
methionine (M) residue within a structure known as a “Met-turn”, a polypeptide chain 
that loops beneath the zinc ion allowing the methionine to act as a hydrophobic base for 
the binding site (2, 4, 7, 8). The cysteine switch motif and mechanism will be discussed 
later. 
 
1.1.2 MMP classification 
 
MMPs have traditionally been classified via their substrate specificity and structural 
domains. The subgroups have been categorised as the collagenases, gelatinases, 
matrilysins, furin-activated secreted MMPs, transmembrane-type MMPs, GPI-anchored 
MT-MMPs, type II transmembrane MMPs, and other MMPs (figure 1.1). 
 
10 
 
 
 
 
 
 
Figure 1.1. Human MMPs classified into subgroups via their substrates 
specificities and structural domains. Taken from (1). 
11 
 
1.1.3 Regulation of MMPs 
 
1.1.3.1 Transcriptional regulation of MMPs 
 
The majority of MMPs are not constitutively expressed, but expressed at certain times 
such as in physiological or pathophysiological tissue remodelling (9). Transcriptional 
regulation plays a key role in the control of expression of MMPs; it can occur by several 
different mechanisms including the epigenetic processes of acetylation and methylation, 
and the action of transcription factors on cis-elements within gene promoter regions. 
 
The principal method of regulation of transcription of MMPs is probably, by the action 
of transcription factors on cis-elements within gene promoter regions, this allows 
controlled cell specific expression. The majority of MMPs have cis-elements in 
common with other members of the family. Response elements that have been identified 
as important in the regulation of MMPs are response elements for activator protein-1 
(AP-1), polyomavirus enhancer-A binding protein-3 (PEA-3), nuclear factor kappa B 
(NFкB), and the signal transducers and activators of transcription (STAT) (3). 
 
Acetylation, in this case a reversible modification of histone proteins, loosens the 
interaction between DNA and histone within the chromatin complex. Loosening allows 
transcription factors access to DNA and mostly promotes the activation of genes. 
Histones are acetylated by a group of proteins called histone acetyl transferases (HATs); 
deacetylation is via a group of proteins called histone deacetylases (HDACs). The fact 
that inhibitors of HDACs have been shown to both repress and augment the expression 
of induced MMPs suggests that their regulation through the mechanism of acetylation is 
12 
 
mainly via its effects on the genes of signalling molecules upstream of MMPs in 
pathways leading to their expression (6).  
  
Methylation of CpG islands within the promoter regions of eukaryotic genes, carried out 
by methyl transferases, in the main acts as a negative regulation mechanism, repressing 
gene expression. Methylation of cytosine bases can hinder the binding of certain 
transcription factors to recognition sequences; additionally methylated DNA binding 
proteins may recruit co-repressor molecules that inhibit gene expression (10). Some 
MMPs have been shown to be partly regulated by methylation status, there was an 
inverse relationship between MMP9 promoter methylation and its expression in 
lymphoma cells (11), also the knockout of methyl transferases in colon cancer cells lead 
to an increase in expression of MMP3 (12).  
 
1.1.3.2 Post-transcriptional regulation of MMPs 
 
MMPs may also be regulated via post transcriptional mechanisms. Stabilisation of 
messenger RNA (mRNA) enhances the expression of genes; mRNA may be stabilised 
by the action of trans-acting factors interacting with cis-elements within mRNA. MMP1 
and MMP3 have been shown to have their mRNA stabilised, and expression enhanced, 
via the interaction of p38 MAPK with AU rich elements (AREs) within their  3‟ 
untranslated regions (UTR) in fibroblasts (13). More recently it was demonstrated that 
MMP-16 is down-regulated by microRNA-146b in glioma (14).  
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1.1.3.3 Activation of zymogens 
 
Nearly all MMPs, with the exception of type I & II transmembrane MMPs, are secreted 
zymogens, requiring the removal of the propeptide before becoming fully active. 
Enzyme activity is blocked with the propeptide via a cysteine switch mechanism, in 
which a cysteine residue within a conserved part of the propeptide forms a covalent 
bond to the zinc ion in the catalytic site. All the methods of MMP activation such as 
treatment with organomercurials, sodium dodecyl sulphate, or other proteases involve 
the dissociation of the cysteine residue from the zinc ion thereby activating the catalytic 
site, and the subsequent autolysis of the propeptide domain (15). 
 
1.1.3.4 Inhibition of MMP activity by TIMPs 
 
The major method of protein regulation of MMPs is via tissue inhibitors of 
metalloproteinases (TIMPs); which as a family are capable of inhibiting all the MMPs. 
There are 4 members of the TIMP family numbered 1-4. Factors effecting the regulation 
of MMPs by TIMPs are varying efficacy against specific MMPs allied with differential 
tissue expression and localisation. Inhibition occurs on a 1:1 ratio with the TIMP 
protein binding to the zinc ion of the catalytic site preventing any protease activity by 
the MMP (1). In the case of MMP8, its form expressed on the surface of 
polymorphonuclear cells is highly resistant to inhibition by TIMPs (16) 
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1.1.3.5 Polymorphisms and MMP gene regulation 
 
Naturally occurring sequence variations such as single nucleotide polymorphisms 
(SNPs) are prevalent throughout the genome; they are variants common across the 
population and may occur anywhere within or in the area surrounding a gene (17). The 
vast majority of SNPs appear to be neutral, at present, having no discernible effect on 
any biological processes. However some SNPs have been shown to exert allele specific 
differences over a biological process, sometimes having an association with disease. 
Functional effects can occur if a SNP changes the coding sequence for a gene bringing 
about an amino acid change in the sequence of a protein, this can alter its structure, 
activity and function. Changes, by SNPs, to cis-elements in the promoter region, or to 
AREs in UTRs may affect trans-acting proteins interaction with DNA and subsequently 
alter gene expression; other changes may be to splice sites or even at loci relatively 
distant to genes that effect DNA folding changes. Not all SNPs of interest will cause 
functional effects but can be biomarkers if in strong linkage disequilibrium (LD) with 
undiscovered functional SNPs.  The concept of LD was eloquently summed up by 
Goldstein & Weale in 2001 (18); “alleles at different loci are sometimes found together 
more or less often than expected based on their frequencies. In population genetics, this 
non-random pattern is called linkage disequilibrium”. Several polymorphisms within 
the promoters of MMPs have been shown to affect their gene expression and be 
associated with disease; the first such polymorphism in MMPs to be described was the 
5A/6A variant in the promoter of MMP3; linked to coronary atherosclerosis (19, 20). It 
has subsequently shown to be situated within an NFкB responsive element (21). 
Multiple SNPs within gene promoters may act in concert to exert haplotypic effects on 
expression as studies on interleukin 6 (IL-6) and cholesteryl ester transfer protein 
(CETP) show (22, 23). Colleagues have shown evidence haplotypic effects on MMP1 
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expression and the risk of myocardial infarction (24). Haplotypes for the purposes of 
this study can be defined as multiple SNPs occurring on the same chromosome that are 
(in relative terms) commonly inherited together. A brief overview of MMP 
polymorphisms in disease is shown in table 1.1, adapted from (3). 
 
  
16 
 
Table 1.1 Functional SNPs in MMP promoters 
Gene Polymorphism rsID 
Promoter 
Activity 
Associated pathology  
Tumour-disease  Non-tumour disease 
      
MMP1 -1607 1G/2G rs1799750 Higher  ↑ Risk: lung [1] and colorectal 
[2] cancer, Poor prognosis: 
breast [3] and ovarian [4] 
cancer, cutaneous malignant 
melanoma [5] 
↑ Risk: idiopathic 
pulmonary fibrosis [6], 
Poor prognosis: cirrhosis 
[7] 
      
MMP2 −1575 G/A  rs243866 Lower  Breast cancer [8] (in vitro 
MCF-7 cells) 
 
      
 −1306 C/T  rs243865 Lower  ↓ Risk: oesophageal [9] and 
lung [10] cancer, gastric 
cardia adenocarcinoma [11], 
oral squamous cell carcinoma 
[12] 
↓ Risk: lumbar disc 
disease [13] 
      
 −735 C/T  rs2285053 Lower   ↓ Risk: oesophageal [9] and 
lung [10] cancer 
 
      
MMP3 −1171 5A/6A rs3025058 Lower  ↓ Risk: lung [14] breast [15] 
and oral [16] cancer  
↑ Risk: atherosclerosis 
[17], Poor prognosis: 
rheumatoid arthritis [18] 
      
MMP7 −181 A/G  rs11568818 Higher  ↑ Risk: gastric [19], cervical 
[20] and oral [21] cancer, 
oesophageal squamous cell 
carcinoma and non-small cell 
lung carcinoma [22] 
Poor prognosis: 
atherosclerosis [23] 
      
MMP8 −799 C/T  rs11225395 Higher  Better prognosis: breast 
cancer [24]  
↑ Risk: preterm 
premature rupture of 
membranes (haplotype) 
[26] 
      
 −381 A/G  rs1320632 Higher   ↑ Risk: preterm 
premature rupture of 
membranes (haplotype) 
[26] 
      
 +17 C/G rs2155052 Higher  ↓ Risk: lung cancer [25]  ↑ Risk: preterm 
premature rupture of 
membranes (haplotype) 
[26] 
      
MMP9 −1562 C/T  rs3918242 Higher ↑ Risk: oral cancer [27]  ↑ Risk: atherosclerosis 
[28, 29], abdominal 
aortic aneurysm [30] 
      
MMP12 −82 A/G  rs2276109 Lower  Poor prognosis: bladder 
cancer [31] 
 
      
[1] (25), [2] (26), [3] (27), [4] (28), [5] (29), [6]  (30),  [7] (31), [8] (32), [9] (33), [10] (34), [11] (35), [12] (36), [13] (37), 
[14] (38), [15] (39), [16] ,(40) [17] (41), [18] (42), [19] (43), [20] (44), [21] (45), [22] (46), [23] (47), [24] (48), [25] (49), 
[26] (50), [27] (51), [28] (52), [29] (53), [30] (54), [31] (55). 
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1.1.4 MMP Genes 
 
1.1.4.1 Location and homology 
 
In humans 9 of the 24 MMP genes occur within a cluster at chromosome 11q22, the 
other genes are widely spread across 10 chromosomes (table 1.2).  
 
Table 1.2 Chromosomal locations of human MMP genes and the site of their highest 
detected expression 
MMP Gene Chromosomal Location Highest human expression via GeneAtlas* 
MMP23a 1p36.3 - 
MMP23b 1p36.3 Heart 
MMP16 8q21 Cardiomyocytes 
MMP21 10q26.13 Skeletal muscle  
MMP26 11p15 Skeletal muscle 
MMP7 11q22.3 Pancreatic islet 
MMP20 11q22.3 Cardiomyocytes 
MMP27 11q22.3 Cardiomyocytes 
MMP8 11q22.3 Bone marrow 
MMP10 11q22.3 Uterus corpus 
MMP1 11q22.3 Smooth muscle cells 
MMP3 11q22.3 Smooth muscle cells 
MMP12 11q22.3 Tonsil 
MMP13 11q22.3 Cardiomyocytes 
MMP19 12q14 Adipocyte 
MMP17 12q24.3 Prefrontal cortex 
MMP14 14q11-12 Smooth muscle cells 
MMP25 16p13.3 Skeletal muscle 
MMP2 16q12 Smooth muscle cells 
MMP15 16q21 Thyroid 
MMP28 17q12 Lung 
MMP24 20q11.2 Cerebellum penduncles 
MMP9 20q13.2 Bone marrow 
MMP11 22q11 Placenta 
*Site of highest expression levels in humans, as detected by GeneAtlas (56) via the BioGPS 
portal (57). 
 
 
Despite the relative diversity of functions and characteristics of the MMP family, there 
is considerable inter-species homology shown between vertebrates; evidence for the 
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ancient origins of MMPs is given by the presence of many orthologue genes in the 
invertebrate Ciona intestinalis (58). The homology of MMPs between vertebrates has 
been taken advantage of in order to further elucidate the biological roles of these 
proteases, particularly using murine models. Of mice and men; 23 have been discovered 
in mice and 24 MMPs discovered in humans. There is a duplication of MMP1 specific 
to mice, and a gain of MMP26 and the duplication of MMP23 specific to humans (3).  
 
1.1.4.2 MMP expression 
 
As mentioned earlier most MMPs are not constitutively expressed, but expressed at 
discrete times within physiological or pathophysiological processes. This occurs at 
times and sites that require cell migration or degradation of the ECM such as 
embryogenesis, tissue remodelling, wound healing and angiogenesis; including 
osteoarthritis, autoimmune diseases, cardiovascular diseases and cancer (5). Tissue sites 
with the highest detected mRNA expression for the respective MMP genes are listed in 
table 1.2, the data was obtained from the GeneAtlas project (56) via the BioGPS portal 
(57). 
 
1.1.5 Biochemistry and substrates of MMPs 
 
It is commonly stated that MMPs as a family are capable of degrading nearly all the 
constituents of the ECM. However their influence is not merely limited to its structural 
modification; sequestered within the ECM are signalling molecules such as growth 
factors which may be released along with collagen fragments with cryptic matrix signals 
(59).  Non-structural and non-matrix proteins are also processed, not limited to cell 
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bound growth factors and receptors, adhesion molecules, cytokines and other MMP 
zymogens (6).  
 
1.1.5 Substrates of MMP1 and MMP8 
 
The two MMPs at the centre of this work are MMP1 and MMP8; both are collagenases, 
also known as collagenase 1 and 2 respectively. The collagenases are the principal 
enzymes that cleave the native fibrillar collagens, types I, II, and III; with the 
hemopexin domain of collagenases being intrinsic to their ability to bind to and cleave 
the triple helix structure (60). MMP1 shows preference to cleave type III over type I and 
II, while MMP8 has preferential activity against type I, then type II, then type III; 
MMP8 seems to be the most potent of all the collagenases against types I and II 
collagens (61-63). The known substrates of MMPs 1 and 8 are shown in table 1.3, 
adapted from (1) and (64). 
 
Table 1.3. Known substrates of MMP1 and MMP8 
MMP Collagenous substrates Other substrates 
   
MMP-1 
(Collagenase-1)  
aggrecan, collagens III> I>II, VII, 
VIII, X, XI 
AAT, ACT, α2M, casein, C1q, fibrin, fibrinogen, IL-1β, MCP-
1, -3, -4, proTNF-α, proMMP-1, proMMP-2,  nidogen, 
fibronectin, MBP, gelatin, IGFBPs, laminin, link protein, 
perlecan, tenascin, vitronectin 
MMP-8 
(Collagenase-2)  
aggrecan, Collagen type I > type II 
> type III, Collagen VII, Collagen X,  
AAT, α2M, C1q, fibrinogen, substance P, proMMP-8, 
tachykinin,  angiotensin, IL-8*, LIX, MIG, IP-10, MCP-1α**, 
IGFBP-5, L-selectin, Laminin-5, nidogen,  fibronectin, 
tenascin 
* Tester, 2007 
** Low-efficiency cleavage by human MMP-8, and no cleavage by murine MMP-8. 
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1.1.6 Role of MMPs in physiological and pathophysiological processes 
 
As noted previously MMPs, through their modulation of cell-ECM interactions, 
influence cell differentiation, signalling and migration and are involved in 
embryogenesis, tissue remodelling, wound healing and angiogenesis. They are also 
involved in many pathological conditions including osteoarthritis, autoimmune diseases, 
cardiovascular diseases and cancer (5). A selection MMPs found to be associated with 
disease are shown in table 1.1. 
 
1.1.6.1 Roles of MMP1 and MMP8 in physiological processes 
 
Examples of physiological situations in which MMP1 is expressed are in the skin during 
embryonic development and in basal keratinocytes in wound healing (65, 66). MMP8 is 
expressed in maturing neutrophils within the bone marrow, then sequestered in granules 
for later action, and is also expressed in articular chondrocytes within the cartilage (67, 
68). 
 
1.1.6.2 Roles of MMP1 and MMP8 in pathophysiological processes 
 
MMP1 has been shown to be expressed in chronic cutaneous ulcers (1); it has also been 
implicated in the weakening of fibrous caps in atherosclerosis increasing the chances of 
plaque rupture, and is expressed in different cell types within atherosclerotic lesions 
(69-71). The majority of studies on MMP1 and disease involve cancer, these are 
discussed elsewhere. MMP8 is implicated in bronchitis and rheumatoid arthritis (1); the 
involvement of MMP8 in cancer and atherosclerosis is also discussed elsewhere. 
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1.2 Cancer 
 
1.2.1 The impact of cancer on the population 
 
Cancer is the term given to a disease caused by the loss of normal growth regulation and 
tissue organisation; these losses can result in the formation of a tumour or neoplasm. In 
all cancers this abnormal growth and regulation is a direct consequence of changes to 
the genetic composition of the cell; be it the loss, mutation, addition or translocation of 
genetic material. The common risk factors of cancer all involve substances or processes 
that can lead to genetic changes; such as smoking, exposure to ultra violet (UV) or 
ionising radiation, or exposure to mutagenic chemicals. Malignant cancers are 
characterised by their ability to spread to and invade other tissues away from the 
original site of neoplastic transformation. Cancer is one of the leading causes of 
mortality globally today, currently 1 in 4 deaths in the United States and 1 in 8 
worldwide are due to cancer (72, 73). 
 
1.2.2 Hallmarks of cancer 
 
The hallmarks of cancer, as characterised by Hanahan & Weinberg (74), are self 
sufficiency in growth signals, insensitivity to antigrowth signals, evasion of apoptosis, 
limitless replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis.  
 
Cancers can become self sufficient in growth signals by manufacturing their own 
thereby producing autocrine stimulation; examples of this are the production of tumour 
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growth factor α (TGFα) by sarcomas and platelet-derived growth factor (PDGF) by 
glioblastomas (75).  
 
One of the best described methods of cancer becoming insensitive to antigrowth factors 
is via the transforming growth factor-β (TGF-β) pathway with TGF-β receptors being 
down-regulated in many cancers (76). TGF-β can halt advancement from the G1 phase 
of the cell cycle the suppression of the c-myc gene, a cell cycle regulator, or by the 
blocking of cyclin:cyclin dependent kinase complexes responsible for phosphorylation 
of the retinoblastoma  protein (pRb).  
 
The avoidance of programmed cell death, apoptosis, is an intrinsic function of cancers 
to tumour survival and successful invasion of naive tissues; one of the many anti-cancer 
activities of the tumour suppressor protein p53 is the upregulation of the pro-apoptotic 
Bax protein in response to DNA damage. The p53 tumour suppressor gene is found 
mutated in over 50% of all human tumours (77). Normal cells are able to replicate a 
finite amount of times, 60 -70 in observations of cultured cells. The counting 
mechanism for cell generations involves telomeres, thousands of hexamer repeats found 
at the ends of chromosomes. Telomeres shorten each successive generation; when they 
are lost the resulting chromosomal instability inevitably leads to cell death. Cancer cells 
acquire seemingly limitless replicative potential via maintenance of telomeres. 
Telomerase is an enzyme which adds hexamer repeats to the end of chromosomes that is 
found unregulated in 85 – 90% of cancers (78).  
 
Sustained angiogenesis is an important part of tumour development, tumours requiring 
increased oxygen and nutrients as they grow. The pro-angiogenic vascular endothelial 
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growth factor (VEGF) is found to be unregulated in tumours; drugs inhibiting VEGF or 
its receptor VEGFR have proven successful in reducing neovascularisation and tumour 
growth in animal studies. Thrombospondin-1, an inhibitor of angiogenesis, is positively 
regulated by p53 in some cell types. Therefore loss of function to p53 can result in 
lower levels of thrombospondin-1 and consequently less thrombospondin-1 dependent 
anti-angiogenic effects (79).  
 
1.2.3 Metastasis 
 
A succinct description of this phase of cancer is given in the review by Gupta & 
Massague, “Metastasis occurs when genetically unstable cancer cells adapt to a tissue 
microenvironment that is distant from the primary tumour”. Its importance is underlined 
by the fact it accounts for 90% of the mortality attributed to solid cancer (80). The steps 
(shown in figure 1.2, taken from Fidler et al. 2003 (81)) from the initial neoplasm (a) 
towards metastasis are the proliferation and vascularisation of the primary tumour (b), 
detachment of cells from the primary tumour and invasion of the vasculature 
(lymphatics, venules, and capillaries) (c), circulation and aggregation (through 
recruitment of platelets and/or lymphocytes), adherence to vessel walls (d), 
extravasation and adaptation of or adaptation to a microenvironment (e), and finally  
further proliferation and angiogenesis (f) to establish the metastasis at the distant site. 
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Figure 1.2. The main steps in the formation of a metastasis (81). 
 
1.2.3.1 Metastatic cell movement 
 
The entry of tumour cells into the vasculature (intravasation) is an important and 
potentially limiting stage of metastasis. It involves the movement of cells from the 
primary tumour through the ECM and then access to the circulation through pores in the 
basement membrane/endothelium.  The fastest observed movement of carcinoma cells 
is when they move along linear paths provided by collagen containing fibres of the 
ECM. The speed is thought to be facilitated by the forming of short lived focal 
complexes with the fibres; the cells exhibit solitary amoeboid motion and shape also 
giving them the ability to squeeze through dense ECM. Imaging studies on the 
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differences between non metastatic and metastatic cell lines derived from the same 
mammary tumour show cells from the metastatic cell line (MTLn3) to linearly move 
along ECM fibres while cells from the non metastatic cell line (MTC) do not. MTLn3 
cells show amoeboid movement and are not polarised except when in the presence of 
epidermal growth factor (EGF) like ligands attracting them to blood vessels, MTC cells 
are generally more polarised but exhibit no chemotaxis to EGF-like ligands and thus 
blood vessels; MTC cells showed notable fragmentation on the exposure of their 
pseudopods to the shear forces of blood flow, MTLn3 cells, expressing higher levels of 
cytokeratins, had greater mechanical strength enabling them to survive this last step of 
intravasation (82). 
 
1.2.4 Breast Cancer 
 
One of the principal cancers investigated in this work, in relation to MMPs, is breast 
cancer; it has the highest rate of incidence and is the second highest cause of cancer 
mortality (15%) amongst females in the United States (72). It has been well established 
that breast cancer has a strong familial association; women with first degree relatives 
with the disease have approximately double the risk of incidence of breast cancer 
compared to the general population (83). Mutations to highly penetrant tumour 
suppressor genes BRCA1 and BRCA2 only account for about 20% of the two fold 
increased risk to close female relatives of breast cancer patients; searches for other high 
penetrance genes and novel foci have failed account for the majority of familial risk, 
suggesting it may be conferred by multiple polygenic low penetrance foci (84). 
Described previously in section 1.2.3.1 metastatic breast cancer cells have been 
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observed, in vivo, to move rapidly along ECM fibres within primary tumours exhibiting 
solitary amoeboid movement also enabling them to pass through dense networks of 
matrix that could retard non-amoeboid cells. They have been seen to only show strong 
polarisation when in the presence of EGF-like ligands indicating blood vessels; the 
chemotactic cytokines may be produced by the high numbers of extremely motile 
macrophages and other leukocytes visualised by intravital imaging in the vicinity of 
blood vessels of mammary tumours (82). 
 
1.2.4.1 Prognostic markers of breast cancer 
 
As with other solid cancers, metastasis is the principal cause of death in breast cancer. 
Prognostic markers currently in clinical use, relating to breast cancer metastasis, are 
described below (table 1.4, adapted from (85)). 
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Table 1.4. Breast cancer metastasis prognostic markers 
Marker Use in clinic Metastatic determinants Details  
    
Tumour size Established  Tumours under 2 cm in diameter have a 
low risk of metastasis; tumours of 2–5 
cm have a high risk of metastasis; 
tumours over 5 cm have a very high risk 
of metastasis 
Independent prognosis 
marker 
Axillary lymph node 
status 
Established If there are no lymph-node metastases, 
the risk of metastasis is low; if lymph-
node metastases are present, the risk 
of metastasis is high; the presence of 
over 4 lymph-node metastases is 
associated with very high metastasis 
risk 
Related to tumour size 
Histological grade Established Grade 1 tumours have a low risk of 
metastasis; grade 2 tumours have an 
intermediate risk of metastasis; grade 3 
tumours have a high risk of metastasis 
Related to tumour size 
Angioinvasion Established in 
patients with lymph-
node negative 
tumours  
The presence of tumour emboli in over 
3 blood vessels is associated with 
metastasis 
In patients with lymph-
node negative tumours  
uPA/PAI1 protein 
level 
Newly established 
marker 
High protein levels of uPA and PAI1 are 
associated with high metastasis risk 
Independent prognosis 
marker 
Steroid-receptor 
expression 
Established for 
adjuvant therapy 
decision 
Low steroid-receptor levels are 
associated with metastasis 
Short-term predictor of 
metastasis risk (5 
years); related to 
histological grade  
ERBB2 gene 
amplification and 
protein expression  
Established for 
adjuvant therapy 
decision  
ERBB2 amplification/over expression is 
associated with metastasis 
In patients with lymph-
node positive tumours  
Gene-expression 
profiling 
Recently established A ‘good signature’ of 70 genes is 
associated with low metastasis risk; a 
‘poor signature’ of 70 genes is 
associated with high metastasis risk  
Tested in patients with 
lymph-node negative 
tumours 
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1.2.5 Malignant melanoma 
 
Melanoma represents the most deadly form of skin cancer. The incidence of this 
aggressive cancer is increasing rapidly. Skin cancer when including basal and squamous 
cell carcinoma is the most common neoplasm in the United States. However melanoma, 
while comprising of approximately 4% of skin cancer is responsible for 80% of the 
attributed deaths of skin cancer. Common risk factors for melanoma are a previous 
family history multiple and/or atypical naevi. Environmental factors include 
immunosuppression, exposure to UV radiation and skin sensitive to sunlight (86, 87). 
The median survival rate of malignant melanoma (MM) is 8-9 months, the  3 year 
overall survival (OS) is less than 15%  (88). Early diagnosis of melanoma enables it to 
be cured by surgical resection. The majority of melanomas are cured this way. Once 
metastasis occurs the disease is extremely resistant to current therapies (89). 
 
The cancer itself is derived from melanocytes, cells which are responsible for the 
pigmentation of the skin. The process of transformation of melanocytes into a malignant 
disease can be said to take place in four stages. Initially in normal skin, melanocytes are 
evenly distributed. Moles or „naevi‟ occur at foci with increased numbers of 
melanocytes; these are considered as benign. Naevi may subsequently undergo a radial-
growth phase (RGP), changing shape, size, and/or colour; this is considered to a 
premalignant stage. The next stage is termed the vertical-growth-phase (VGP), the 
tumour invades the dermis and subcutaneous tissue; the possibility of invasion of the 
lymphatic and vascular systems means this stage is the first considered to have 
malignant potential and can lead directly to metastasis (89, 90).  Characteristic of the 
VGP is the expression of basement membrane and matrix degrading enzymes, such as 
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MMPs that may facilitate invasion through the dermis; MMP1 in particular has been 
implicated as an important player in this phase (90-92).  
Molecular studies have indicated that amongst the more common melanomas the gene 
most frequently mutated is the serine–threonine protein kinase B-RAF (BRAF).  
Another commonly mutated gene that is mutually exclusive of BRAF is NRAS (93). 
Table 1.5 adapted from (89), highlights the more common genetic alterations found in 
MM. 
 
Table 1.5. Common genetic alterations found in malignant melanoma 
Gene type Gene 
Alteration frequency/type(s) in 
melanoma (%) 
Reference 
    
Oncogenes BRAF  50–70% mutated (94) 
 NRAS 15–30% mutated (94, 95) 
 AKT3 Overexpressed (96) 
Tumour 
suppressors 
CDKN2A  30–70% deleted, mutated or silenced (97) 
 PTEN 5–20% deleted or mutated (95, 98) 
 APAF-1 40% silenced (99) 
 P53 10% lost or mutated (100) 
Others Cyclin D1 6–44% amplified (101) 
 MITF 10–16% amplified (101) 
Abbreviations: serine–threonine protein kinase B-RAF (BRAF), Neuroblastoma RAS viral oncogene homolog (NRAS), V-akt 
murine thymoma viral oncogene homolog 3 (AKT3), Cyclin-dependent kinase inhibitor 2A (CDKN2A), Phosphatase and tensin 
homolog (PTEN), Apoptotic protease activating factor 1 (APAF-1), tumour protein 53 (p53), Microphthalmia-associated 
transcription factor (MITF) 
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1.2.5 MMPs and cancer 
 
The prevailing scientific doctrine regarding MMPs and cancer for many years was that 
tumour-associated MMPs provided a route for metastasis by degrading the surrounding 
ECM thereby granting access to the vasculature and lymphatic systems; this was backed 
up by various studies showing the upregulation of several MMPs to be associated with 
multiple types of neoplastic disease. However subsequent clinical trials for broad 
spectrum MMP inhibitors as anti-cancer therapeutics yielded poor and sometimes 
adverse results (102). Further evidence has since come to light of a much more complex 
role in both physiological and disease situations, in cancer not all MMPs are 
detrimental, some MMPs have been shown to have a protective effect while others are 
either pro-tumourigenic or protective depending on the situation (103). MMP2 is an 
example of an MMP that to date seems to be only pro-tumourigenic; a promoter 
haplotype (rs243865-C, rs2285053-C) that shows increased activity in luciferase 
vectors, increased mRNA expression, and interaction with a DNA binding protein, 
confers increased risk of oesophageal cancer and metastasis, and increased risk of lung 
cancer (33, 34). The C allele of rs243865 (present in the aforementioned haplotype) has 
also been shown to confer increased risk of gastric cardia adenocarcinoma and oral 
squamous cell carcinoma (35, 36). MMP9 when co-localised with CD44, a cell surface 
proteoglycan, increases tumour cell invasiveness (104). However it can also play a 
protective role; expression levels of MMP9 are inversely correlated with liver 
metastasis in colorectal cancer, and low levels of MMP9 caused increased tumour 
vascularisation in mice (103, 105). MMP12 is thought to have a largely beneficial effect 
against cancer; murine studies indicate MMP12 expression decreased tumour growth 
rates (106), and in human subjects homozygote carriers of the low expressing allele of a 
promoter polymorphism (rs2276109) had increased risk of bladder cancer metastasis 
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(55). Further examples of MMPs - their polymorphisms and their effects on cancers can 
be found in table 1.1. 
 
1.2.5.1 MMP1 and cancer 
 
The presence or high levels of expression of MMP1 is associated with a poor prognosis 
in many types of cancer, including colorectal cancer, oesophageal cancer, pancreatic 
ductal adenocarcinoma, breast cancer, and melanoma (107-111). One promoter variant 
in particular is shown to influence expression; a guanine (G) insertion (-1607; 
rs1799750) creates a binding site for the E-twenty six (Ets) transcription factor that 
contributes to increased transcription (112). Subsequent investigations show the 2G 
allele, with augmented expression of MMP1 has been associated with increased risk 
lung and colorectal cancers and a poorer prognosis with breast cancer, ovarian cancer 
and melanoma (25-29, 113-116).  
 
1.2.5.2 MMP8 and cancer 
 
The role of MMP8 in tumour progression is less straightforward; it has been detected in 
vivo in head and neck small cell squamous carcinomas (117), and it has been implicated 
with and associated with the invasiveness of ovarian cancer (118, 119). Other studies 
give an anti-tumour role to MMP8; one group found that expression levels of MMP8 
inversely correlated with pro-metastatic behaviour in isogenic breast cancer cell lines 
(120), the same group, following up their previous work, were able to engineer altered 
metastatic phenotypes in the two cell lines by changing the MMP8 expression; by 
knocking down MMP8 in the non-metastatic cell line to give it an invasive phenotype, 
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conversely upregulating MMP8 in the metastatic cell line to give it a non-invasive 
phenotype (121). Researchers based in Spain found that MMP8 knockout mice have 
increased susceptibility to chemically induced skin carcinogenesis (122). 
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1.3 Atherosclerosis 
 
Atherosclerosis is a progressive condition often termed hardening or furring of the 
arteries. It is a chronic inflammatory disease, which occurs over decades, although 
serious acute clinical symptoms brought about by this disease can manifest in minutes. 
It is the principal contributing factor for both cardiovascular disease (CVD) and 
cerebrovascular disease; combined they are the largest cause of death on the planet 
today (123, 124).  In Europe the latest available data puts the cause of death for men at 
21% for coronary heart disease (CHD), 11% for stroke, and 11% for other 
cardiovascular disease; for women the figures are 22% for CHD, stroke 17%, and 15% 
for other CVD (125).  As diet and lifestyle of world becomes more westernised the 
epidemic cardiovascular disease and associated mortality is spreading to more 
undeveloped countries.  
 
1.3.1 Clinical manifestations of atherosclerosis 
 
1.3.1.1 Angina Pectoris 
 
Angina pectoris is severe pain in the chest caused by ischaemia of the myocardium. 
This is mainly due to obstruction of coronary vessels supplying the heart by 
atherosclerotic plaques, although it can occur as a result of vasospasm. There are two 
subtypes of angina pectoris termed stable and unstable. 
Stable angina is most common subtype; sufferers typically experience chest discomfort 
that lasts several minutes, which will have been precipitated by increased activity and 
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oxygen demand. The discomfort reflects atherosclerosis advanced enough to restrict 
maximal blood flow during exercise (126).  
 
Unstable angina (UA) is the more grave condition and is also a subtype of acute 
coronary syndrome (acute coronary syndrome covers unstable angina, non-ST segment 
elevation myocardial infarction (NSTEMI) and ST segment elevation myocardial 
infarction (STEMI). Sufferers of UA may experience increased discomfort for 
prolonged periods (over 15 minutes). Symptoms can occur unpredictably even at rest or 
following minimal activity; the severity, frequency and duration of these symptoms 
increase over time. The mechanism of this condition is plaque rupture and subsequent 
thrombotic events (127); without medical intervention the possibility of myocardial 
infarction is extremely high. 
1.3.1.2 Acute Myocardial Infarction 
 
Myocardial infarction (MI) more commonly known as „heart attack‟ is classified, under 
acute coronary syndrome, into two further subtypes, NSTEMI and STEMI. These 
subtypes are named for their appearance on an electrocardiogram (ECG/EKG) (128). 
Pathologically MI is defined as myocardial cell death due to prolonged ischaemia (129). 
Myocardial infarction is the single largest cause of death in the world today (130), once 
again the major underlying cause is coronary heart disease/atherosclerosis; plaque 
rupture and subsequent thrombosis leading to occlusion of coronary vessels. Extended 
lack of blood and oxygen to the affected heart muscle causes necrosis and apoptosis in 
the cardiomyocytes. 
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1.3.1.3 Stroke 
 
When the blood supply to part of the brain is cut or reduced the resulting loss of 
neurological function is termed „stroke‟. Short term ischaemia may only produce 
reversible loss of function, prolonged ischaemia leads to infarction, irreversible cell 
death in the affected brain tissue. Brain damage caused by stroke can lead to physical 
and/or mental impairment, and death, particularly if the region of the brain affected 
controls the respiratory or cardiovascular system (131). 
 
1.3.2 Risk factors of atherosclerosis 
 
Common systemic risk factors strongly associated with atherosclerosis are 
hypercholesterolaemia, hypertension, smoking and diabetes; a closer look at the factors 
involved in the aetiology of atherosclerosis is given in table 1.6, taken directly from the 
review by Lusis in 2000 (132). 
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Table 1.6 Genetic and environmental factors associated with atherosclerosis and 
coronary heart disease (CHD) (132) 
Factors with a strong genetic component Comments 
  
Elevated levels of LDL/VLDL Associations demonstrated in epidemiological studies and supported 
by studies of genetic disorders and animal models. Clinical trials have 
shown benefits of cholesterol reduction. 
  
Reduced levels of HDL Associations demonstrated by numerous epidemiological studies and 
supported by studies of genetic diseases and animal models. 
Elevated levels of lipoprotein(a) Associations observed in many, but not all, epidemiological studies. 
Animal studies have been contradictory. 
  
Elevated blood pressure Associations observed in epidemiological studies. Clinical trials have 
demonstrated benefits of blood pressure reduction, with particularly 
strong effects on stroke. 
  
Elevated levels of homocysteine Associations have been observed in epidemiological studies, and 
homocystinuria results in severe occlusive vascular disease. 
  
Family history When all known risk factors are controlled for, family history remains a 
very significant independent factor. 
  
Diabetes and obesity Associations observed in epidemiological studies and in studies with 
animal models. 
  
Elevated levels of haemostatic factors Significant independent associations have been observed with 
elevated levels of fibrinogen, plasminogen activator inhibitor type 1 
and platelet reactivity. 
  
Depression and other behavioural traits Associations observed in several population studies. 
Gender (male) 
Below age 60, men develop CHD at more than twice the rate of 
women. 
  
Systemic inflammation Elevated levels of inflammatory molecules such as C-reactive protein 
are associated with CHD, as are inflammatory diseases such as 
rheumatoid arthritis. 
  
Metabolic syndrome This cluster of metabolic disturbances, with insulin resistance as a 
central feature, is strongly associated with CHD. 
Environmental factors  
  
High-fat diet Population migration and epidemiological studies indicate strong 
associations with lifestyle, and diet appears to be the most significant 
factor. High-fat, high-cholesterol diets are usually required for 
development of atherosclerosis in experimental animals. 
  
Smoking Strong associations observed in numerous epidemiological studies. 
Clinical trials have demonstrated the benefit of stopping smoking. 
  
Low antioxidant levels Results of clinical trials with antioxidants have not been conclusive. 
Fat-soluble antioxidants protect against atherosclerosis in 
experimental animals, however. 
Lack of exercise Significant independent associations with CHD. 
  
Infectious agents Epidemiological studies provide suggestive evidence for associations 
with various infectious agents, such as Chlamydia pneumoniae. 
Preliminary animal studies support the relationship. 
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1.3.3 Sites of lesion development 
 
Atherosclerosis is characterised by development of lesions/plaques in large to medium 
sized arterial vessels (132). The lesions develop at specific locations within the vessels 
that experience low or oscillatory shear stress such as those proximal to branches, 
bifurcations or within highly curved arteries (133). A clue as to why atheromas develop 
at these sites may be given by the architecture of the endothelium; in areas of laminar 
flow endothelial cells show a regular elliptical morphology and orientation giving a 
tightly packed formation. Areas experiencing low or oscillatory shear stress cells have a 
more polygonal shape with little uniform orientation and a less dense formation. It is 
these areas of non-uniform endothelial cells which have increased permeability to large 
molecules such as low density lipoprotein (LDL) that are much more vulnerable to 
plaque (134, 135). 
 
1.3.4 Growth of atheroma 
 
The first signs of atherosclerosis are small fatty streaks made up almost entirely of lipid 
laden macrophages and T-lymphocytes; this earliest form of the disease can commonly 
be found in infants and young children. In this initial stage of the disease progression 
occurs in the form of expansion of the lesions both laterally and vertically with adjacent 
lesions coalescing. Plaque formation follows with the recruitment of smooth muscle 
cells from the intima and deposition of a collagen matrix to form a fibrous cap (136). It 
is easy to think of the above process as a smooth continuum occurring throughout life of 
a patient with the chronic condition. Angiographic studies however point to 
discontinuous stenosis and plaque development. 
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Three types of events have been put forward for these bursts in the expansion of 
atheromatous lesions. Within atherosclerotic lesions microvasculature develops in 
response to pro-angiogenic molecules secreted by macrophages, such as fibroblast 
growth factors, vascular endothelial growth factor (VEGF), and certain MMPs. It aids 
lesion growth by supplying nutrients but critically these vessels are fragile and 
susceptible to haemorrhage leading to production of thrombin. Further lesion 
development occurs when the in situ thrombin activates platelets to release platelet-
derived growth factor (PDGF), stimulating SMC migration and proliferation, and 
transforming growth factor beta (TGF-β) which in turn stimulates SMCs to produce 
interstitial collagen. The most important event in terms of plaque growth and clinical 
outcomes is the rupture of the fibrous cap. This type of rupture is responsible for 
approximately 75% of acute Myocardial infarctions, but in all probability most of these 
ruptures remain sub-clinical. The release of previously sequestered tissue factor and 
other thrombogenic material may often lead incomplete occlusion of the afflicted 
vasculature; circulating thrombolytic agents enable the thrombus to be re-absorbed. The 
re-absorption process as with microvascular haemorrhage involves the build up of 
SMCs and collagen deposition; this can advance fatty streaks to fibrous plaques and/or 
lead more regions of the adjacent vasculature to become likely sites of atherogenesis. 
The final case is the erosion of small areas of the endothelial monolayer; in areas 
affected by erosion von Willebrand factor and collagen can be exposed; these molecules 
provide an aggregatory stimulus for platelet thrombus formation. The majority of these 
events are sub-clinical although this process may account for nearly 25% of fatal 
thromboses (123). 
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1.3.5 Two types of plaque 
 
Atherosclerotic plaques can be divided into two categories, stable and unstable. Stable 
plaques have a thick fibrous cap; they can still cause clinical problems related to 
stenosis of the arterial vessels, but they are much less likely to rupture leading to acute 
clinical events. Unstable plaques are characterised by thin fibrous caps and increased 
levels of MMPs and are much more prone to rupture. If the fibrous cap then ruptures 
thrombogenic materials can be released, such as lipids and tissue factor. The resulting 
thrombus formation can lead to the occlusion of vessels, leading to myocardial 
infarction and/or stroke (123, 132, 137). 
 
1.3.6 Formation of an atherosclerotic plaque 
 
Figure 1.3. Formation of an atherosclerotic plaque (© 2010 InViVo Communications™ Inc.) 
Figure 1.3 shows the stages in the formation of an atherosclerotic plaque; the section below 
describes the stages of plaque formation; bold numbers in brackets in the section below help 
marry the description with the stages in the illustration. 
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In hypercholesterolaemia LDL enters the endothelium [1], here it can, among other 
modifications, be lightly oxidised. Lightly oxidised LDL has some pro-inflammatory 
properties and can contribute to the activation of endothelial cells. Activated endothelial 
cells have upregulated expression of cytokine inducible adhesion molecules, from the 
immunoglobulin gene superfamily, such as vascular cell adhesion molecule 1 (VCAM-
1) and inter-cellular adhesion molecule 1 (ICAM-1). VCAM-1 on the endothelial cell 
surface is able to attach to cells expressing VLA4 particularly monocytes and T-cells [2] 
(138). Once attached monocytes are easily able to enter the intima via tight cell 
junctions, attracted by chemokine gradients of molecules such as monocyte chemo 
attractant protein-1 (MCP-1) [3]. Within the intima monocytes proliferate and 
differentiate into macrophages [4].  Macrophages in the presence of highly oxidised 
LDL internalise it via scavenger receptors and turn into foam cells [5]. Foam cells 
produce inflammatory cytokines, reactive oxygen species (ROS) and MMPs [6]. A 
mixture of foam cells and extracellular lipids deposited from dead foam cells form the 
necrotic core of the plaque [7].  Cytokines and growth factors produced from the 
macrophages and T-cells within the lesion induce smooth muscle cell migration and 
proliferation. Smooth muscle cells cover the foam cells and lipid laden necrotic core 
forming a fibrous cap along with matrix proteins, such as collagen and proteoglycans 
(123, 132, 137).  
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1.3.7 MMPs and atherosclerosis 
 
The stability of a fibrous cap depends upon the thickness and integrity of the ECM that 
gives it scaffolding, strength and structure.  As MMPs can degrade nearly all the 
constituents of the ECM, participate in inflammation and play a crucial role in tissue 
and vascular remodelling, it stands to reason that they are involved in atherosclerosis; 
numerous studies have taken place to elucidate this involvement. Just as in the case of 
cancer the relationship between atherosclerosis and MMPs is not straightforward.  
Genetic studies in MMP1 have seemingly produced conflicting results; one study finds 
that the more transcriptionally active 2G allele of the rs1799750 polymorphism confers 
a decreased risk of CHD (139), while another study finds that the same allele confers an 
increased risk of carotid stenosis (140). Numerous studies associate increased levels of 
MMP9 with increased risk or incidence of unstable angina, acute MI, and coronary 
artery disease (141); less consistent results were found in murine models of 
atherosclerosis and MMP9 deficiency, Johnson  et al, in 2005 (142) showed that the 
atherosclerotic lesions in the braciocephalic arteries of knockout mice were significantly 
larger than those in the controls suggesting a protective role for this enzyme; in the 
same year Choi  et al (143) found a reduction in intimal lesion size and volume  in 
knockout mice compared to controls, this time suggesting a detrimental role. A 
summary of the experimental and clinical findings on MMPs and CAD is shown below 
(table 1.7; adapted from (141)). 
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Table 1.7. MMPs in atherosclerosis (adapted from (141)) 
 
     
MMP Sources in plaque SNPs Mouse models; 
atherosclerosis phenotype 
As Biomarkers for CAD 
     
MMP-1 (collagenase 1) Endothelial cells, 
SMCs, 
macrophage 
rs1799750 (2G) associated with CAD, not 
with carotid stenosis;  rs1144393-
rs514921(A-C haplotype) increased risk of 
MI 
hMMP1
+/+
 ApoE
−/−
; 
decreased 
Higher levels found in UA, acute MI, 
CAD, carotid stenosis. Other studies 
found levels to be unchanged in CAD 
MMP-8 (collagenase 2) see next section - - - 
MMP-13 (collagenase 3)  Endothelial cells, 
SMCs, 
macrophage  
- MMP13
−/−
 ApoE
−/−
; 
increased collagen 
- 
MMP-2 (gelatinase A)  Endothelial cells, 
SMCs, fatty 
streaks, plaques  
rs243864 associated with CAD MMP2
−/−
 ApoE
−/−
; 
decreased 
Higher levels found in UA, stable 
angina, and acute MI 
MMP-9 (gelatinase B)  Leukocytes and 
their precursors  
rs3918242 associated with CAD, 
peripheral arterial occlusive disease; 
rs78639889 (CA) carotid stenosis 
 MMP9
−/−
 ApoE
−/−
; 
decreased an increased 
Higher levels found in UA, acute MI, 
CAD, carotid stenosis, peripheral 
artery disease (many studies) 
MMP-3 (stromelysin 1)  SMCs, 
macrophage, 
lymphocytes  
rs3025058 associated with carotid 
stenosis, reduced risk of MI 
MMP3
−/−
 ApoE
−/−
; 
increased 
Found decreased in symptomatic 
CAD, increased in first 96 hours post 
MI, acute coronary syndrome 
MMP-10 (stromelysin 2) Endothelial cells, 
macrophage 
- - Associated with intima-media 
thickness 
MMP-11 (stromelysin 3)  - - MMP11
−/−
; increased 
intimal hyperplasia  
- 
MMP-7 (matrilysin 1) Macrophage  rs11568818 associated with CAD MMP7
−/−
 ApoE
−/−
; neutral Higher levels found in CAD 
MMP-14 (membrane-
type1- MMP) 
SMCs, 
macrophage 
- MMP14
−/−
 bone marrow 
transfer to LDLR
−/−
; neutral 
- 
MMP-12 (macrophage 
elastase)  
Macrophage rs2276109 associated with CAD MMP12
−/−
 ApoE
−/−
; 
decreased, other study 
found neutral 
Higher levels found in CAD 
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1.3.7.1 MMP8 in atherosclerosis 
 
 
Despite being the most potent processor of native fibrillar type I collagen, the major 
structural component ECM in plaques (61-63, 144), MMP8 was first overlooked as a 
candidate in plaque rupture because it was only thought to be expressed in maturing 
neutrophils; the cellular composition of plaques was reported to rarely contain 
neutrophils (145). It has since been shown, however, that endothelial cells, smooth 
muscle cells and mononuclear phagocytes within atherosclerotic lesions all express 
MMP8 (Herman, 2001) (146). Further lines of evidence suggest a role for MMP8 in 
atherosclerosis; elevated serum and plasma levels of MMP8 have been associated with 
worst cardiovascular outcome, and the presence and severity of CAD (147-149). Levels 
of active MMP8 were found to be higher in rupture prone or progressive plaques, co-
localising with macrophages at the shoulder region of fibrous caps (150, 151).  
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1.4 Aims and objectives  
 
The overall aim of this project was to investigate effects of variations of MMP1 and 
MMP8 genes in the development of cancer and atherosclerosis. 
 
Objectives: 
1. To investigate effects of variation in the MMP1 gene on MMP1 promoter activity in 
cancer cells. 
 
2. To conduct genetic epidemiological studies to investigate genetic variation in MMP1 
and MMP8 regarding breast cancer and malignant melanoma. 
 
3. To perform a functional characterisation of the genetic variants, including the MMP1 
polymorphism rs19799750, previously associated with multiple cancers. 
 
4. To study whether MMP8 played a role in the development of atherosclerotic lesion 
formation using a mouse model and to investigate the related mechanisms. 
 
5. To conduct genetic epidemiological studies to investigate whether MMP8 
polymorphisms were associated with the development and progression of 
atherosclerosis.  
 
  
45 
 
2.0 Materials and Methods 
 
2.1 Subjects 
 
2.1.1 Southampton Atherosclerosis Study - Southampton CAD patients  
 
Consecutive British European CAD patients were recruited from the Wessex 
Cardiothoracic Unit, Southampton General Hospital. All patients had > 50% Stenosis in 
at least 1 epicardial coronary artery, as determined by coronary angiography. Clinical 
and demographic data were recorded including age, gender, weight, height, smoking 
habit, the presence or absence of hypertension (defined as diastolic blood pressure 
>95mmHg and/or systolic blood pressure >160 mmHg), the presence or absence of type 
1 or type 2 diabetes (152). The clinical and demographic characteristics of the 
Southampton CAD patients are presented below. 
 
 
Table 2.1. Demographic and clinical characteristics of the Southampton CAD patients 
(n=2000) 
 
Variable means (SD) or % 
Age - year 63.5 (10.0) 
Male gender 74.4% 
Body mass index 27.4 (4.3) 
Smoking 72.8% 
Hypertension 42.4% 
Diabetes 12.7% 
SD, standard deviation 
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2.1.2 Leuven breast cancer study 
 
Between the years 2005 and 2006, 140 patients newly diagnosed with primary operable 
breast cancer at the Multidisciplinary Breast Centre of the University Hospital of 
Leuven were recruited into the Leuven breast cancer study. Clinical and pathological 
data was extracted from patient files and reports. Typing of primary tumours was 
performed under WHO guidelines with the Elston & Ellis system used for tumour 
grading (153). Lymph nodes pathological examination was with haematoxylin and eosin 
using 3 sections per node. To reduce the chance of false negative results sentinel lymph 
nodes classified as negative were additionally stained with epithelial markers to detect 
micrometastases (48). Breast cancer staging was carried out according to the tumour-
node-metastasis (TNM) system, which classifies breast cancers according to size, lymph 
node involvement, and metastasis (154).  
 
2.1.3 Strangeways breast cancer case/control study  
 
 
The case/control samples described below are referred to as “Set 1” by the research 
laboratory in possession of the study set: Cancer Research UK Department of 
Oncology, Strangeways Research Laboratory. Participants in both the cases and 
controls were of > 98% European Caucasian phenotype   (155, 156). 
 
2.1.3.1 Strangeways breast cancer cases  
 
Strangeways breast cancer cases were drawn from the „Studies of Epidemiology and 
risk Factors in Cancer Hereditary‟ (SEARCH) study. Recruitment took place via the 
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Eastern Cancer Registration and Information Centre ECRIC, Cambridge, UK. Inclusion 
criteria were women under the age of 55 years diagnosed with invasive breast cancer 
between January 1, 1991 and June 30, 1996; median age 48. Also admitted were women 
below the age of 70 years diagnosed from 1996 onwards; median age 48. The total 
number of cases available for analysis under the above criteria was 4470, the 2270 cases 
analysed were randomly chosen from the first 3500 women recruited. There was no 
significant difference in the morphology, histopathologic grade, or clinical stage of the 
cases analysed or not analysed (156, 157). 
 
Strangeways controls  
 
 
Strangeways controls were selected at random from participants of the Norfolk 
component of European Prospective Investigation of Cancer (EPIC). The controls 
inhabit the same geographic region as the cases and have similar median age (155, 156). 
 
2.1.4 Bruneck study 
 
The Bruneck Study is a prospective population-based survey on the epidemiology and 
aetiology of carotid atherosclerosis. 1000 healthy subjects were randomly recruited 
from the population of the Bruneck area in the Bolzano province, Italy in 1990. Subjects 
were then stratified by age and sex (125 Men and 125 women in each of the fifth to the 
eighth decade, n=1000). The total number of people to participate in the study was 936 
with data collection complete 919 subjects. At 5 year intervals follow ups took place, in 
1995 owing to death or relocation away from the area 826 were available, the second 
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follow up took place in the summer of 2000. Within the current study population 
genotyping was successful for 782 participants. Atherosclerosis was assessed, initially 
and in each follow up, by means of ultrasonography measuring carotid intima-media 
thickness (cIMT), a biomarker of carotid artery atherosclerosis. Blood samples were 
taken after an overnight fast and 12 hours of abstinence from smoking. Plasma levels of 
inflammation markers were measured by standard methods, including soluble VCAM-1 
(ELISA, R&D Systems). Demographic and clinical characteristics of the subjects are 
shown below (158-161). 
 
Table 2.2. Demographic and clinical characteristics of the Bruneck study subjects (n=782) 
 
Variable means (SD) or %  
Age – year  62.8 (11.1) 
Male gender 49.4% 
Body mass index 25.6 (3.9) 
Smoking 19.3% 
Hypertension 68.1% 
Diabetes 10.0% 
SD, standard deviation 
 
 
2.1.5 Polish breast cancer and melanoma study 
 
Polish study cases were recruited from the International Hereditary Cancer Center, 
Szczecin, Poland. 
 
2.1.5.1 Polish melanoma cases  
 
Melanoma cases consisted of 300 consecutive individuals (175 women and 125 men) 
with histologically confirmed malignant melanoma of the skin (including in-situ and 
49 
 
invasive tumours) treated in Szczecin between 2003 and 2006; mean age at diagnosis 
was 55 years.  
 
2.1.5.2 Polish breast cancer cases  
 
Breast cancer cases consisted of 300 prospectively ascertained cases of consecutive 
invasive breast cancer treated in Szczecin; mean age at diagnosis was 56 years. 
 
Polish controls 
 
Melanoma controls were 300 healthy adults (175 women and 125 men, mean age of 55 
years), who had a negative cancer family history and were sex matched and age 
matched (±2 years) with the patients with melanoma. The control participants were 
drawn from a larger study involving the residents of West Pomerania, Poland. Healthy 
adults had a negative family of cancer. Exclusion criteria were cancers among 1
st
 or 2
nd
 
degree relatives. 
 
Breast cancer controls were 300 healthy women (mean age of 56 years) who had a 
negative cancer family history and were age matched (±2 years) with the breast cancer 
cases. Other than gender, the population, inclusion and exclusion criteria were the same 
as the melanoma controls. Controls for melanoma and breast cancer were not 
necessarily mutually exclusive (162). 
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2.2 Genetic investigations into the role of MMPs in breast cancer, 
malignant melanoma and atherosclerosis 
 
2.2.1 DNA extraction from whole blood 
 
Genomic DNA from the different sets of subjects described above, with the exception 
of genomic DNA from subjects of the Leuven study, was extracted either by colleagues 
or collaborators (152, 158, 163-165). DNA was extracted from blood samples from the 
Leuven breast cancer study by a salting out method adapted from Miller et al 1988 
(166). Peripheral blood samples collected into EDTA coated tubes were shipped from 
Belgium to Southampton on dry ice. Before DNA extraction the samples were stored at 
-80°C for at least 24 hours as this, anecdotally, increases the final yield. Prior to 
extraction samples were thawed overnight at 4°C on a rolling mixer. In a 50 ml conical 
tube (Falcon) 5 ml of blood was mixed with 30 ml of cold 1X erythrocyte lysis buffer 
(ELB) (appendix 1) for 15 minutes on ice on a rotary shaker at a slow speed for 15 
minutes. The tube was then centrifuged at 500 g at 4°C for 10 minutes. The supernatant 
was discarded and the pellet resuspended in a further 30 ml of 1X ELB and mixed as 
described previously for 15 minutes. The tube was spun again at 500 g, 4°C, for 10 
minutes and the supernatant discarded. The pellet was then washed into a 15 ml conical 
tube topped up with 1X ELB and centrifuged at 500 g, 4°C, for 10 minutes, and the 
supernatant discarded. The pellet was resuspended in 1-2 ml of nuclear lysis buffer 
(NLB) (appendix 1), followed by overnight protease K digestion at 37°C using 0.2 ml 
of 10% SDS and 0.5 ml of proteinase K (Sigma) solution (1 mg/ml proteinase K, 1% 
SDS and 2 mM Na2EDTA) in a shaker incubator. 750 µl of saturated NaCl solution was 
added to the overnight digest, shaken vigorously for 15 seconds, and spun at 3400 g for 
15 minutes at room temperature. As much supernatant as possible (approximately 3 ml) 
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was transferred into a fresh 15 ml conical tube to which 2X the volume  of ice cold 
absolute ethanol was added. The tube was inverted gently until the DNA could be seen 
to form a fluffy precipitate. The precipitated DNA was removed using a 200 µl pipette 
tip or glass rod and placed into a 1.5 ml microfuge tube containing 1 ml 70% ethanol. 
The microfuge tubes were pulsed on a centrifuge to pellet the DNA, the ethanol 
removed and the pellet allowed to air dry. 300-500 µl TE buffer was added to each 
pellet, depending on size, in which it dissolved over 24-48 hours. Quantification of 
genomic DNA was carried out by colleagues using Picogreen (167).  
 
2.2.2 SNP selection and genotyping of the MMP1 gene 
 
2.2.2.1 SNP selection and genotyping of the MMP1 promoter within subjects from the SAS study  
 
In order to identify common haplotypes and the level of LD between SNPs a group of 
276 unrelated individuals of British Caucasian phenotype, drawn from the SAS study, 
were genotyped for 7 proximal promoter SNPs of the human MMP1 gene (rs1799750, 
rs473509, rs498186, rs1144393, rs475007, rs514921, and rs494379). The 
polymorphisms had previously been identified by the PCR amplification and 
sequencing of the 1.9 kb MMP1 promoter in 30 unrelated British Caucasians (24). The 
genotyping involved the PCR amplification of the polymorphic sequences and digestion 
by suitable restriction endonucleases which cleaved one of the alleles, allowing 
discrimination following visualisation on an agarose gel. The genotyping was 
performed in Southampton; the amplification primer sequences and restriction 
endonucleases used for each SNP can be found in appendix 2. 
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2.2.2.2 SNP selection for genotyping MMP1 locus within individuals from the Polish breast cancer 
and melanoma study 
 
18 SNPs at the MMP1 locus were selected using the Tagger algorithm (168) which was 
configured to select tagging SNPs with the minimum threshold for pairwise correlation 
coefficients (r
2
) of 0.8. The Tagger algorithm forms part the Haploview LD and 
haplotype analysis software available from the HapMap website. The MMP1 SNPs 
selected for analysis were: rs498186, rs1144393, rs475007, rs514921, rs494379, 
rs3213460, rs470358, rs996999, rs5031036, rs491152, rs1051121, rs11225426, 
rs71250626, rs2071231, rs470215, rs2071230, rs7945189, and rs1729376. 
2.2.3 SNP selection for the genotyping of MMP8  
 
2.2.3.1 in relation to breast cancer in the Leuven & Strangeways studies 
 
The HapMap database was used to identify common SNPs (>0.05 minor allele 
frequency (MAF)) in the MMP8 gene region, including 3.5 kb upstream and 
downstream. In January 2006, when the database was queried, there were 35 SNPs that 
met these criteria. To cover these 35 SNPs the Tagger algorithm was configured to 
select tagging SNPs with the minimum threshold for pairwise correlation coefficients 
(r
2
) of 0.8, and forced to include the promoter SNPs rs11225395 and rs1320632, 
previously suggested to have a functional role in MMP8 expression (50) and rs1940475 
a non-synonymous exon 2 SNP. The SNPs selected for analysis were rs10895353, 
rs7943404, rs11225395, rs1320632, rs1940475, rs1892886, rs17099436, rs2508383, 
and rs1276284. 
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2.2.3.2 in relation to breast cancer in the Polish breast cancer study 
 
Genotyping for the Polish breast cancer and melanoma study was subsequent to that 
involving the Leuven & Shanghai populations; based upon the those prior results it was 
decided that the rs11225395 would be a worthwhile candidate to test.   
 
2.2.3.3 in relation to atherosclerosis 
 
MMP8 SNPs to genotype in relation to atherosclerosis were identified by the re-
sequencing described below and tagging SNPs selected from the HapMap database to 
capture (r2 ≥ 0.8) common SNPs (MAF ≥ 0.05) in the introns, 5‟ upstream sequence 
and 3‟-untranslated region. The SNPs are detailed in the results section Table 3.10. 
 
2.2.4 MMP8 resequencing 
 
All 10 exons of MMP8 were amplified from the genomic DNA of 30 unrelated 
individuals of British Caucasian phenotype, drawn from the SAS study, using 
Touchdown PCR (TDPCR). The sequencing of 30 unrelated individuals gives the study 
a power of more than 90% to detect polymorphisms with a MAF >5% (169). The 
primers used to amplify the MMP8 exons were designed using the online primer design 
program „Primer3‟(170) using sequence information available from the „Ensembl‟ 
genome browser (www.ensembl.org) build 39 (171). The Primer sequences can be 
found in appendix 3.  
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2.2.4.1 Touchdown PCR 
 
The polymerase chain reaction (PCR) is one of the most widely used and fundamental 
techniques used in biological research.  The technique exponentially amplifies DNA 
from a given starting template. The enzyme responsible for this reaction a thermostable 
DNA polymerase, isolated from the bacterium Thermus aquaticus, is commonly 
referred to as Taq polymerase or even Taq. The cyclic process of DNA amplification 
takes place in 3 main stages; denaturation of double stranded DNA, annealing of primer 
oligonucleotides to the single stranded DNA, and extension of a complementary strand 
of DNA, from the  double stranded start position provided by the annealed primers, 
along the single strand. Complete denaturation of double stranded DNA typically takes 
place around 95ºC; the temperature for the annealing of primers is dependent upon their 
size and base composition but is commonly around 60ºC. Taq polymerase‟s optimum 
temperature for extension is 72ºC. This amplification cycle doubles the amount of DNA 
each time it occurs. Targeted amplification is achieved with the use of specific primers; 
since both strands can be used as templates, the primers can be chosen to flank the 
region of interest. The thermostability of Taq removes the need for replacement of 
enzyme for each cycle, a step previously required when the DNA polymerases used 
would be inactivated by the high temperatures needed for DNA denaturation; this has 
enabled PCR to become a routine automated process carried out on thermal cyclers 
(172). TD PCR is a modification of PCR designed to reduce mis-priming and the 
generation of non-specific products, without the need for time consuming empirical 
optimisation of all conditions. The method relies the fact that higher temperatures 
increase the stringency of the reaction by favouring correct base hybridisation of 
primers over mis-matched base priming; additionally sub - melting point (Tm) 
annealing temperatures that occur towards the end of the touchdown stage help to 
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increase the overall yield of the reaction, after sufficient correct template has been 
created by the previous higher annealing steps, when buffer conditions may be less than 
optimal.  Tm is defined as the temperature at which one half of a DNA duplex molecule 
is dissociated into single strands. TD PCR typically starts with an annealing temperature 
that is several degrees higher than the expected Tm of the primers used in the reaction; 
the touchdown stage ends with the annealing temperature slightly lower than the 
expected Tm of the reaction primers. Subsequent to the touchdown stage there are 20 -
30 cycles of denaturation, annealing and extension with the annealing temperature 2 -
5ºC lower than the calculated Tm. All 10 amplicons of MMP8 exons including intron 
junctions) were amplified with the following TD PCR protocol template. 
 
Table 2.3. Touchdown PCR cycling conditions 
Step Temperature 
/Condition 
Time/Additional 
cycles 
01 95°C 10 min 
02 95°C 30 sec 
03 65 - 68°C 30 sec (-1°C/cycle) 
04 72°C 1 minute 
05 Goto step 02 X 9 
06 95°C 30 sec 
07 55 - 58°C 30 sec 
08 72°C 1 minute 
09 Goto step 06 X 29 
10 72°C 10 minutes 
11 End  
 
In a 30 µl reaction 3 µl of 10X Amplitaq Gold PCR buffer (Applied Biosystems) was 
added to 21.15 – 20.55 µl of H2O followed by 1.2 µl of dNTPs (5 mM), 2.5 - 3 µl of 
MgCl2 solution (25 mM), 0.1 µl of each primer (10 μM) and 0.05 µl of Amplitaq Gold 
DNA Polymerase (5.0 U/µl, Applied Biosystems). 2 µl of genomic DNA template (7 
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ng/µl) was added to the relevant reaction. PCR was performed on an on an MJ-Tetrad 
PTC-225 thermal cycler. 
 
2.2.4.1.1 PCR optimisation 
 
The optimal reaction conditions for PCR primer pairs were typically determined by 
testing a range of annealing temperatures starting 2°C below the manufacturer stated 
Tm up to 2°C above, in conjunction with four different MgCl2 concentrations 1 mM – 3 
mM. 
 
2.2.4.2 Agarose Gel Electrophoresis 
 
This technique allows the characterisation and visualisation nucleic acids, separating 
DNA or RNA fragments. It is an important step in the purification of specific DNA 
sequences. Agarose gel provides a matrix of cross-linked molecules; enabling DNA 
fragments to be separated by their size, in the presence of an electric field. Nucleic acids 
are charged molecules; most DNA fragments will have a comparable size charge ratio. 
When an electric field is applied to a gel DNA will migrate towards the positive 
terminal (anode). The DNA within the gel is visualised with aid of dyes that fluoresce 
under ultra-violet light; initially in this project the dye used was ethidium bromide 
(EtBr) which intercalates between bases, the DNA-EtBr complex providing a strong 
clear band. Later on in the project the dye used was „Gel Red‟ (Biotum) which works in 
a similar way to EtBr but is less toxic.  Typically in this project 1% or 2% w/v agarose 
gels were used. Lower percentage gels (less cross-links) give better resolution between 
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larger size fragments; higher percentage gels (denser matrix) give better resolution in 
between small size fragments.  
 
Separation of DNA on a 1% agarose gel was as follows:   
 
1 g of agarose was added to 100 ml of 1x TAE or 1x TBE buffer (appendix 1) in a 250 
ml Pyrex glass conical flask;  This mix was then heated to boiling and allowed to cool 
for 2 minutes while being stirred with a magnetic stirrer.  6 µl of Gel Red nucleic acid 
dye was then added and the flask was allowed to cool until it was comfortable to hold. 
The gel was then poured into a rectangular Perspex mould and allowed to set with a 
rigid comb in place to create sample-loading wells. The gel is submerged in 1x 
TAE/TBE buffer solution, in a gel electrophoresis tank, that acts as an electrolyte 
between the positive and negative electrodes.  DNA samples were mixed with DNA 
loading buffer, to give them a higher density than the TAE or TBE buffer and provide a 
visual reference of the progression of the electrophoresis, and then loaded into the wells. 
Along with the samples a DNA weight marker was used, this consists of fragments of 
known size that provide a reference against the PCR products. The gel was run under 
constant voltage at 110 V for 45 minutes. Samples were visualised on a dual intensity 
trans-illuminator under UV-light.    
 
2.2.4.3 Sequencing 
 
Sequencing of MMP8 amplicons was performed externally by Kbiosciences using an 
ABI 3100 DNA Sequencer. Analysis of the sequencing results, sent from Kbiosciences, 
and SNP identification was performed using the Seqman tool, an application which 
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forms part of the Lasergene sequence analysis software (DNASTAR). SNPs were 
detected either visually as heterozygotes, showing clear „peaks within peaks‟ (Fig 3.7), 
or as homozygotes differing from the publically available consensus sequence.    
 
2.2.5 Genotyping of MMP8 in relation to breast cancer 
 
2.2.5.1 Genotyping of MMP8 within the Leuven study population and the Strangeways breast 
cancer case/control study  
 
Breast cancer patients from the Leuven study and patients and controls from the 
Strangeways breast cancer case/control study were genotyped for the 9 polymorphisms 
mentioned in section 2.2.3.1 using the Taqman SNP genotyping system (Applied 
Biosystems) based upon the 5‟ nuclease assay. The Applied Biosystems assays used for 
each SNP are listed in the table below.  
 
Table 2.4. List of MMP8 SNPs genotyped in the Leuven Breast Cancer Study 
population and Strangeways breast cancer case/control study with corresponding ABI 
assay # 
SNP ABI assay # 
rs10895353 C__27134501_10 
rs7943404 C__29361216_10  
rs11225395 C___1366493_10 
rs1320632 C___7492587_10 
rs1940475 C__11484594_1_ 
rs1892886 C__11484595_10 
rs17099436 C__34384563_10  
rs2508383 C___7492589_10  
rs1276284 C___7492595_10 
 
The allelic discrimination of the Taqman 5‟ nuclease assay relies on the amplification 
and 5‟ nuclease activities of the enzyme Taq Polymerase. In the assay forward and 
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reverse primers, adjacent to the region of interest, are combined with 2 short allele 
specific oligonucleotide probes each labelled with either the Applied Biosystems VIC 
(VIC) or 6-carboxy-fluorescein (FAM) fluorescent dyes, along with a quencher dye. For 
unbound probe the proximity of the quencher molecule drastically reduces the 
fluorescent signal of the fluorophores. During the polymerisation step of PCR Taq 
Polymerase, on encountering specifically hybridised probe, cleaves the probe with its 5‟ 
nuclease activity; the fluorophores produce a readily quantifiable signal subsequent to 
their release from the proximity of the quencher molecule (173).  
 
The procedure for the genotyping of the samples is as follows; 5 ng genomic DNA 
samples were added to 384 well optical reaction PCR plates. The DNA was allowed to 
air dry over 24-48 hours. A master mix of the reaction components was prepared with 
sufficient quantity for the total number of samples plus 10% to account for pipetting 
errors. The total volume of each reaction was 5 µl; each reaction contained 2.5 µl 2X 
Taqman Universal Master Mix, 0.25 µl 20X SNP Genotyping assay Mix, and 2.25 µl 
water. 5 µl of the reaction mix was pipetted into each well, the plate sealed with an 
optical adhesive cover, and spun down in a centrifuge at 2000 g for 1 minute. PCR was 
performed on an MJ-Tetrad PTC-225 thermal cycler; the cycling conditions were 95°C 
initiation for 10 min, followed by 40 cycles of denaturation at 92°C for 15 seconds and 
annealing/extension at 60°C for 1 minute.  Plates were read using the Applied 
Biosystems 7900HT sequence detection system. The results were then analysed on 
Applied Biosystems SDS analysis software V2.1. 
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2.2.5.2 Genotyping of MMP1 and MMP8 within Polish cancer patients and controls 
 
As above, the genotyping of MMP1 and MMP8 within Polish cancer patients and 
controls used „off the shelf‟ Taqman assays (Applied Biosystems). The methodology 
remained the same with the exception of the volumes used. A single reaction consisted 
of : 5 ng dried genomic DNA, 1 µl of Taqman assay universal master mix, 0.05 µl of 
SNP genotyping assay mix and 0.95 µl of sterile, deionised water. 
 
2.2.6 Genotyping of MMP8 in relation to atherosclerosis 
 
1000 CAD patients from Southampton General Hospital were genotyped for MMP8 
SNPs rs1276284, rs11225395, and rs1940475 using the Taqman SNP genotyping 
system (Applied Biosystems), and the respective assays C___7492595_10, 
C___1366493_10, and C__11484594_1_; the methodology was as described 
previously.  
 
2.2.6.1 Genotyping using KASPar 
 
The 1000 CAD patients from Southampton General Hospital were also genotyped for 
the other SNPs selected (rs10895353, rs7943404, rs1320632, rs2155052, rs17099450, 
rs3765620, rs12803000, rs1892886, rs17099436, rs3740938, rs2508383, rs1276282, 
rs1291327) by KBiosciences using the KASPar system. KASPar is a proprietary 
genotyping system developed by KBioscience LTD. The system is a competitive PCR 
assay that utilises the specificity of Taq polymerase with the detection of FAM™ and 
VIC™ labelled oligos, non-fluorescent quencher molecules and passive reference dye 
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ROX™. The system requires 2 allele specific probes, 1 for each allele, combined with a 
common primer. These unlabelled oligos can either be designed by KBioscience or with 
the use the design program „Primer Picker‟ available at 
www.kbioscience.co.uk/primerpicker. The non-synonymous SNP rs1940475 was 
associated with the extent of coronary atherosclerosis and remained so after correction 
for multiple SNP testing. A further 1000 CAD patients from Southampton general 
hospital were then genotyped for this SNP. Subjects from the prospective population-
based Bruneck Study were also genotyped for the rs1940475 SNP. 
 
2.2.7 Determination of linkage disequilibrium between MMP1 promoter 
polymorphisms and identification of common haplotypes 
 
The LD between the 7 MMP1 promoter SNPs and the frequencies of common 
haplotypes was determined from the genotype data using the Haploview program, 
which implements an accelerated expectation-maximisation (EM) algorithm (174, 175). 
Colleagues concurrently utilised the THESIAS and PHASE_V2.1 programs to the same 
ends. THESIAS uses the Stochastic-EM algorithm (176) and PHASE uses a Bayesian 
method (177, 178). The Haploview program may be downloaded from the following 
web address: http://www.broadinstitute.org/haploview/haploview-downloads    
 
2.2.8 Acquisition and presentation of MMP1 promoter genetic 
recombination rates 
 
Data and graphical representations pertaining to the recombination rates in and around 
the MMP1 gene were obtained by colleagues from the HapMap database: 
http://hapmap.ncbi.nlm.nih.gov. 
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2.2.9 In silico analysis of transcription factor binding sites lost or gained in 
the MMP1 promoter, as caused by SNPs 
 
It was assessed whether alleles of the SNPs studied in the MMP1 promoter caused a 
loss or gain of putative transcription factor binding sites using the SNPInspector 
program; SNPInspector is a variant of the Genomatix program MATInspector (179). 
 
2.2.10 Statistical analysis of MMP8 gene variation in relation to cancer  
2.2.10.1 Statistical analysis of MMP8 gene variation and breast cancer prognosis 
 
Statistical analysis involving the Leuven breast cancer study was performed by 
colleagues; the gene counting method was used to calculate allele and genotype 
frequencies. Association between clinical and pathological characteristics and 
genotypes or alleles was tested by χ2 analysis. The THESIAS program, which utilises a 
stochastic EM (Expectation-Maximisation) algorithm (176) was used to determine the 
SNP pair-wise linkage disequilibrium coefficient, haplotype frequencies, and any 
haplotypic effects on lymph node metastasis. 
 
2.2.10.2 Statistical analysis of MMP8 gene variation and breast cancer in the Strangeways study  
 
Genotypic statistical analysis involving the Strangeways breast cancer case/control 
study was performed by collaborators at the Strangeways Research Laboratory (156); 
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the gene counting method was used to calculate genotype frequencies. Allelic 
association was calculated using PLINK V1.07 (180). 
 
2.2.10.3 Statistical analysis of MMP8 gene variation in the Polish breast cancer and melanoma 
study 
 
Statistical analysis involving the Polish patients and controls was performed by 
collaborators in Poland.  χ2 analysis was used to assess whether allelic and genotypic 
frequencies differed from those expected under Hardy–Weinberg equilibrium (HWE). 
Potential haplotype effects of MMP1 variation on cancer were assessed using the 
THESIAS program. Since the Polish study involved matched case-controls, conditional 
logistic regression was used calculate disease risk associated with particular genotypes 
or alleles. Multiple testing was taken into account by the use of all other SNPs as 
covariates when querying each SNP. 
 
2.2.10.4 Meta-analysis of data from the analyses of the MMP8 SNP rs11225395 in the Strangeways 
and Polish breast cancer studies 
 
The meta-analysis function of PLINK V1.07 (180) was used to assess the combined 
effect sizes of any association between the rs11225395 SNP and breast cancer in the 
Strangeways and Polish case/control studies. The meta-analysis function of PLINK tests 
both random and fixed effect models, heterogeneity is quantified using both Cochran‟s 
Q test (181) and the I
2 
heterogeneity index (182). 
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2.2.11 Statistical analysis of genotyping data for MMP8 SNPs in relation to 
atherosclerosis 
 
Statistical analysis of genotyping data for MMP8 SNPs tested in CAD patients from 
Southampton and members of the Bruneck study cohort was performed by colleagues. 
Logistical and linear regression analyses were performed to uncover any significant 
relationship between the number of coronary arteries with >50% stenosis and MMP8 
SNPs in Southampton CAD patients and whether there was a relationship between the 
progression of carotid atherosclerosis in the Bruneck Study cohort and the rs1940475 
SNP. ANOVA was used to test a difference in plasma soluble VCAM-1 level between 
rs1940475 genotypes in the Bruneck study cohort. To account for multiple testing, 16 
SNPs in the Southampton CAD patients, the SNPSpD method (183, 184) was used, 
giving a significance threshold of 0.005; this method was not required for the 
interpretation of rs1940475 data in the Bruneck study as only 1 SNP was tested, 
therefore the significance threshold of 0.05 was used. 
 
  
65 
 
2.3 Functional investigations of MMP genes in cancer and 
atherosclerosis 
 
2.3.1 Generation of MMP1 promoter haplotype luciferase reporter gene 
constructs 
 
All MMP1 promoter plasmid constructs were generated previously (24). For each of the 
10 commonest haplotypes, identified by the Haploview, THESIAS, and PHASE 
programs, a 1.9 kb promoter sequence was amplified by PCR, using the genomic DNA 
of individuals carrying the specific haplotype as a template. The promoter sequences 
were then cloned into the pCR-Blunt II-TOPO vector (Invitrogen, San Diego, CA) and 
then subcloned via the multiple cloning site upstream of the firefly luciferase reporter 
gene in the pGL3-basic vector (Promega, Madison, WI). All constructs were then 
sequenced to verify correct orientation and absence of misincorporations.  
 
2.3.2 Cloning of the MMP8 promoter 
 
For each of the two alleles of the rs11225395 SNP, -799 bp relative to the 
transcriptional start site, in the MMP8 gene promoter, a 967 bp DNA fragment, from 
positions -872 to +96, was generated by PCR from the genomic DNA of individuals 
homozygous for each allele. The PCR primers used to clone the MMP8 promoter 
fragment were: 
 
MMP8_prom_F: 5‟ CTGTTGAAGGCCTAGAGCTGCTGCTCC 3‟ 
MMP8_prom_R: 5‟ GATCTTCTCTTCAAACTCTACC 3‟ 
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In a 50 µl reaction 5 µl of 10X Pfx amplification buffer was added to 35.5 µl of H2O 
followed by 3 µl of dNTPs (5 mM), 1 µl of MgSO4 solution (50 mM), 1.5 µl of each 
primer (10 μM) and 0.5 µl of Platinum® Pfx DNA Polymerase (2.5 U/µl, Invitrogen). 2 
µl of genomic DNA template (7 ng/µl) was added to the relevant reaction. The cycling 
conditions on a MJ Tetrad PTC – 225 thermal cycler were 94°C for 2 minutes, then 25 
cycles of 94°C for 15 seconds, 55°C for 30 seconds, and 68°C for 1 minute. The PCR 
products were checked on a 1.5% TBE agarose gel and purified using a QIAquick gel 
extraction kit (Qiagen).  
 
The purified products were then cloned into the pCR-Blunt II-TOPO vector (Invitrogen) 
using the Zero Blunt® TOPO® PCR cloning kit (Invitrogen). To 4 µl of PCR product 1 
µl salt solution (1.2M NaCl, 0.06M MgCl2), and 1 µl of TOPO vector (10 ng/µl) were 
added; this reaction was left to incubate at room temperature for 5 minutes before being 
placed on ice. 2 µl of the cloning reaction was added into a vial of One Shot® 
chemically competent E.coli and mixed and incubated on ice for 10 minutes. The cells 
were then heat-shocked for 30 seconds at 42°C and transferred onto ice. 250 µl of room 
temperature S.O.C. medium (Invitrogen; cat#15544-034) added to each tube which 
were then capped and incubated for 1 hour at 37°C at 200 rpm in a shaking incubator. 
50 µl from each transformation was spread on a pre-warmed (50 μg/ml kanamycin) 
selective plate and incubated overnight at 37°C.  
 
Transformants were picked the following morning and transferred onto a numbered grid 
lined reference Luria Bertani agar (LB) plate and incubated 37°C for several hours. 
Selected colonies were grown up overnight in 3 ml of LB Broth (50 μg/ml kanamycin) 
in 15 polypropylene ml tubes at 37°C at 200 rpm in a shaking incubator. Plasmids from 
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the transformed colonies were purified using the QIAprep miniprep kit (Qiagen).  
Clones were verified against misincorporation and mis-orientation by sequence 
analysis. 
 
2.3.2.1 Subcloning of MMP8 gene promoter inserts into the pGL3-basic luciferase reporter vector. 
 
The MMP8 gene promoter inserts were directionally subcloned from the pCR-Blunt II-
TOPO vector into the pGL3-basic luciferase reporter vector (Promega) by restriction 
with restriction endonucleases KpnI and XhoI (New England Biolabs) and T4 DNA 
ligase (Roche). 1 μg of MMP8-pCR-Blunt II-TOPO was added to 10U of KpnI 
(10U/µl), 10U of XhoI (10U/µl), 3 µl 10X NEBuffer 1, 0.3 µl of BSA ( Bovine serum 
albumin, 10 mg/ml), H2O to make up to 30 µl and incubated for 3 hours at 37°C. The 
pGL3-basic vector was linearised using the same enzymes and conditions. Both digests 
were run and separated on a 1.5% gel by agarose gel electrophoresis, the relevant inserts 
and vector purified with the QIAquick gel extraction kit (Qiagen). Ligation was 
performed using a 1:3 molar ratio of vector DNA to insert DNA in 1X T4 DNA ligase 
buffer with 1 unit of T4 DNA ligase in a 10 µl reaction incubated at 4°C for 16 hours, 
halted at 65°C for 15 minutes. 2 µl of the ligation reactions were transformed in the 
same manner described above, with the exception that the LB selective plates contained 
100 μg/ml of ampicillin. Transformants were picked the following morning and 
transferred onto a numbered grid lined reference LB plate and incubated 37°C for 
several hours. Selected colonies were grown up overnight in 3 ml of LB Broth (100 
μg/ml ampicillin) in 15 polypropylene ml tubes at 37°C at 200 rpm in a shaking 
incubator. Plasmids from the transformed colonies were purified using the QIAprep 
miniprep kit (Qiagen). Plasmids were screened for correct sized inserts by digestion 
68 
 
with restriction endonucleases KpnI and XhoI. Colonies on the reference plate that had 
been shown to contain the correct sized insert were grown up in 50 ml of LB broth (100 
μg/ml ampicillin) in 250 ml conical flasks overnight at 37°C at 150 rpm in a shaking 
incubator. Plasmids were then purified using an EndoFree plasmid maxi kit (Qiagen). 
Clones were then checked for misincorporation by sequence analysis. 
 
2.3.3 Cloning of the murine VCAM-1 promoter 
 
The VCAM-1 promoter sequence (263bp) was amplified from genomic murine DNA 
with primers that also introduced restriction endonuclease recognition sites. The 
sequences were incorporated at the 5‟ ends of the forward and reverse primers with an 
additional 4 bases upstream of the respective restriction sequence to aid digestion of the 
amplicon creating the correct „sticky ends‟ for ligation into an appropriate vector. The 
forward primer complementary for the 5‟ end of the VCAM-1 promoter sequence 
introduced a Kpn1/Acc65I (shown in red) restriction site. The reverse primer introduced 
a BglII (shown in red) recognition site. The primer sequences are shown below. 
 
mVCAM1prom_Kpn1_F 5‟ GTTCGGTACCTCTTTTCAGGAGAGATAGCCCTTTC 3‟ 
mVCAM1prom_BglII_R 5‟ GTTGAGATCTGCCGGGCTGGTGTGAGTGA3‟  +2tss 
 
PCR products were checked for correct size (283 bp) on a gel, once the correct size was 
verified the products were co-digested with Acc65I and BglII (New England Biolabs) 
ligated with a similarly digested and linearised pGL3-Promoter (Promega) plasmid. 
Ligation, transformation and checking by sequencing analysis were performed as shown 
in section 2.3.2.1. 
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2.3.3.1 Ablation of NF-kB transcription site in murine VCAM-1 promoter 
 
The promoter sequence of human VCAM-1 has been shown to contain a functional NF-
kB element (185). This site is also found in murine VCAM-1, which shows a high 
degree of homology, with human VCAM-1, in both the gene and promoter sequences 
and the translated amino acid sequence (186). In order to ablate the NF-kB element 
within the murine VCAM-1 promoter in vitro mutagenesis was used, based upon the 
method demonstrated by Scott et al in 2002 (187). Complementary forward and reverse 
oligos were designed similar to those used to ablate the. NF-kB element in the human 
sequence by Neish et al in 1992 creating non-complementary transversion mutants, i.e. 
G changed to T, C changed to T and vice versa (185). Underlined nucleotides have been 
changed. 
 
VCAM1PROMMUT_F 5‟ CTGGGTTTCCCCTTGAATTTATTTAAATCCGCCTC 3‟ 
VCAM1PROMMUT_R 5‟ GAGGCGGATTTAAATAAATTCAAGGGGAAACCCAG 3‟  
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In a 50 μl reaction 75 ng of the plasmid template was added to 125 ng of each 
oligonucleotide along with 3.75U PfuTurbo™ DNA polymerase (Stratagene, La Jolla, 
CA, USA) and buffer, and 300 μM dNTPs. Cycling was performed on an MJ Tetrad 
under the following conditions: 
Step Temperature 
/Condition 
Time/Additional 
cycles 
01 95°C 2 min 
02 95°C 40 sec 
03 58°C 50 sec 
04 68°C 1.5  min/kb 
05 Goto step 02 X15 
06 End   
 
A 10 μl aliquot from the mutagenesis PCR is run on a 1% Agarose gel to check size of 
the amplicon. The correct sized amplicon was digested for 3 hours at 37°C with 30U of 
the restriction enzyme DpnI. DpnI will only cleave methylated or hemimethylated DNA 
at the sequence G
m6
ATC. Template/Parental DNA isolated from most strains of E.coli is 
Dam methylated (188). This step removed the non-mutated template DNA and 
increased the efficiency of mutagenesis. The clean up used the Promega SV kit, 
followed by transformation into xl-gold, and verification by sequencing. 
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2.3.4 Cell culture  
 
All cell culture was performed in a class II microbiological safety cabinet. The table 
below lists the cells lines used, a description of the cell line, source of the cells, and the 
gene promoters investigated. 
 
Table 2.5. Cell lines used in this study 
 
 
The propagation, media and culture conditions for each of the above cancer cell lines 
were as follows: 
 
A2058 – melanoma cell line 
A2058 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
containing 4.5 g/l glucose and 1.5 g/l sodium bicarbonate, supplemented with 4 
mmol/l of L-glutamine, 10% heat-inactivated foetal bovine serum, 100 µg/ml of 
streptomycin and 100 units/ml of penicillin; the cells were incubated at 37°C in 
5% CO2. 
Cell Line Description Source Gene promoter 
investigated 
A2058 Human Caucasian metastatic melanoma ECACC* MMP1/MMP8 
A375 Human malignant melanoma ECACC* MMP1 
MCF7 Human Caucasian breast adenocarcinoma ECACC* MMP1 
MDA-MB-231 Human Caucasian breast adenocarcinoma ECACC* MMP1/MMP8 
A549 Human Caucasian lung carcinoma ECACC* MMP1 
H69 Human Caucasian lung small cell carcinoma ECACC* MMP1 
HT-29 Human Caucasian colon adenocarcinoma Dr Simon Joel**
 MMP1 
SW-620 Human Caucasian colon adenocarcinoma Dr Simon Joel**
 MMP1 
C166 Mouse endothelial cell line ATCC*** VCAM-1 
bEnd.3 Mouse endothelial cell line ATCC*** VCAM-1 
* European Collection of Cell Cultures 
** Kindly donated by Dr Simon Joel, Institute of Cancer, Barts and The London School 
of Medicine, London, United Kingdom. 
***  American Type Culture Collection 
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A375 – melanoma cell line 
A375 cells were cultured in DMEM containing 4.5 g/l glucose and 1.5 g/l 
sodium bicarbonate, supplemented with 4 mmol/l of L-glutamine, 10% heat-
inactivated foetal bovine serum, 100 µg/ml of streptomycin and 100 units/ml of 
penicillin; the cells were incubated at 37°C in 5% CO2. 
MCF7 – breast cancer cell line 
MCF7 cells were cultured in Eagle‟s minimal essential medium (EMEM) with 
Earle‟s balanced salt solution supplemented with 2 mmol/l of L-glutamine, 1.0 
mmol/l of sodium pyruvate, 0.1 mmol/l of nonessential amino acids, 10% heat-
inactivated foetal bovine serum, 100 µg/ml of streptomycin and 100 units/ml of 
penicillin; the cells were incubated at 37°C in 5% CO2. 
MDA-MB-231 – breast cancer cell line 
MDA-MB-231 cells were cultured in Leibovitz‟s L15 medium supplemented 
with 2 mmol/l of L-glutamine, 1.0 mmol/l of sodium pyruvate, 0.1 mmol/L of 
nonessential amino acids, 10% heat-inactivated foetal bovine serum, 100 µg/ml 
of streptomycin and 100 units/ml of penicillin; the cells were incubated at 37°C 
in 100% air. 
A549 – lung cancer cell line 
A549 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
containing 4.5 g/l glucose and 1.5 g/l sodium bicarbonate, supplemented with 4 
mmol/l of L-glutamine, 10% heat-inactivated foetal bovine serum, 100 µg/ml of 
streptomycin and 100 units/ml of penicillin; the cells were incubated at 37°C in 
5% CO2. 
H69 – lung cancer cell line 
H69 cells were cultured in RPMI 1640 with 2 mmol/l of L-glutamine adjusted to 
contain 1.5 g/l of sodium bicarbonate, 4.5 g/l of glucose, 10 mmol/l of HEPES, 
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1.0 mmol/l of sodium pyruvate, 10% foetal bovine serum, 100 µg/ml of 
streptomycin and 100 units/ml of penicillin; the cells were incubated at 37°C in 
5% CO2. 
HT-29 – colorectal cancer cell line 
HT-29 cells were cultured in RPMI 1640 with 2 mmol/l of L-glutamine adjusted 
to contain 1.5 g/l of sodium bicarbonate, 4.5 g/l of glucose, 10 mmol/l of 
HEPES, 1.0 mmol/l of sodium pyruvate, 10% foetal bovine serum, 100 µg/ml of 
streptomycin and 100 units/ml of penicillin; the cells were incubated at 37°C in 
5% CO2. 
SW-620 – colorectal cell line 
SW-620 cells were cultured in DMEM containing 4.5 g/l glucose and 1.5 g/l 
sodium bicarbonate, supplemented with 4 mmol/l of L-glutamine, 10% heat-
inactivated foetal bovine serum, 100 µg/ml of streptomycin and 100 units/ml of 
penicillin; the cells were incubated at 37°C in 5% CO2. 
 
C166 – mouse endothelial cell line 
C166 cells were cultured in DMEM containing 4.5 g/l glucose and 1.5 g/l 
sodium bicarbonate, supplemented with 4 mmol/l of L-glutamine, 10% heat-
inactivated foetal bovine serum, 100 µg/ml of streptomycin and 100 units/ml of 
penicillin; the cells were incubated at 37°C in 5% CO2. 
 
bEnd.3 – mouse endothelial cell line 
bEnd.3 cells (189) were cultured in DMEM containing 4.5 g/l glucose and 1.5 
g/l sodium bicarbonate, supplemented with 4 mmol/l of L-glutamine, 10% heat-
inactivated foetal bovine serum, 100 µg/ml of streptomycin and 100 units/ml of 
penicillin; the cells were incubated at 37°C in 5% CO2. 
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2.3.4.1 Procedure for passage of adherent cell lines 
 
Cells were passaged on reaching 70-80% confluency. The culture medium was removed 
from over the attached monolayer using a sterile serological pipette, and discarded into 
1% Virkon (DuPont) solution. The monolayer was then washed with 1 to 2 ml of 
trypsin-EDTA; the wash solution discarded into 1% Virkon. 3 ml of the trypsin-EDTA 
solution was added to the flask and which was placed back into an incubator at 37ºC for 
approximately 5 minutes. Progress of the detachment can be checked with an inverted 
phase contrast microscope. While the cells were detaching 10 ml of pre-warmed fresh 
medium was added to the required number of new T75 flasks. Once the cells were 
detached 6 ml of fresh medium was added to the flask containing the cell and trypsin-
EDTA solution, to inactivate the trypsin-EDTA. 3ml of the medium containing the cells 
was then added to the requisite flasks, achieving a 1:3 split ratio, the flask sealed and 
placed into the 37°C incubator. Alternatively after cells were detached, 3 ml of fresh 
medium was added a 0.5 ml aliquot of the cell suspension taken and added to the 
automated Vi-CELL XR cell viability and cell counter (Beckman Coulter). The cell 
viability and density values obtained were used to dilute (with fresh medium) the cell 
suspension to the required seeding density for seeding in T75 tissue culture flasks, 6 
well tissue culture plates or 24 well tissue culture plates as required. 
 
2.3.5 Transient transfection to investigate the effects of MMP1 promoter 
haplotypes in cancer cells 
 
Transfection, in this case is the introduction of foreign DNA into human or animal cells. 
In transient transfection, the foreign DNA does not enter the host cell‟s genome and is 
therefore lost during subsequent cell division and mitosis. Each of the cell lines (A2058, 
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A375, MCF7, MDA-MB-231, A549, H69, HT-29, and SW-620) were transiently 
transfected with each of the haplotype reporter constructs described above, an empty 
pGL3-basic vector, and the pGL3-control vector; the pGL3-control vector contains the 
SV40 promoter upstream of the luciferase gene which induces high expression of the 
luciferase in mammalian cells. In all experiments the pRL-TK plasmid was co-
transfected, a vector which expresses renilla luciferase, to serve as an internal reference 
for transfection efficiency. Cell lines A2058, A375, MCF7, A549, HT-29, and SW-620 
were transfected using the Fugene 6 (Roche) transfection reagent. Cell lines MDA-MB-
231 and H9 proving to have poor transfection efficiency with Fugene 6 were transfected 
with Effectene (Qiagen). 
2.3.5.1 Transient transfection with Fugene 6 transfection reagent 
 
The Fugene 6 transfection reagent is what is known as a “cationic amphiphile” due to its 
ability to coat DNA with positively charged lipid micelles (190), this fugene/DNA 
complex has the ability to disrupt and pass through eukaryotic cell membranes, thereby 
delivering the DNA into cells and achieving transfection (191). The procedure used 
with the Fugene 6 transfection reagent, adapted from the official protocol, is as follows: 
 
Working stock DNA was made to a concentration of 50ng/µl containing 19 parts 
luciferase reporter construct (pGL3-MMP1_promoter_haplotype or pGL3-basic or 
pGL3-control) to 1 part renilla luciferase vector (pRL-TK). The optimal renilla/vector 
ratio, (20:1) ratio, Fugene 6/DNA ratio, and cell seeding densities were derived 
experimentally.  
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On the day prior to the transfection experiment cells were seeded in 0.5ml of media per 
well in a 24 well plate at the required cell density 6.0 x 10
5
 cells/ml. The following day 
cell confluency was checked using a phase contrast microscope; transfection 
experiments were only performed in wells averaging 70-80% confluency. For 
transfection of the cancer cell lines a 4:1 (Fugene 6(µl):DNA(µg)) transfection mix ratio 
was used i.e. 0.8 µl transfection reagent and 200 ng of DNA. To make up the 
transfection mix 15.2 µl of room temperature serum-free media was added to a sterile 
1.5 ml tube, 0.8 µl of Fugene 6 was added directly into the media without touching the 
sides of the tube followed by 4 µl of DNA (50 ng/µl); for transfecting more than 1 well 
the above amounts are multiplied accordingly (n +1). The tube containing the 
transfection mix was tapped gently, to mix, and incubated at room temperature for 15 
minutes. After the incubation 20 µl was added dropwise to each well, swirling to allow 
even distribution. The plate was then returned to the 37°C incubator. 
 
2.3.5.2 Transient transfection with Effectene transfection reagent 
 
Effectene is a non-liposomal lipid transfection reagent; details of its DNA delivery 
mechanism are commercially sensitive and not publicly available, although as a cationic 
lipid (192) it may function in a similar manner to Fugene6. The procedure used with the 
Effectene transfection reagent, adapted from the official protocol, is as follows: 
 
Working stock DNA was made to a concentration of 50 ng/µl containing 19 parts 
luciferase reporter construct (pGL3-MMP1_promoter_haplotype or pGL3-basic or 
pGL3-control) to 1 part renilla luciferase vector (pRL-TK). 
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On the day prior to the transfection experiment cells were seeded in 0.5ml of media per 
well in a 24 well plate at the required cell density 6.0 x 10
5
 cells/ml. The following day 
cell confluency was checked using a phase contrast microscope; transfection 
experiments were only performed in wells averaging 70-80% confluency. To make up 
the transfection mix 54.4 µl of room temperature Buffer EC was added to a sterile 1.5 
ml tube. 200 ng of DNA was then added to the tube, followed by 1.6 µl of Enhancer; the 
mixture was then vortexed and incubated at room temperature for 3 minutes. 5 µl of 
Effectene transfection reagent was then added and the contents of the tube mixed by 
pipetting up and down 5 times. The DNA-transfection complex was then incubated at 
room temperature for a further 10 minutes. During the incubation period the medium in 
the wells was aspirated, the cells were washed twice with 1 ml sterile PBS, and 0.5 ml 
fresh (pre-warmed) medium was added to each well. 350 µl of medium was then added 
to the DNA-transfection complex, and pipetted up and down twice. 415 µl of the 
transfection mix was added dropwise to each well, while swirling to allow even 
distribution. The plate was then returned to the 37°C incubator. 
 
2.3.6 Transient transfection for the purpose of investigating the effects of 
MMP8 promoter SNPs in the MDA-MB-231 and A2058 cancer lines 
 
Transient transfection used to investigate the MMP8 promoter was as that used for 
investigating MMP1 promoter haplotypes, with the substitution of the MMP8 promoter 
luciferase reporter constructs for the MMP1 haplotype promoter luciferase reporter 
constructs. MDA-MB-231 cells were transfected using Effectene and A2058 cells were 
transfected using Fugene 6. 
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2.3.7 Transient transfection used to measure the effect of the cleavage 
products of angiotensin I by MMP8 on VCAM-1 promoter activity 
 
Transient transfection of C166 and bEnd.3 cells was used to measure the effect of the 
cleavage products of angiotensin I by MMP8 on VCAM-1 promoter activity. The 
transfection reagent in both cases was Fugene 6. The transfection mix ratio 3:2 (Fugene 
6(µl):DNA(µg)) was found to be optimal for both cell lines; Plasmid amounts were 
optimised at 400 ng of the vector (either pGL3-VCAM-1, or pGL3-VCAM-1_Mut or 
pGL3-basic or pGL3-control) to 10 ng renilla luciferase vector (pRL-TK)). All other 
parameters were as in section 2.3.5.1. 
 
2.3.7.1 Treatment of cells transfected with the VCAM-1 promoter 
 
All treatments were carried out 18 hours post transfection and 6 hours pre-lysis. The 
medium in the wells was aspirated, the cells were washed twice with 1 ml sterile PBS, 
and 0.5 ml fresh (pre-warmed) medium was added to each well. The treatments 
(angiotensin I, MMP8, MMP8 and angiotensin I, or no treatment) were prepared as in 
section 2.4.1, with the relevant components added or removed. 500 µl of medium 
(containing the respective treatments) was added dropwise to each well, while swirling 
to allow even distribution. The plate was then returned to the 37°C incubator. The 
concentrations of MMP8 and angiotensin I were 52 ng/ml and 130 ng/ml respectively. 
 
2.3.8 Dual-luciferase assay 
 
The Dual-luciferase assay (Promega), used in conjunction with pGL3 luciferase vectors 
(Promega) relies on the expression and measurement of 2 distinct luciferases, firefly 
luciferase (Photinus pyralis) and sea pansy luciferase (Renilla reniformis). The firefly 
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luciferase serves as a readily detectable surrogate for the genes under the control of the 
promoters being tested by this method. 
 
Kit components: 
 
Luciferase Assay Buffer II 
Luciferase Assay Substrate (Lyophilized Product) 
Stop & Glo® Buffer 
Stop & Glo® Substrate (50X) 
Passive Lysis Buffer (5X) 
 
In each experiment, all samples and controls were in triplicate (3 wells each).Dual-
luciferase assays were performed 18 hours post transfection. 100 µl luciferase assay 
reagent II (LARII) was dispensed into the required amount of clear 1.5 ml tubes. 
Medium was aspirated from transfected cells. The cells were washed twice in with 1 ml 
PBS and 100 µl 1X passive lysis buffer added. The plate was then placed on an orbital 
shaker, at 50 rpm for 15 minutes at room temperature. 20 µl of the cell lysate was then 
transferred into one of the 1.5 ml tubes containing the pre-dispensed LARII and mixed 
by pipetting. The tube was then placed into the Glomax luminometer (Turner 
BioSystems) and a 10 second measurement of the firefly luciferase activity taken. On 
prompting by the luminometer 100 µl of 1X Stop & Glo reagent was added and mixed, 
followed by a 10 second measurement of renilla luciferase activity. MMP1 promoter 
activity was measured as the ratio of firefly luciferase activity of MMP1 promoter 
construct versus renilla luciferase activity, divided by the ratio of firefly luciferase 
activity of pGL3-control plasmid versus renilla luciferase activity. 
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2.3.9 Statistical analysis of MMP1 promoter haplotype luciferase assays 
 
Statistical analysis of MMP1 promoter haplotype luciferase assays was carried out by 
colleagues using a 2 tailed T-test to obtain p-values (193).  
 
2.3.10 Statistical analysis of MMP8 promoter luciferase assays 
 
MMP8 promoter SNP rs11225395 luciferase data p-values were obtained using a 2-
tailed t-test. 
 
2.3.11 Statistical analysis of VCAM-1 promoter luciferase assays 
 
VCAM-1 promoter luciferase data pairwise p-values were obtained using a 2-tailed t-
test. Analysis of Variance (ANOVA) was used to determine 2-tailed p values for any 
difference in treatments overall. 
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2.4 Biochemical investigations of the role of MMP8 in atherosclerosis 
 
2.4.1 Angiotensin I cleavage by MMP8 
 
To confirm the reported ability of MMP8 to cleave angiotensin I (Ang I) into 
angiotensin II (Ang II);  Ang I cleavage by MMP8 was performed following the 
protocol of the reporting study (194). Ang I (Phoenix Pharmaceuticals) was incubated in 
TCNB (50 mmol/l Tris, 10mmol/l CaCl2, 150 mmol/l NaCl, 0.05% Brij 35 (Sigma), pH 
7.5) with human neutrophil purified MMP8 (Biomol International, SE-492) in the 
presence of 0.5mmol/l 4-aminophenylmercuric acetate (APMA) to activate proMMP8. 
The incubation was at 37°C for 20 hours at a substrate concentration of 25 µmol/l and 
an enzyme substrate ratio of 1:100; an uncleaved control was prepared by incubating 
angiotensin I in TCNB at 37°C for 20 hours without MMP8. 
 
2.4.1.1 Analysis of cleavage products of Ang I by MMP8 via LC-MS/MS 
 
Colleagues analysed the cleavage products and controls described above via liquid 
chromatography-electrospray tandem mass spectrometry (LC-MS/MS). The mass 
spectral data were processed into peak lists and searched against the Swiss Prot 
database. The relative intensity of the angiotensin peptides was calculated using the 
total ion count of each peptide.  
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2.4.2 Biochemical and animal investigations of the role of MMP8 in 
atherosclerosis  
 
2.4.2.1 Animals 
 
All experiments were conducted according to the Animals (Scientific Procedures) Act 
of 1986 (United Kingdom). MMP8/ApoE double knockout mice (MMP8-/-ApoE-/-) 
and littermate controls (MMP8+/+ApoE-/-) were generated by crossing MMP8 
knockout mice (122) with ApoE knockout mice (195, 196). Initially MMP8-/-apoE+/+ 
mice with a C57BL/6 background, (Jackson Laboratory, stock number 005514, strain 
name B6;129X1-Mmp8tm1Lotn/J) were crossed with MMP8+/+apoE-/- mice also of a 
C57BL/6 background (Jackson Laboratory, stock number 002052, strain name 
B6.129P2-Apoetm1Unc/J) to generate MMP8+/-/apoE+/- double heterozygous mice. 
The double heterozygous mice were bred to produce MMP8-/-/apoE-/- double knockout 
mice and MMP8+/+/apoE-/- littermate controls; the breeding was performed by the 
Jackson Laboratory (Bar Harbor, USA). From the age of 6 weeks male mice from the 
double knockout group and the MMP8 wild type littermate controls were fed a high fat, 
Western diet (Research Diet, D12108, containing 21% fat, 1.25% cholesterol and 0% 
cholate) for a total of 12 weeks. 
2.4.2.2 Quantification of plasma angiotensin I with a competitive enzyme immunoassay kit (Phoenix 
Pharmaceuticals, EK-002-01) 
 
Kit Components 
1. 20x assay buffer concentrate (50ml). 
2. 96 well immunoplate (1 plate). 
3. Acetate plate sealer (APS), (3 pieces). 
4. Primary antiserum (rabbit anti-peptide IgG) (1 vial). 
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5. Peptide standard (Ang I) (1 vial). 
6. Biotinylated peptide (1 vial). 
7. Streptavidin-horseradish peroxidase (SA-HRP) (30µl).  
8. Positive control (2 vials). 
9. Substrate solution (TMB) (12ml). 
10. 2N HCl (15ml). 
 
All kit components were allowed to come to room temperature for 30 minutes before 
starting. The 20x assay buffer was diluted in 950 ml of deionised H2O to make 1x assay 
buffer solution. The standard peptide (1 mg Ang I) was diluted with 1 ml of 1x buffer 
solution and left for 10 minutes at room temperature to make a 1000 ng/ml stock 
standard peptide solution. Standards were made by serially diluting this solution as 
follows (table 2.6). 
Table 2.6 Ang I standard dilution series. 
Standard No. Std. volume 1x Assay buffer Concentration 
(ng/ml) 
Stock 1000 µl ---- 1000 ng/ml 
#1 25 µl 975 µl 25 ng/ml 
#2 200 µl of #1 800 µl 5 ng/ml 
#3 200 µl of #2 800 µl 1 ng/ml 
#4 200 µl of #3 800 µl 0.2 ng/ml 
#5 200 µl of #4 800 µl 0.04 ng/ml 
 
Both the primary antibody and the biotinylated peptide were each separately dissolved 
in 5 ml of 1x assay buffer and incubated at room temperature for 5 minutes. The 
positive control was rehydrated with 200 µl of 1x assay buffer and incubated at room 
temperature for 5 minutes. 2 wells of the immuno-plate were left empty as blank, 50 µl 
1x assay buffer was added of a further two wells to provide a total binding reference. 50 
µl of all standards, positive controls and prepared samples (at desired dilution) were 
added to the appropriate wells in duplicate. 25 µl of primary antibody was added to all 
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wells except the blank wells. 25 µl of biotinylated peptide was added to all wells except 
the blank wells, the plate sealed with the provided APS and incubated at room 
temperature for 2 hours at 400 rpm on an orbital shaker. 12 µl of SA-HRP was added to 
12 ml of 1x assay buffer to make the SA-HRP solution. Each well was washed 4 times 
with 350 µl 1x assay buffer. 100 µl of SA-HRP solution was added to each well, the 
plate resealed and incubated at room temperature for 1 hour at 400 rpm on an orbital 
shaker. After incubation the plate was washed a further 4 times as above and 100 µl of 
TMB substrate solution added to each well and the plate sealed. Incubation with the 
TMB solution was 1 hour at room temperature in the dark. After 1 hour 100 µl of 2N 
HCl was added to each well and the absorbance read at 450 nm within 20 minutes. 
Values were calculated by plotting a standard curve on semi-log graph paper. Known 
concentrations of the standard were plotted on the log scale (X axis) versus O.D. 
reading on the linear scale (Y axis). Sample concentration was determined via 
interpolation of its O.D. As the assay is a competitive immunoassay relying on the 
displacement of biotinylated peptide by angiotensin I, the standard curve is of reverse 
sigmoidal shape, the lower angiotensin I concentration giving a higher intensity 
absorbance and the higher angiotensin I concentration giving low absorbance values.  
 
2.4.2.3 Quantification of plasma angiotensin II with a competitive enzyme immunoassay kit 
(Phoenix Pharmaceuticals, EK-002-012) 
 
The quantification of angiotensin II was identical in protocol to that of angiotensin I 
with the relevant components being substituted, such as the peptide standard (1 mg Ang 
II), the biotinylated peptide, the positive control and the primary antibody. 
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2.4.2.4 Analysis of other angiotensin forming enzymes 
 
Tissue samples were prepared using a method adapted from a previous study (197). 
Aortas from MMP8+/+ApoE-/- or MMP8-/-ApoE-/- mice were cut into small pieces 
and immediately placed into ice cold 20 mM Na-phosphate buffer pH 7.4 in Precellys 
CK14 bead tubes, and lysed at 4°C at 2X 6500 rpm for 15 seconds in a Precellys24 
homogeniser. The lysate from each aorta was transferred into a microfuge tube and 
centrifuged at 25,000g for 30 minutes at 4°C. The pellet was resuspended in 10 mM Na-
phosphate buffer pH 7.4, containing 2 M KCl and 0.01% Nonidet P-40. The suspension 
was divided into 2 microfuge tubes and centrifuged at 25000g for 30 minutes at 4°C. 
The pellet from one tube was resuspended in 150 µl 10 mM Na-phosphate buffer pH 
7.4, containing 2 M KCl and 0.01% Nonidet P-40. After storage at 4°C for 18 hours this 
suspension was subjected to analyses of chymase and cathepsin activity. The pellet from 
the other tube was resuspended in 150 µl 10 mM Na-phosphate buffer pH 7.4, 
containing 2 M KCl and 0.6% Nonidet P-40, and after storage at 4°C for 18 hours 
centrifuged again as above; the resulting supernatant was used in the ACE activity 
assay. The protein content of both the ACE sample preparation and the 
chymase/cathepsin sample preparation was ascertained via the Bradford method (198). 
 
2.4.2.5 Quantification of protein in chymase/cathepsin sample preparations via the Bradford 
method  
 
Reagents and materials 
 
Dye Reagent Concentrate (Biorad, 500-006) 
Optical microplate (96 well) 
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Quantification of protein in chymase/cathepsin sample preparations was via the 
Bradford method (198). Working dye reagent was prepared by diluting 1 part Dye 
Reagent Concentrate with 4 parts deionised water. This solution was then filtered to 
remove particulates. A set of bovine serum albumin (BSA; Sigma) standards (0.2 – 1.0 
mg/ml) was prepared using 10 mM Na-phosphate buffer pH 7.4, containing 2 M KCl 
and 0.01% Nonidet P-40. 10 µl of each standard and sample solution were pipetted into 
separate microtiter plate wells, in duplicate. 200 µl of diluted dye reagent was added 
into each well; the samples were then mixed thoroughly using an orbital shaker. After 5 
minutes incubation at room temperature absorbance values were read at 595 nm on a 
spectrophotometer (Dynex MRX Revelation).  Sample protein concentrations were 
calculated from the standard curve in Microsoft Excel: 
 
2.4.2.6 Quantification of protein in ACE sample preparations via the Bradford method 
 
This was as that of the chymase/cathepsin protein quantification with some changes. 
BSA standards were made up in 10 mM Na-phosphate buffer pH 7.4, containing 2 M 
KCl and 0.1% Nonidet P-40. Prior to analysis ACE sample preparations were diluted 1 
in 6 in 10 mM Na-phosphate buffer pH 7.4, containing 2 M KCl; this dilution was to 
prevent the relatively high Nonidet P-40 concentration of the above samples (0.6%) 
from interfering with the assay. Post analysis the protein values obtained were 
multiplied by 6 to account for the dilution factor. 
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2.4.2.7 Determination of ACE activity 
 
ACE activity was determined with the use of fluorogenic peptide substrate V (Mca-Arg-
Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH; R&D Systems). Using a final sample 
volume of 100 µl to measure ACE activity, 10 µl of Mus aorta extract sample was 
added to assay buffer that contained 50 mM 2-(N-morpholino)ethanesulfonic acid 
(MES, pH 6.5; Sigma) and chymostatin (Chymase Assay Kit #CS1140, Sigma) with or 
without the ACE inhibitor captopril (100 µM); chymostatin was used to exclude 
chymase and/or cathepsin activity from the assay. The reaction was started by the 
addition of 2.5 µl of the fluorogenic substrate (10 µM, final concentration). The reaction 
mixture was incubated on a Wallac Victor II spectrofluorometer at 37°C for 90. 
Fluorescence was measured at an excitation wavelength of 340 nm and emission 
wavelength of 400 nm. The assays for each sample were performed in duplicate. For 
each sample, ACE activity was calculated by subtracting the fluorescence reading in the 
assay with captopril from the fluorescence reading in the assay without captopril, and 
standardised against the protein concentration in the sample. 
 
2.4.2.8 Determination of chymase/cathepsin activity 
 
Chymase/cathepsin activity was determined with the use of the colorimetric substrate 
(N-Succinyl-Ala-Ala-Pro-Phe p-nitroanilide, Chymase Assay Kit, Sigma). Using a final 
sample volume of 100 µl to measure chymase/cathepsin activity, 10 µl of Mus aorta 
extract sample was added to assay buffer (A9606, Sigma) and captopril (100 µM) with 
or without the chymase/cathepsin inhibitor chymostatin (Chymase Assay Kit #CS1140, 
Sigma); captopril was used to exclude ACE activity from the assay. The reaction 
mixture was incubated at 37°C for 30min, and absorbance at 405nm was measured 
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using a spectrophotometer (Dynex MRX Revelation). The assays for each sample were 
carried out in duplicate. For each sample, enzymatic activity was calculated by 
subtracting the absorbance reading in the assay with chymostatin from the absorbance 
reading in the assay without chymostatin, and standardised against the protein 
concentration in sample 
 
2.4.2.9 Quantification of Substance P with a competitive enzyme immunoassay kit 
(Substance P Correlate™ EIA Kit, 900-018) 
 
Kit components: 
1. 96 well goat anti-rabbit IgG microtiter plate (1 Plate) 
2. Substance P EIA alkaline phosphatase conjugate (6 ml; blue) 
3. Substance P EIA antibody (6 ml; yellow) 
4. Assay Buffer (30 ml) 
5. Wash buffer concentrate (30 ml)  
6. Substance P standard (100000 pg/ml, 0.5 ml) 
7. p-nitrophenyl phosphate (p-Npp), substrate (20 ml) 
8. Stop solution, (5 ml) 
9. Substance P assay layout sheet (1) 
10. Acetate plate seal (1) 
 
All kit components were allowed to come to room temperature for 30 minutes before 
starting. Standards (viable for 1 hour after preparation) were made up in the following 
manner: The 100,000 pg/mL substance P standard solution (room temperature) was 
diluted in 6 individual 1.5 ml microtubes. Volumes are detailed in table X; tubes were 
capped and vortexed thoroughly in between dilutions. 
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Table 2.7 Substance P standard dilution series 
Standard No. Std. volume 1x Assay buffer Concentration (ng/ml) 
Standard solution   100000 pg/ml 
#1 100 µl of standard 900 µl 10000 pg/ml 
#2 250 µl of #1 750 µl 2500 pg/ml 
#3 250 µl of #2 750 µl 625 pg/ml 
#4 250 µl of #3 750 µl 156.25 pg/ml 
#5 250 µl of #4 750 µl 39.06 pg/ml 
#6 250 µl of #5 750 µl 9.76 pg/ml 
 
Wash buffer was prepared by adding 5 ml of wash buffer concentrate to 95 ml of 
deionised water. Assays were carried out as per manufacturer‟s instructions. 
 
All wells were in duplicate. 50 μl of assay buffer was pipetted into the NSB (non-
specific binding) and the B0 (0 pg/ml standard) wells. 50 μl of the diluted standards (#1 
- #6) were pipetted into the appropriate wells. 50 µl of prepared samples were added to 
the appropriate wells. A further 50 µl of assay buffer was added to the NSB wells. 50 µl 
of blue conjugate was added to all wells except total activity (TA) and blank wells 
(blank and TA wells had not had anything added at this point). 50 μl of yellow antibody 
was added to all wells, except the blank, TA and NSB wells; the plate sealed with the 
provided APS and incubated at room temperature for 2 hours at 400 rpm on an orbital 
shaker. Each well was washed 3 times with 400 µl of wash buffer; after washing each 
well was aspirated and the plate tapped firmly upside-down to remove residual wash 
buffer. 5 μl of the blue conjugate was added to the TA wells. 200 µl of the p-Npp 
substrate solution was added to every well and the plate incubated at room temperature 
for 1 hour without shaking. After 1 hour 50 µl of stop solution was added to all wells. 
The optical density (OD) was then read on a spectrophotometer (Dynex MRX 
Revelation) at 405nm, correcting at 570nm, also subtracting the blank wells.  
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The average net OD for each sample and standard was calculated by subtracting the 
average NSB OD from each. The binding for each of the standards (as a percentage) 
was calculated using the following formula:  
Percentage binding =  
                
       
     
A standard curve (as an approximate straight line between points) was then drawn on 
Logit-Log paper plotting percentage bound against the known concentration of the 
standards. Sample values were determined by interpolation. 
 
2.4.2.9.1 Extraction of substance P from Mus mesentery 
 
Required items: 
CK14 bead tubes (Precellys)  
C18 SEP-COLUMN (Phoenix Pharmaceuticals)  
Precellys24 homogeniser (Precellys) 
Savant SpeedVac system (Thermo Scientific) 
Elution Solvents: 
 Buffer A: 1% trifluoroacetic acid (TFA) (HPLC grade, Sigma) in H2O. 
 Buffer B: 60% acetonitrile (HPLC grade; Sigma) in 1% TFA. 
Buffers: 
 20 mM Na-phosphate buffer pH 7.4 
 1X assay buffer from (Substance P Correlate™ EIA Kit, 900-018) 
 
Samples of Mus mesentery were cut into small pieces and immediately placed into ice 
cold 20 mM Na-phosphate buffer pH 7.4 (10 volumes w/v, at least 300 µl in CK14 bead 
tubes; Precellys). The samples were lysed at 4°C in a Precellys24 homogeniser (2x 6500 
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rpm for 15 seconds). The CK14 tube contents (minus the ceramic beads) were 
transferred to 1.5 ml microfuge tubes and centrifuged at 16400 rpm (25000g) for 30 
minutes at 4°C. For each sample a SEP-COLUMN was equilibrated by washing with 
buffer B (1ml, once) followed by buffer A (3 ml, 3 times). The sample supernatant was 
acidified by mixing 1:1 with 1% trifluoroacetic acid in H2O and loaded onto the pre-
treated column. Once the sample was bound to the column matrix, the column was 
washed slowly with buffer A (3 ml, twice) and the wash discarded. The peptide was 
eluted slowly with buffer B (3 ml, once) into a polypropylene tube and then divided into 
4x 1.5 ml microtubes. The eluant was evaporated to dryness by SpeedVac.  
 
Samples were reconstituted with 1x assay buffer (from Correlate™ EIA Kit) before 
quantification. Protein concentration for sample normalisation was performed using the 
Bradford method (198) 
 
2.4.2.10 Quantification of protein substance P mesentery sample preparations via the Bradford 
method  
 
This was the same as section 2.4.2.5 with the substitution of 1x assay buffer for the 10 
mM Na-phosphate buffer pH 7.4, containing 2 M KCl and 0.01% Nonidet P-40. 
2.4.2.9 Measurement of the extent of atherosclerosis 
 
The characterisation of atherosclerotic lesions was performed by colleagues. The extent 
of atherosclerotic lesions was analysed in both the double knockout (n = 10) group and 
the controls (n = 10) by en face staining with oil red of aortas (199).  
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2.4.2.10 Measurement of plasma cholesterol 
 
The plasma cholesterol concentrations of the double knockout group and the controls 
were compared using a Cholesterol/Cholesteryl Ester Quantitation Kit (Calbiochem, 
428901). The principal of this assay is as follows; enzymes provided in the kit, 
cholesterol esterase and cholesterol oxidase, react with the different forms of cholesterol 
in the sample forming hydrogen peroxide (H2O2) as a by-product.  Hydrogen peroxide 
then reacts with the cholesterol probe to form a substance that can be detected at 570 
nm.  
 
Kit components 
 
• Cholesterol Reaction Buffer (1 bottle, 25 ml).  
• Cholesterol Probe (1 vial, lyophilised).  
• Dimethylsulfoxide (400 µl DMSO).  
• Enzyme Mix (1 vial, lyophilised).  
• Cholesterol Esterase (1 vial, lyophilised).  
• Cholesterol Standard (1 vial, 100 µl, supplied at 5 µg/µl). 
All kit components were allowed to come to room temperature for 20 minutes before 
starting. The cholesterol probe was prepared by dissolving it in 220 µl DMSO. The 
cholesterol esterase was reconstituted by the addition of 220 µl cholesterol reaction 
buffer. The enzyme mix was reconstituted by the addition of 220 µl cholesterol reaction 
buffer. The cholesterol standard was diluted with 180 µl cholesterol reaction buffer to 
produce a stock solution of 0.5 µg/µl and allowed to sit at room temperature for 5 
minutes. A set of standard duplicates were made up in wells (table 2.7). 
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Table 2.8. Cholesterol standard dilution series 
Volume of 0.5 µg/µl 
diluted cholesterol 
standard 
Cholesterol 
reaction buffer 
Final amount of 
cholesterol per well 
0 µl 50 µl 0 µg 
4 µl 46 µl 2 µg 
8 µl 42 µl 4 µg 
12 µl 38 µl 6 µg 
16 µl 34 µl 8 µg 
20 µl 30 µl 10 µg 
 
Enough reaction mix was prepared for the required amount of wells; in a single well the 
constituents of the added reaction mix were: 
 
44 µl Cholesterol Reaction Buffer  
2 µl Cholesterol Probe  
2 µl Enzyme Mix  
2 µl Cholesterol Esterase 
 
2 µl of each sample were made up to 50 µl addition of 48 µl cholesterol reaction buffer. 
50 µl of the reaction mix was added to each well followed by incubation for 1 hour at 
37°C away from the light. Absorbances were read on a microplate reader at 570 nm. 
The no cholesterol control value was subtracted from all samples. Samples were 
calculated from the standard curve.  
 
2.4.2.11 Measurement of plasma triglyceride 
 
The plasma triglyceride concentrations of the double knockout group and the controls 
were compared using a Serum Triglyceride Determination Kit (Sigma, TR0100). 
Triglycerides within the sample are hydrolysed to glycerol. Glycerol is then 
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phosphorylated by glycerol kinase to form glycerol-1-phosphate. Glycerol-1-phosphate 
is then oxidised by glycerol phosphate oxidase to dihydroxyacetone phosphate and 
hydrogen peroxide. Hydrogen peroxide is then coupled with 4-aminoantipyrine and 
sodium N-ethyl-N-(3-sulfopropyl) m-anisidine by peroxidase to produce a quinone-
imine dye. The amount quinone-imine dye, detectable at 540 nm, is directly 
proportional to the triglyceride concentration in the sample.   
 
Kit Components 
 
 Triglyceride Reagent (10 ml - T2449) 
 250,000 units/l Lipase (microbial), 0.05% Sodium azide. 
 Free Glycerol Reagent (40 ml - F6428) 
 0.75 mM ATP, 3.75 mM Magnesium salt, 0.188 mM 4-Aminoantipyrine, 2.11 
mM N-Ethyl-N-(3-sulfopropyl) m-anisidine, sodium salt, 1,250 units/l Glycerol 
Kinase (microbial), 2,500 units/l Glycerol Phosphate Oxidase (microbial), 2,500 
units/l Peroxidase (horseradish) Buffer, pH 7.0 ± 0.1, 0.05% Sodium azide. 
 Glycerol Standard Solution, 2.5 mg/ml equivalent triolein concentration 
(G7793) 
 
Note: All H2O 18Ω 
 
All reagents were allowed to attain room temperature before reconstitution. The free 
glycerol reagent was reconstituted by adding 40 ml of H2O, the triglyceride reagent by 
adding 10 ml. both reagents were mix by inversion in stoppered vials. The triglyceride 
working reagent was prepared by mixing reconstituted free glycerol reagent with 
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reconstituted triglyceride reagent in a 4:1 ratio and storing in an amber bottle to protect 
it from the light. The triglyceride reagent blank was prepared by mixing the 
reconstituted free glycerol reagent with H2O in a 4:1 ratio. 198 µl of triglyceride 
working reagent was added to each well. 2 µl of water or glycerol standard or sample 
was added to each well (all blanks, standards, samples in duplicate). True blanks, their 
absorbance to be subtracted from all other wells were made with 200 µl of H2O. The 
contents of the microplate were then mixed and incubated at 37°C for 5 minutes; 
absorbance was read at 540 nm. Total triglyceride was calculated using the following 
calculation: 
 
     
   (Asample – ABlank*)   x Concentration of Standard 
   (AStandard – ABlank*) 
 
 
* Blank in the calculation refers to the one containing triglyceride working reagent and 
water. 
 
2.4.2.12 Quantification of mouse plasma soluble VCAM-1 with Quantikine Mouse sVCAM-1 
Immunoassay (R&D Systems, MVC00) 
 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
specific monoclonal antibody is bonded onto the microplate solid surface. Samples are 
added and any mouse sVCAM-1 present is bound by the immobilized antibody. A 
secondary specific enzyme linked antibody is then added. Following the addition of 
substrate a colour change occurs, the intensity in proportion to the amount of sample 
sandwiched between the two antibodies.  
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Kit Components 
 
 Mouse sVCAM-1 Microplate ((12 strips of 8 wells) Coated with a monoclonal 
antibody specific for mouse sVCAM-1) 
 Mouse sVCAM-1 Conjugate Concentrate (650 µl of concentrated solution 
containing monoclonal antibody against mouse sVCAM-1 conjugated to 
horseradish peroxidise) 
 Type 2 Conjugate (12.5 ml of diluent for diluting the conjugate concentrate. 
 Mouse sVCAM-1 Standard (3 vials of 40 ng lyophilized)) 
 Mouse sVCAM-1 Control (3 vials, lyophilized) 
 Assay Diluent RD1-47 (12.5 ml of a buffered protein solution) 
 Calibrator Diluent RD5-26 Concentrate (21 ml of a concentrated buffered 
protein solution) 
 Wash Buffer Concentrate (50 ml of a concentrated solution of a buffered 
surfactant) 
 Colour Reagent A (12.5 ml of stabilised hydrogen peroxide) 
 Colour Reagent B (12.5 ml of stabilised chromogen (tetramethylbenzidine)) 
 Stop Solution (23 ml of a diluted hydrochloric acid solution) 
 Plate Covers (4 adhesive plate seals) 
 
All kit components were allowed to come to room temperature for 30 minutes before 
starting. The mouse sVCAM-1 control was reconstituted in 1 ml of deionised H2O. 0.5 
ml of conjugate concentrate was added to 11 ml of conjugate diluent to make 1x 
working conjugate. Wash buffer was prepared by adding 25 ml of wash buffer 
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concentrate to 600 ml of deionised H2O. 20 ml of calibrator diluent RD5-26 
Concentrate was added 60 ml of deionised H2O to prepare 80 ml of 1x calibrator diluent 
RD5-26. Mouse sVCAM-1 standard was reconstituted with 2.0 ml of 1x calibrator 
diluent RD5-26 to produce a stock solution of 20 ng/ml and allowed to sit at room 
temperature for 5 minutes. A set of standards were made by serially diluting mouse 
sVCAM-1 standard in 1x calibrator diluent RD5-26 as follows (table 2.8). 
 
Table 2.8. Mouse sVCAM-1 standard dilution series 
Standard No. Std. volume 1x Diluent RD5-26 [ng/ml] 
Stock 200 µl ---- 20 ng/ml 
#1 200 µl 200 μl 10 ng/ml 
#2 200 μl of #1 200 μl 5 ng/ml 
#3 200 μl of #2 200 μl 1.25 ng/ml 
#4 200 μl of #3 200 μl 0.62 ng/ml 
#5 200 μl of #4 200 μl 0.31 ng/ml 
#6 ---- 200 µl 0 ng/ml 
 
Mouse plasma samples were diluted 50 fold in RD5-26. 50 µl of assay diluent RD1-47 
was added to each well. 50 μl of all standards, controls and prepared samples were 
added to the appropriate wells in duplicate, sealed and incubated at room temperature 
for 3 hours. Each well was washed 5 times with 400 μl wash buffer and the excess 
liquid blotted away on clean paper towels. 100 μl of mouse sVCAM-1 conjugate was 
added to each well, the plate sealed and incubated for 1 hour at room temperature. The 
plate was washed 5 times as above. The substrate solution was made up by combining 
colour reagents A and B in equal volumes 15 minutes prior to use. 100 μl of substrate 
solution was added to each well and the plate incubated at room temperature for 30 
minutes away from the light. The reaction was halted with the addition of 100 μl of stop 
solution and the absorbance read on a microplate reader at 450 nm, with a correction 
wavelength of 540 nm, within 30 minutes. Values were calculated by plotting a standard 
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curve; known concentrations of the standard were plotted on the log scale (X axis) 
versus O.D. reading on the log scale (Y axis). Sample concentration was determined via 
its O.D. and its intersection with the curve and the Y axis. 
 
2.4.3 Statistical analysis of investigations into the role of MMP8 in 
atherosclerosis 
 
The differences between MMP8-/-ApoE-/- double knockout mice and MMP8+/+ApoE-
/- littermate control mice in terms of plasma levels of Ang I, Ang II, soluble VCAM-1, 
substance P, cholesterol and triglycerides were assessed by 2-tailed t-Test. Colleagues 
also used the t-Test to ascertain differences between the 2 groups in the extent and 
content of atherosclerotic lesions, including macrophage, smooth muscle cell, collagen, 
Ang II and VCAM-1, as well as blood pressure, leukocyte rolling and adhesion, and 
mean fluorescence intensity in flow cytometric analysis.  
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3. Results  
 
3.1 Investigation into the effects of MMP1 promoter haplotypes on gene 
expression in cancer cells 
 
3.1.1 Linkage disequilibrium between MMP1 promoter polymorphisms 
 
A group of 276 unrelated individuals of British Caucasian phenotype were genotyped 
for seven MMP1 promoter polymorphisms, to measure LD and identify common 
haplotypes. The promoter polymorphisms had previously been identified by Pearce et al 
in 2005 (24) by the sequencing of the 1.9 kb MMP1 promoter in 30 unrelated British 
Caucasians (from the same cohort as above). The reference SNP ID, the position 
relative to the start of transcription and the substitution for each SNP is shown in table 
3.1. 
 
Table 3.1. 
rs number Position relative to the start 
of transcription (bp) 
Substitution/deletion 
rs494379 -320  C>T 
rs514921 -340 C>T 
rs475007 -422 T>A 
rs1144393 -519 A>G 
rs498186 -755 G>T 
rs473509 -839 G>A 
rs1799750 -1607 GG>G 
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Analysis of the genotyping data with Haploview showed strong but incomplete LD 
between the seven SNPs (Figure 3.1). 
 
At the time of analysis genotype data for only three of these SNPs was available on the 
HapMap database rs498186, rs475007, and rs514921 and are shown in figure 3.2 to be 
located in a recombination hotspot. This remains the case with the latest available data, 
submitted June 2008. 
FIGURE 3.1. Linkage disequilibrium plot. Coefficients (D’) of 
pairwise linkage disequilibrium coefficients between the 
seven polymorphisms in the MMP1 gene promoter. 
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FIGURE 3.2. Recombination rates. Information obtained from the HapMap database 
showing a recombination hotspot around the MMP1 gene rs498186 (-755G>T) 
polymorphism (shaded). 
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3.1.2 The 10 most frequent haplotypes of the MMP1 promoter 
polymorphisms 
 
Haplotype analyses using Haploview, THESIAS, and PHASE programs showed 10 
common haplotypes (freq of > 2.5%; table 3.2) 
 
Table 3.2. 
Haplotype THESIAS Haploview PHASE 
G-A-T-G-A-T-T 0.141 0.144 0.170 
GG-G-G-A-T-T-T  0.112 0.116 0.129 
G-A-T-G-T-T-T  0.105 0.103 0.092 
GG-G-G-A-T-C-T  0.100 0.091 0.100 
GG-G-T-A-T-T-C  0.060 0.059 0.065 
GG-G-G-A-A-C-T  0.045 0.046 0.053 
GG-G-G-A-A-T-T  0.039 0.036 0.042 
G-G-T-A-A-C-T  0.032 0.032 0.031 
GG-G-G-A-T-T-C  0.029 0.027 0.031 
G-A-T-G-A-C-T  0.028 0.026 0.025 
NOTE: The table shows the 10 most common haplotypes and their frequencies 
estimated using the THESIAS, Haploview, and PHASE programs. The haplotypes 
were derived from the rs1799750, rs473509, rs498186, rs1144393, rs475007, 
rs514921, and rs494379 SNPs, with G-A-T-G-A-T-T denoting a haplotype 
encompassing rs1799750-G, rs473509-A, rs498186-T, rs1144393-G, rs475007-A, 
rs514921-T, and rs494379-T, and so on. All haplotypes retain the same SNP order. 
 
3.1.3 MMP1 promoter haplotype luciferase activity 
 
As variation in the MMP1 gene has reportedly been associated with several types of 
cancer (25-29); the potential effects of the 10 MMP1 promoter haplotypes on 
expression in cancer cell lines was tested by luciferase reporter assay. In all eight cancer 
cell lines were tested with MMP1 promoter haplotypes, two melanoma cell lines 
(A2058, and A375), two breast cancer cell lines (MDA-MB-231 and MCF7), two lung 
cancer cell lines (A549 and H69), and two colorectal cancer cell lines (HT-29 and 
SW620). They were transiently transfected with pGL3-basic vectors into which MMP1 
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promoters of the corresponding haplotype had been cloned, and subjected to luciferase 
assay. The data here represents 3 independent experiments; furthermore in each 
experiment samples and controls were in triplicate. 
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Figure 3.3. 
 
 
 
    
  
  
FIGURE 3.3. MMP1 gene promoter activity in cancer cells. Columns, relative transcriptional activity of the 10 
differentMMP1 promoter haplotypes in A2058 (melanoma), A375 (melanoma), MDA-MB-231(breast cancer), 
MCF7 (breast cancer), A549 (lung cancer), H69 (lung cancer), HT-29 (colorectal cancer), and SW-620 (colorectal 
cancer) cells. Promoter activities were measured by luciferase assays as described in Materials and Methods. 
pGL3-basic vector columns, mean background luciferase expression levels from three independent experiments; 
bars, SD. 
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In the melanoma cell line A2058 two of the haplotypes containing the 2G allele of the 
rs1799750 polymorphism (GG-G-G-A-T-T-T and GG-G-G-A-T-C-T) had at least four- 
fold higher activity than haplotypes with the 1G allele of rs1799750. The other 2G 
containing haplotypes (GG-G-G-A-A-C-T, GG-G-T-A-T-T-C, GG-G-G-A-A-T-T, and 
GG-G-G-AT- T-C) had two to three fold higher promoter activity than the 1G 
containing haplotypes. Significant differences between haplotypes with the rs1799750 
2G allele were that haplotypes GG-G-G-A-T-T-T and GG-G-G-A-T-C-T had 
approximately two fold higher activities than the others (Fig. 3.3). 
 
In A375, the second melanoma cell line tested, there was less than two fold higher 
activity in haplotypes containing the 2G allele of rs1799750 than those containing the 
1G allele with the exception of the G-A-T-G-A-T-T haplotype which had a had a 
similar activity to the 2G containing haplotypes (Fig. 3.3) 
 
The breast cancer cell line MDA-MB-231 showed similar results to A375 melanoma 
cells in that there was less than two fold higher activity in haplotypes containing the 2G 
allele of rs1799750 than those containing the 1G allele with the exception of the G-A-T-
G-A-T-T haplotype which had a had a similar activity to the 2G containing haplotypes 
(Fig. 3.3) 
 
In MCF7, another breast cancer cell line, the highest promoter activity was in the 
rs1799750 1G allele containing haplotype G-G-T-A-A-C-T followed by the GG-G-G-
A-T-T-T haplotype. The promoter strength of the remaining haplotypes was one and a 
half to four fold lower than the G-G-T-A-A-C-T and GG-G-G-A-T-T-T haplotypes 
(Fig. 3.3). 
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Once again in the A549 lung cancer cell line as in A2058, A375, and MDA-MB-231 
cells the GG-G-G-A-T-T-T haplotype had the highest promoter activity. There was also 
a trend, though not significant of higher activity in rs1799750 2G containing haplotypes 
along with the G-A-T-G-A-T-T haplotype compared to other rs1799750 1G allele 
containing haplotype. 
 
There were no significant differences between the haplotypes when tested in H69 lung 
cancer cells or the 2 colorectal cell lines (HT-29 and SW620), although contrasting to 
all the other cell lines (A2058, A375, MCF7, MDA-MB-231, and A549) the empty 
pGL3-basic vector had similar expression levels to pGL3 vectors containing the MMP1 
promoter sequences. 
 
The above data illustrate a potential for haplotypic effects on the MMP1 promoter to 
influence cancer through differential gene expression.  
 
In the table below (Table 3.3) putative transcription factor binding sites are shown at 
each of the SNP loci. The in silico analysis shows the putative sites that might be gained 
or lost dependent on the allele present. Libraries of transcription factor binding sites and 
the algorithms used to predict them are improving all the time, but ultimately each site 
needs to be confirmed experimentally in the relevant cell or tissue types.     
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Table 3.3. Results of in silico search for putative transcription factor binding sites using 
the Genomatix SNPinspector program 
 
Position  rsID Allele  Transcription factor  Strand  Core 
similarity  
Matrix 
similarity 
       
-1607 rs1799750 GG Ecotropic viral integration site 1 
encoded factor, amino-terminal 
zinc finger domain 
(-)  1 0.958 
  G GATA-binding factor 3  (-)  1 0.958 
   Brn-2, POU-III protein class  (-)  0.933 0.886 
-839 rs473509 G  PAX-5 B cell – specific 
activator protein 
(-)  1 0.733 
  A  PAX-1 (+) 0.75 0.626 
   Thyrotrophic embryonic 
factor/hepatic leukaemia factor 
(+) 0.784 0.802 
-755 rs498186 G  Neuron-specific olfactory factor  (+) 1 0.9 
  T  —    
-519 rs1144393 A  Pancreas transcription factor 1, 
heterotrimeric transcription 
factor 
(+) 0.857 0.791 
  G Nuclear factor 1 (-) 1 0.987 
-422 rs475007 T Myoblast determining factor (-) 1 0.983 
   PAX-3 binding site (+) 0.78 0.779 
   Atp1a1 regulatory element 
binding factor 6 
(+) 1 0.985 
  A  —    
-340 rs514921 C  Hepatic nuclear factor 4 (+) 0.75 0.762 
  T Abd-B – like homeodomain 
protein Hoxb-9 
(+) 1 0.94 
-320 rs494379 C  —    
  T Grainyhead-like 3 (+) 1 0.879 
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3.2 Investigation of MMP8 in relation to breast cancer 
 
3.2.1 Characteristics of Leuven breast cancer study patients 
 
The characteristics of patients of the Leuven breast cancer study, as characterised by 
colleagues in Leuven are as follows. The median age of patients at diagnosis was 56, 
ranging from 33-86. Of a total of 140, there were 53 premenopausal and 87 
postmenopausal patients. In 68 patients the tumour size was defined as small (2 cm) 
and large (2 cm) in 72 patients. 14 patients had well differentiated tumours, 52 patients 
had moderately differentiated tumours and 74 had poorly differentiated tumours. Lymph 
node involvement was found in 79 patients, and 61 patients were negative for lymph 
node involvement. Under the tumour node metastasis (TNM) staging system (American 
Joint Committee on Cancer) there were 39 patients classified with stage I, 74 were 
classified with stage II, and 27 with stage III. 
 
3.2.2 Genotyping of MMP8 in relation to breast cancer in the Leuven cohort 
 
Leuven breast cancer study patients were genotyped for nine tagging SNPs in and 
around the MMP8 gene. SNP selection using HapMap data from January 2006 and the 
Tagger algorithm (168) is described in the methods section. There was no association 
found between any of the SNPs and tumour size, tumour grade, or the subtypes of 
luminal A, luminal B, basal-like, Her2+/ER-; Table 3.4. There was association found 
between four SNPs and lymph node metastasis. The minor alleles of these SNPs were 
found to have lower frequencies in patients with lymph node metastasis; the T allele of 
the promoter SNP rs11225395, the G allele of the non-synonymous SNP, in exon 2, 
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rs1940475, the A allele of the intron 4 SNP rs1892886, and the A allele of rs1276284, 
from the 3‟ downstream region of the MMP8 gene (P = 0.02, P = 0.03, P = 0.03, and P = 
0.03, respectively, Table 3.5). 
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Table 3.4. MMP8 genotypes and clinicopathological characteristics (other than lymph node status) of breast cancer patients   
          
  all rs10895353 p* rs7943404 p* rs11225395 p* rs1320632 p* rs1940475 p* 
    AA AG GG   AA AG GG   CC CT TT   TT CT   TT CT CC   
                                         
age at 
diagnosis, 
median 
56 59 54 44 0.13 59 56 59 0.56 58 56 61 0.15 58 57 0.89 58 55 61 0.12 
                                          
tumour size                                         
<= 2 cm 68 50 16 0 0.53 29 26 13 0.28 25 26 17 0.36 58 10 0.89 22 25 21 0.33 
> 2 cm 72 55 14 1   23 28 21   31 29 11   62 10   30 27 15   
                                          
grade                                         
well/moderate 66 51 14 0 0.62 28 24 14 0.45 25 24 16 0.47 55 11 0.45 22 22 22 0.15 
poor 74 54 16 1   24 30 20   31 31 12   65 9   30 30 14   
                                          
tumour 
subtype 
                                        
luminal A 114 87 22 1 0.54 41 46 27 0.81 44 47 22 0.29 97 17 0.19 41 44 29 0.48 
luminal B 11 7 4 0   3 4 4   6 4 1   11 0   6 4 1   
basal-like 10 6 4 0   5 3 2   4 4 2   9 1   4 3 3   
Her2+/ER- 5 5 0 0   3 1 1   2 0 3   3 2   1 1 3   
                                          
note: results tabulated as patients per genotype                         
* Pearson Chi square test                  
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Table 3.4 continued. MMP8 genotypes and clinicopathological characteristics (other than lymph node status) of breast cancer patients 
 
  all rs1892886 p* rs17099436 p* rs2508383 p* rs1276284 p* 
    AA AT TT   AA AT   GG AG AA   GG AG AA   
                                  
age at 
diagnosis, 
median 
56 57 58 65 0.23 58 60 0.46 58 58 60 0.9 57 59 58 0.66 
                                  
tumour size                                 
<= 2 cm 68 36 25 5 0.63 62 6 0.92 46 18 3 0.86 31 28 9 0.55 
> 2 cm 72 43 25 3   66 6   50 18 2   38 23 10   
                                  
grade                                 
well/moderate 66 37 24 5 0.7 60 6 0.84 39 22 3 0.09 30 25 11 0.52 
poor 74 42 26 3   68 6   57 14 2   39 26 8   
                                  
tumour 
subtype 
                                
luminal A 114 66 40 6 0.75 104 10 0.62 75 32 4 0.31 56 42 15 0.37 
luminal B 11 6 5 0   10 1   10 1 0   6 5 0   
basal-like 10 5 3 1   10 0   8 2 0   6 2 2   
Her2+/ER- 5 2 2 1   4 1   3 1 1   1 2 2   
                                  
note: results tabulated as patients per genotype                 
* Pearson Chi square test              
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Table 3.5. MMP8 SNPs in relation to lymph node metastasis in the Leuven Breast 
Cancer Study 
 
Genotype  Number (%)  P* P** Allele Number (frequency) OR (95% CI) P*** 
 LN+ LN-    LN+ LN-   
rs10895353          
AA 56 (73.7) 49 (81.7) 0.23 0.17 A 132 (0.87) 108 (0.90) 1.4 (0.6, 2.9) 0.42 
AG 20 (26.3) 10 (16.7)   G 20 (0.13) 12 (0.10)   
GG – 1  (1.7)        
rs7943404          
TT 26 (32.9) 26 (42.6) 0.27 0.12 T 82 (0.52) 76 (0.62) 1.5 (1.0, 2.5) 0.08 
CT 30 (32.9) 24 (39.3)   C 76 (0.48) 46 (0.38)   
CC 23 (39.1) 11 (18.0)        
rs11225395          
CC 36 (46.2) 20 (32.8) 0.09 0.04 C 103 (0.66) 64 (0.52) 0.6 (0.4, 0.9) 0.02 
CT 31 (39.7) 24 (39.3)   T 53 (0.34) 58 (0.48)   
TT 11 (14.1) 17 (27.9)        
rs1320632          
AA 69 (87.3) 51 (83.6) 0.53 0.53 A 148 (0.94) 112 (0.92) 0.8 (0.3, 1.9) 0.55 
AG 10 (12.7) 10 (16.4)   G 10 (0.06) 10 (0.08)   
rs1940475          
AA 35 (44.3) 17 (27.9) 0.12 0.5 A 97 (0.61) 59 (0.48) 0.6 (0.4, 1.0) 0.03 
AG 27 (34.2) 25 (41.0)   G 61 (0.39) 63 (0.52)   
GG 17 (21.5) 19 (31.1)        
rs1892886          
TT 51 (67.1) 28 (45.9) 0.04 0.03 T 123 (0.81) 85 (0.70) 0.5 (0.3, 0.9) 0.03 
AT 21 (27.6) 29 (47.5)   A 29 (0.19) 37 (0.30)   
AA 4 (5.3)  4 (6.6)        
rs17099436          
TT 73 (92.4) 55 (90.2) 0.64 0.64 T 152 (0.96) 116 (0.95) 0.8 (0.2, 2.4) 0.65 
AT 6 (7.6)  6 (9.8)    A 6 (0.04) 6 (0.05)   
rs2508383          
CC 55 (70.5) 41 (69.5) 0.73 0.9 C 131 (0.84) 97 (0.82) 0.9 (0.5, 1.7) 0.7 
CT 21 (26.9) 15 (25.4)   T 25 (0.16) 21 (0.18)   
TT 2 (2.6) 3 (5.1)        
rs1276284          
GG 47 (59.6) 22 (36.7) 0.02 0.04 G 116 (0.73) 73 (0.61) 0.6 (0.3, 0.9) 0.03 
AG 22 (27.8) 29 (48.3)   A 42 (0.27) 47 (0.39)   
AA 10 (12.7) 9 (15.0)        
          
Note: LN+, patients with lymph node metastasis; LN-, patients without lymph node metastasis 
OR, odds ratio for minor allele 
P*, p value for genotypic  Pearson chi squared test 
P**, p value for trend test 
P***, p value for allelic chi squared test 
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3.2.3 MMP8 haplotypes in relation to lymph node metastasis in the Leuven 
Breast Cancer Study 
 
There were four haplotypes present in patients of the Leuven Breast Cancer Study with 
a frequency > 5% derived from the from the nine MMP8 SNPs. Using the most 
common haplotype A-C-C-A-A-T-T-C-G  (Haplotype 1) as the reference, the second 
most common haplotype A-T-T-A-G-A-T-C-A (Haplotype 2) was associated with 
lower odds ratio [0.52 (95% CI 0.29 – 0.96)] for lymph node metastasis (p=0.037, Table 
3.6). There was not a statistically significant association between the lymph node 
metastasis and the other two major haplotypes G-T-C-A-A-T-T-C-G (Haplotype 3) and 
A-T-T-G-G-T-T-T-A (Haplotype 4), Table 3.6. 
 
Table 3.6. MMP8 haplotypes in relation to lymph node metastasis in the Leuven Breast 
Cancer Study 
 
Haplotype No. Haplotype composition* Haplotype 
frequencies 
Odds ratio (95% 
CI), p-value** 
  LN+ LN-  
Haplotype 1 A-C-C-A-A-T-T-C-G 0.45 0.36 1.00 (reference) 
Haplotype 2 A-T-T-A-G-A-T-C-A 0.18 0.30 0.52 (0.29 - 0.96), 
p=0.04 
Haplotype 3 G-T-C-A-A-T-T-C-G 0.13 0.09 1.29 (0.52 – 3.22), 
p=0.58 
Haplotype 4 A-T-T-G-G-T-T-T-A 0.06 0.08 0.75 (0.29 – 1.96), 
p=0.57 
Note: LN+, patients with lymph node metastasis; LN-, patients without lymph node involvement. 
*Haplotypes deriving from the following SNPs in order: rs10895353; rs7943404, rs11225395, 
rs1320632, rs1940475, rs1892886, rs17099436, rs2508383 and rs1276284. 
**p-values were obtained using the stochastic EM algorithm 
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3.2.4 Genotyping of MMP8 in relation to the occurrence of breast cancer in 
the Strangeways study 
 
Strangeways study patients and controls were genotyped for nine tagging SNPs in and 
around the MMP8 gene. SNP selection was as with the Leuven study. There was 
association found between 3 SNPs and breast cancer. The minor alleles of these SNPs 
were found to have higher frequencies in patients with breast cancer compared to 
controls; the T allele of the promoter SNP rs11225395, the A allele of the intron 4 SNP 
rs1892886, and the A allele of rs1276284, from the 3‟ downstream region of the MMP8 
gene (p = 0.04, p = 0.01, and p = 0.001, respectively, Table 3.7). 
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Table 3.7. MMP8 SNPs in relation to breast cancer in the Strangeways Breast Cancer Case Control Study  
Genotype  Number p* p** Allele Number (frequency) OR (95% CI) P*** 
  Case Controls       Case Controls     
rs10895353                
AA 1864 (85.1) 1894 (83.4) 0.25 0.18 A 4031 (0.92) 4142 (0.91) 0.9 (0.77 - 1.04) 0.15 
AG 303 (13.8) 354 (15.6)     G 349 (0.08) 398 (0.09)     
GG 23 (1.1) 22 (1.0)             
rs7943404                 
TT 734 (33.7) 763 (33.5) 0.46 0.44 T 2538 (0.58) 2618 (0.58) 0.97 (0.89 - 1.05) 0.44 
CT 1070 (49.2) 1092 (48)     C 1812 (0.42) 1932 (0.42)     
CC 371 (17.1) 420 (18.5)             
rs11225395                 
CC 628 (28.9) 735 (32.4)     C 2361 (0.54) 2566 (0.57) 1.09 (1.01 - 1.19) 0.04 
CT 1105 (50.9) 1096 (48.3) 0.04 0.04 T 1983 (0.46) 1970 (0.43)     
TT 439 (20.2) 437 (19.3)             
rs1320632                 
AA 1815 (83.6) 1894 (83.8) 0.44 0.64 A 3965 (0.91) 4140 (0.92) 1.04 (0.89 - 1.2) 0.64 
AG 335 (15.4) 352 (15.6)     G 379 (0.09) 382 (0.08)     
GG 22 (1.0) 15 (0.7)             
rs1940475                 
AA 528 (24.4) 620 (27.5)     A 2159 (0.50) 2322 (0.51) 1.07 (0.98 - 1.16) 0.13 
AG 1103 (50.9) 1082 (48) 0.05 0.13 G 2171 (0.50) 2190 (0.49)     
GG 534 (24.7) 554 (24.6)             
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rs1892886                 
TT 1140 (52.9) 1274 (56.4) 0.04 0.01 T 3136 (0.73) 3395 (0.75) 1.13 (1.03 - 1.25) 0.01 
AT 856 (39.7) 847 (37.5)     A 1178 (0.27) 1125 (0.25)     
AA 161 (7.5) 139 (6.2)             
rs17099436                 
TT 1963 (89.8) 2017 (88.7) 0.34 0.18 T 4144 (0.95) 4283 (0.94) 0.88 (0.74 - 1.06) 0.18 
AT 218 (10) 249 (10.9)     A 228 (0.05) 267 (0.06)     
AA 5 (0.2) 9 (0.4)             
rs2508383                 
CC 1433 (65.9) 1436 (63.7) 0.28 0.18 C 3521 (0.81) 3601 (0.80) 0.93 (0.84 - 1.03) 0.18 
CT 655 (30.1) 729 (32.3)     T 825 (0.19) 907 (0.20)     
TT 85 (3.9) 89 (3.9)             
rs1276284                 
GG 886 (40.5) 1016 (44.9) 0.003 0.001 G 2774 (0.63) 3033 (0.67) 1.17 (1.07 - 1.27) 0.001 
AG 1002 (45.9) 1001 (44.2)     A 1596 (0.36) 1497 (0.33)     
AA 297 (13.6) 248 (10.9)             
OR, odds ratio for minor allele, p*, p value for genotypic  Pearson χ2 test, P**, p value for trend test, P***, p value for allelic χ2 test 
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3.2.5 MMP8 gene variation in the Polish breast cancer and melanoma study 
 
All SNPs were in HWE. There were no statistically significant differences in allele or 
genotype frequencies detected, when analysed by conditional logistic regression, for 
MMP1 or MMP8 SNPs in the breast cancer part of the study. Similarly there were no 
significant differences detected for MMP1 SNPs in relation to the risk of malignant 
melanoma. Table 3.8 shows the MAF of the MMP1 SNPs and the MMP8 SNP 
rs11225395, in the Polish breast cancer and melanoma cases and their respective 
controls. 
 
Table 3.8 MAF of the MMP1 SNPs and the MMP8 SNP rs11225395, in the cases and 
controls of the Polish study 
MMP1 SNP Location MM cases (%) MM controls BC cases BC controls 
rs498186 Promoter 224/590 (0.38) 213/552 (0.386) 229/574 (0.399) 240/590 (0.407) 
rs1144393 Promoter 252/592 (0.426) 235/554 (0.424) 249/584 (0.426) 248/612 (0.405) 
rs475007 Promoter 251/586 (0.428) 249/558 (0.446) 256/598 (0.428) 268/616 (0.435) 
rs514921 Promoter 144/588 (0.245) 129/552 (0.234) 153/592 (0.258) 145/616 (0.235) 
rs494379 Promoter 124/592 (0.209) 127/542 (0.234) 108/586 (0.184) 145/602 (0.241) 
rs3213460 Exon 1 78/588 (0.133) 72/556 (0.129) 95/584 (0.163) 89/608 (0.146) 
rs470358 Intron 1 242/570 (0.425) 222/524 (0.424) 226/576 (0.392) 239/592 (0.404) 
rs996999 Intron 4 132/590 (0.224) 121/544 (0.222) 122/582 (0.21) 132/598 (0.221) 
rs5031036 Intron 5 45/580 (0.078) 47/526 (0.089) 43/588 (0.073) 51/602 (0.085) 
rs491152 Intron 5 0/582 (0) 0/544 (0) 0/582 (0) 0/602 (0) 
rs1051121 Exon 6 6/564 (0.011) 15/536 (0.028) 16/586 (0.027) 15/602 (0.025) 
rs11225426 Intron 6 38/580 (0.066) 43/544 (0.079) 39/580 (0.067) 36/598 (0.06) 
rs71250626 Intron 6 164/574 (0.286) 127/514 (0.247) 158/574 (0.275) 166/594 (0.279) 
rs2071231 Intron 9 10/586 (0.017) 9/540 (0.017) 5/582 (0.009) 8/610 (0.013) 
rs470215 Exon 10 208/586 (0.355) 184/538 (0.342) 207/584 (0.354) 201/602 (0.334) 
rs2071230 Exon 10 41/570 (0.072) 40/536 (0.075) 36/558 (0.065) 39/590 (0.066) 
rs7945189 3' region 62/584 (0.106) 51/544 (0.094) 53/580 (0.091) 70/610 (0.115) 
rs1729376 3' region 37/588 (0.063) 40/554 (0.072) 41/592 (0.069) 42/608 (0.069) 
MMP8 SNP 
     
rs11225395 Promoter 268/592 (0.453) 220/580 (0.379) 262/594 (0.441) 258/606 (0.426) 
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A positive association was found between MMP8 rs11225395 SNP and the occurrence 
of malignant melanoma. Conditional logistic regression analysis showed that the minor 
allele homozygote (T/T) was associated an increased risk of melanoma (OR 1.69, 95% 
CI 1.02 – 2.08; p = 0.040) with reference to the major homozygote (C/C); similarly the 
heterozygote genotype (C/T) also carried an increased risk of melanoma (OR 1.49 95% 
CI 1.03 – 2.17; p = 0.035) table 3.9. The frequency of risk allele was 0.453 in MM cases 
compared with 0.379 in controls (OR 1.54 95% CI 1.08 – 2.2; p = 0.017; Table 3.9). 
 
Table 3.9 Genotype and allele frequencies of the MMP8 rs11225395 SNP Polish in 
melanoma cases and controls (conditional logistic regression) 
 cases, n (%) Controls, n (%) OR (95% CI, P value) 
C/C genotype  86 (29.1) 113 (39.0) Reference 
C/T genotype  152 (51.4) 134 (46.2) 1.49 (1.03 – 2.17, 0.035) 
T/T genotype  58 (19.6) 43 (14.8) 1.69 (1.02 – 2.08, 0.040) 
    
C allele  0.55 0.38 Reference 
T allele  0.45 0.62 1.54 (1.08 – 2.2, 0.017) 
    
CI, confidence interval; OR, odds ratio 
 
 
Meta-analysis of rs11225395 SNP in association with breast cancer in the Strangeways and Polish 
studies 
 
It was possible to perform a meta-analysis of the data for the rs11225395 SNP as this 
variant was tested in both the Strangeways and Polish case/control studies regarding 
breast cancer. The Strangeways study showed a significant association between 
rs11225395 and breast cancer, the Polish study did not. Meta-analysis of the two studies 
showed an association between the minor allele (T) and the occurrence of breast cancer 
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(OR 1.09, p = 0.03; both random and fixed effects).  No significant heterogeneity was 
detected (Cochran‟s Q = 0.82, I2 = 0). 
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3.2.6 Functional investigations into MMP8 and breast cancer 
 
To test whether the rs11225395 (-799bp) promoter SNP has a direct functional effect on 
MMP8 expression in breast cancer cells luciferase reporter assays were carried out in 
the MDA-MB-231 breast cancer cell line. Experiments, in which luciferase reporter 
constructs incorporating MMP8 promoter segments containing either the C or T allele 
of the rs11225395 SNP were transfected into breast cancer cells, showed that the T 
allele had approximately 1.8-fold higher promoter activity than the C allele (p = < 0.05, 
Fig 3.6). 
 
 
Figure 3.6. MMP8 gene promoter activity of the T and C alleles of the -799C>T SNP 
(rs11225395). Columns, relative MMP8 promoter activity of the T and C alleles in MDA-MB-231 
breast cancer cells, measured by dual-luciferase assays as described in Materials and 
Methods. Data shown are mean (±SD) from three independent experiments. 
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3.2.7 Functional investigations into MMP8 and melanoma 
 
To test whether the rs11225395 (-799bp) promoter SNP has a direct functional effect on 
MMP8 expression in melanoma cells luciferase reporter assays were carried out in the 
A2058 cell line. Experiments, in which luciferase reporter constructs incorporating 
MMP8 promoter segments containing either the T or C allele of the rs11225395 SNP 
were transfected into melanoma cells, showed that the T allele had approximately 2-fold 
higher promoter activity than the C allele (p = 0.015, Fig 3.7). 
 
 
 
 
 
Figure 3.7. MMP8 gene promoter activity of the C and T alleles of the -799C>T SNP 
(rs11225395). Columns, relative MMP8 promoter activity of the C and T alleles in A2058 
melanoma cells, measured by dual-luciferase assays as described in Materials and Methods. 
Data shown are mean (±SD) from three independent experiments. 
  
T alleleC allele
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3.3 Investigation into the role of MMP8 in atherosclerosis 
 
3.3.1 MMP8 gene variation in relation to atherosclerosis 
 
To study MMP8 gene variation in relation to atherosclerosis SNPs from the HapMap 
database were selected to capture/tag (r
2
 ≥ 0.8) common SNPs (with a minor allele 
frequency of ≥ 0.05) within the 5‟ upstream sequence, introns and 3‟ untranslated 
region. In addition to this the MMP8 gene proximal promoter (2 kb) and coding regions 
were resequenced. Examples of SNPs seen or identified by resequencing are exon 2 
coding SNPs rs12803000 (synonymous) and rs1940475 (non-synonymous), and 
synonymous exon 6 SNP rs3740938 are shown in figure 3.8. 
 
 
rs1940475 
rs12803000 
rs3740938 
(B) 
(A) 
(C) 
Figure 3.8. MMP8 SNPs identified by resequencing. (A) chromatogram of MMP8 exon 2  forward 
sequence segment showing rs12803000 A>C heterozygote, (B) chromatogram of MMP8 exon 2 forward 
sequence segment showing rs1940475 A>G (Lys>Glu) heterozygote, (C) chromatogram of MMP8 exon 6 
reverse sequence segment showing rs3740938 G>A heterozygote. 
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Initially 1000 CAD patients from Southampton General Hospital were genotyped for 
the 16 SNPs that were identified with the combined strategies of resequencing and 
HapMap tagging; details of the SNPs are given in table 3.10.  
 
Table 3.10: Human MMP8 gene SNPs examined in relation to atherosclerosis 
  
dbSNP ID 
 
Major 
allele  
 
Minor 
allele 
MAF 
in this 
study 
MAF 
in 
HapMap 
 
SNP location 
 
Comment 
rs10895353 A G 0.10 0.07 Promoter, 
position -3345 
tagging SNP 
rs7943404 A G 0.42 0.42 Promoter, 
position -2926 
tagging SNP 
rs11225395  C T 0.43 0.48 Promoter, 
position -799 
 
rs1320632 A G 0.09 0.11 Promoter, 
position -381 
 
rs2155052 C G 0.10 0.10 Promoter, 
position -17 
 
rs17099450 G  C 0.05 0.04 Exon 1  non-synonymous 
(Cys3Ser) 
rs3765620 A G 0.43 0.48 Exon 1  non-synonymous 
(Ile32Thr) 
rs12803000 T G 0.05 0.04 Exon 2  Synonymous 
rs1940475 C T 0.49 0.52  Exon 2 tagging SNP, non-
synonymous 
(Glu87Lys) 
rs1892886 T A 0.25 0.28 Intron 4 tagging SNP 
rs17099436 T A 0.05 0.06 Intron 4 tagging SNP 
rs3740938 G A 0.06 0.06 Exon 6 Synonymous 
rs2508383 G A 0.20 0.21 Intron 7 tagging SNP 
rs1276282 C T 0.09 - 3’-untranslated 
region 
 
rs1291327 G A 0.10 - 3’-untranslated 
region 
 
rs1276284 G A 0.34 0.38 3’-untranslated 
region  
tagging SNP 
 
 
The rs1940475 SNP was found to be associated with the extent of coronary 
atherosclerosis (p=0.01). The genotyping of an additional 1000 CAD patients from 
Southampton General Hospital for this SNP strengthened the association with the extent 
of coronary atherosclerosis, when analysed for the entire study population (n=2000, 
p=0.0008). The (T) allele had a lower frequency in patients with multi-vessel disease 
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than in patients with >50% stenosis in only 1 vessel (OR=0.80, 95% CI 0.70 – 0.91; 
Table 3.11). The above findings remain significant when taking into account multiple 
testing as calculated using the SNPSpD method. This method is less stringent the 
commonly used Bonferroni method; it does not assume all the SNPs are completely 
independent and utilises a spectral decomposition of matrices of pairwise LD between 
SNPs (183, 184, 200).  
 
Table 3.11. Association between MMP8 gene variation and extent of coronary 
atherosclerosis in patients with coronary artery disease (n=2000) 
 
rs1940475 
SNP 
Subjects with 
significant 
atherosclerosis*
 
in one coronary 
artery
 
Subjects with 
significant 
atherosclerosis*
 
in two or three coronary 
arteries
 
Odds ratio (95% confidence 
interval) †
 
for significant 
atherosclerosis*
 
in two or three coronary 
arteries
 
 
Genotype 
 
n (%) 
 
n (%) 
 
C/C 170 (22.2) 342 (27.7) reference 
C/T 398 (52.0) 632 (51.2) 0.77 (0.62-0.97), p=0.028 
T/T 198 (25.8) 260 (21.1) 0.63 (0.49-0.83), p=0.0008 
Total 766 (100.0) 1234 (100.0)  
    
Allele frequency frequency  
C 0.48 0.53 reference 
T 0.52 0.47 0.80 (0.70-0.91), p=0.0008 
*Significant atherosclerosis was defined by >50% stenosis 
†calculated by logistic regression analysis with adjustment for age, gender, smoking, hypercholesterolemia, 
hypertension and diabetes. 
 
The rs1940475 SNP associated with the extent of coronary atherosclerosis in CAD 
patients from Southampton was further evaluated in the Bruneck study, a population 
based prospective study. In agreement with the above study the  (T) allele was found to 
be associated with a protective effect against carotid atherosclerosis over a 10 year 
follow up  period; (OR 0.77, 95% CI 0.60 – 0.98) for atherosclerosis progression 
between 1990 and 1995; (OR 0.74, 95% CI 0.56 – 0.99) for atherosclerosis progression 
between 1995 and 2000 (table 3.12). 
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Table 3.12. Association between MMP8 gene variation and carotid atherosclerosis 
progression in the Bruneck study cohort (n=782) 
 
Carotid atherosclerosis 
progression*
 
Odds ratio (95% confidence 
interval) ‡ 
Odds ratio (95% confidence 
interval)§ 
1990-1995 0.77 (0.60-0.98), p=0.032 0.73 (0.57-0.95), p=0.018 
1995-2000 0.74 (0.56-0.99), p=0.040 0.78 (0.58-1.04), p=0.090 
   
Change in carotid 
atherosclerosis score†
 
Regression coefficient (95% 
confidence interval)|| 
Regression coefficient (95% 
confidence interval)# 
1990-1995 
-0.022 (-0.004 to -0.040), 
p=0.011 
-0.025 (-0.042 to -0.008), 
p=0.003 
1995-2000 
-0.022 (-0.002 to -0.042), 
p=0.025 
-0.022 (-0.042 to -0.002), 
p=0.032 
 
*Carotid atherosclerosis progression was defined by the occurrence of atherosclerotic lesions in 
segments previously free of atherosclerosis or enlargement of non-stenotic lesions by a relative 
increase in the plaque diameter exceeding twice the measurement error of the carotid ultrasound 
examination method (158-161). 
†Carotid atherosclerosis score, an indicator of atherosclerosis severity, was calculated by 
summing the maximum diameter of atherosclerotic plaques at 8 well-defined segments of the 
common and internal carotid arteries (158-161). 
‡Odds ratio for carotid atherosclerosis progression related to each copy of the T allele, calculated 
by logistic regression analysis with adjustment for age, gender and baseline carotid 
atherosclerosis score. 
§Odds ratio for carotid atherosclerosis progression related to each copy of the T allele, calculated 
by mutltivariate logistic regression analysis with adjustment for age, gender, baseline carotid 
atherosclerosis score, smoking, alcohol consumption, hypertension, diabetes,  body mass index, 
waist-to-hip ratio, LDL and HDL levels, lipoprotein a, fibrinogen, the factor V Leiden mutation, C-
reactive protein, ferritin and urinary albumin. Additional adjustment for soluble VCAM-1 yielded 
virtually identical results. 
||Regression coefficient calculated by linear regression analysis of loge-transformed carotid 
atherosclerosis score in relation to the T allele, with adjustment for age, gender and baseline 
carotid atherosclerosis score. 
#Regression coefficient calculated by linear regression analysis of loge-transformed carotid 
atherosclerosis score in relation to the T allele, with adjustment for age, gender and baseline 
carotid atherosclerosis score and other variables as above. 
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Plasma levels of soluble VCAM-1 were found to be lower in individuals from the 
Bruneck study carrying the T allele of the rs1940475 SNP (p=0.014, table 3.13). 
 
Table 3.13. Association between MMP8 genotype and plasma VCAM-1 level in the 
Bruneck study cohort (n=782) 
 
MMP8 Genotype* VCAM-1 (ng/ml)† p value 
C/C 661.2 0.014 
C/T 624.5  
T/T 603.7  
*Genotype of the rs1940475 SNP; †Data shown are age- and sex-
adjusted genometric means. 
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3.3.2 Functional investigations into MMP8 in atherosclerosis 
 
3.3.2.1 Analysis of the effects of Ang 1 cleavage products by MMP8 on the murine VCAM-1 
promoter via luciferase assay in endothelial cells 
 
In endothelial cells transfected with luciferase reporter vectors containing a 263 bp 
sequence of the murine VCAM-1 promoter with either the NF-kB response element 
intact or ablated confirmed that the NF-kB element is functional. The promoter 
sequence in which the NF-kB element is ablated showed significantly less luciferase 
activity than the normal promoter sequence (untreated C166 cells p = 0.013, untreated 
bEnd.3 cells p = 0.039; fig 3.9 A and B respectively). ANOVA showed there was no 
significant difference of relative luciferase activity, for the intact VCAM-1 promoter, 
between any of the post transfection treatments (angiotensin I, MMP8, MMP8 and 
angiotensin I, or no treatment) in the C166 cell line or the bEnd.3 cell line (p = 0.574, p 
= 0.112; Fig 3.9 A and B respectively).  
 
Figure 3.9. Relative promoter activity the VCAM-1 promoter with or without the NF-kB element 
ablated after post transfection treatments of angiotensin I, or MMP8, or MMP8 and angiotensin 
I, or no treatment; in (A) C166 cells, or (B) bEnd.3 cells. Activities were measured by dual 
luciferase assay described in the methods section. Representative of two independent 
experiments, each combination of treatment and plasmid was in triplicate. Error bars represent 
standard error of mean. 
  
A B 
p = 0.013 
p = 0.039 
p = 0.574 
p = 0.112 
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3.3.3 Biochemical and animal investigations of the role of MMP8 in 
atherosclerosis 
 
3.3.3.1 Cleavage of Angiotensin I  
 
A reported substrate of MMP8 is angiotensin I, which it converts into angiotensin II and 
Angiotensin 1-7 (194)). Angiotensin II is a potent vasoconstrictor and well established 
atherogenic molecule (201-203). To verify this MMP8 was incubated with angiotensin 
I, the cleavage products were then analysed by colleagues using liquid chromatography–
electrospray tandem mass spectrometry. The results show that MMP8 converts Ang I 
principally into Ang II but also Ang 1-7 (fig 3.10) 
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Figure 3.10. Cleavage of Ang I by MMP8, producing Ang II and Ang 1–7. A, Chromatogram of mass 
spectrometric analysis of uncleaved Ang I, showing the detection of Ang I peptide ion (m/z 432.84
3+
_). B, 
Chromatogram of mass spectrometry analysis of products of Ang I cleavage by MMP8, showing the 
presence of Ang II (m/z 523.79
2+
) and Ang 1–7 (m/z 450.25
2+
) peptide ions, in addition to Ang I (m/z 
432.91
3+
). The presence of Ang II, Ang 1–7, and Ang I in the respective peaks were confirmed by peptide 
fragmentation sequencing. 
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3.3.3.2. Reduced angiotensin II levels in double KO mice 
 
To investigate whether the ability of MMP8 to process Ang I into Ang II could be 
reflected in the double knockout and control groups, plasma levels of Ang I and Ang II 
were measured. Ang II plasma levels were found to be lower in the double knockout 
group compared to the control group; contrastingly plasma Ang I levels, the precursor 
of Ang II, were found to be higher in the control group compared to the double 
knockout group (p=0.026 and p=0.018 respectively; fig 3.11 A and 3.11 B).  
 
 
 
 
3.3.3.3 No change in other angiotensin forming enzymes 
 
While it has been established that MMP8 can process Ang I into Ang II, other enzymes 
are capable of performing this role particularly ACE, chymase and cathepsins (194, 
203); with this in mind the activity of ACE, and chymase and cathepsins was assessed 
to check for differences between the two groups. There was no significant difference 
between the 2 groups in the levels of ACE activity or the levels of chymase and 
cathepsins (p=0.921 and p=0.495 respectively; fig 3.12 A and 3.12 B). 
A B
Figure 3.11. Reduced Ang II levels in MMP8-/-ApoE-/- mice. A and B, 
charts showing lower plasma Ang II level, but higher plasma Ang I level, in 
MMP8-/-ApoE-/- mice than in MMP8+/+ApoE-/- mice.  
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3.3.3.4 Characterisation of atherosclerotic lesions 
  
Results from the characterisation of atherosclerotic lesions of MMP8/ApoE double 
knockout mice (MMP8-/-ApoE-/-), fed a Western diet, and MMP8 wild type/ApoE 
knockout littermate controls (MMP8+/+ApoE-/-), also fed a Western diet, performed by 
colleagues are shown below. 
 
MMP8/ApoE double knockout mice (MMP8-/-ApoE-/-) were generated, by crossing 
MMP8 knockout mice (122) with ApoE knockout mice (195, 196). MMP8-/-/ApoE-/- 
double knockout mice (n=10) and MMP8+/+ApoE-/- littermates (controls, n=10) were 
fed a Western high cholesterol diet for 12 weeks. Extensive aortic atherosclerotic 
lesions were observed in MMP8 wild type controls (Figure 3.13). The double knockout 
mice had substantially less aortic atherosclerosis (36% reduction compared with 
controls, p=0.007, Figure 3.13).  
A
  
B
  
Figure 3.12. A and B, charts showing that there is no significant difference in the activity of other angiotensin II 
forming enzymes (A, ACE, B, chymases and cathepsins) between MMP8+/+/ApoE-/- and MMP8-/-/ApoE-/- 
mice. Data shown are mean ± standard error of mean. 
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Figure 3.13. Reduced atherosclerosis in MMP8-/-ApoE-/- mice. Panel A: representative images of Oil Red O stained en
face preparations of aortas of MMP8+/+/ApoE-/- (n = 10) and MMP8-/-/ApoE-/- (n = 10) mice, and chart showing
percentages of aortic surface area with atherosclerosis in the two groups of mice. Data presented are mean and standard
error of mean.
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3.3.3.5. Measurement of plasma triglyceride and cholesterol 
 
Plasma levels of triglyceride were measured, there was no significant difference 
between the two groups (p=0.117; fig 3.14 A); neither was there a significant difference 
in plasma cholesterol levels (p=0.887; fig 3.14 B).  
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Figure 3.14. Plasma triglyceride and cholesterol in MMP8-/-
ApoE-/- (n =10) and MMP8+/+ApoE-/- (n = 10) mice. Error bars 
represent standard error of mean. 
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3.3.3.6 Plasma VCAM-1 reduced in double knockout mice 
 
Results from the animal studies agreed with those from the in vitro studies. Plasma 
sVCAM-1 levels, detected by ELISA, were found to be higher in MMP8+/+ApoE-/- 
mice than in MMP8-/-ApoE-/- mice (p=0.039; fig 3.15) 
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-/-
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p=0.039 
Figure 3.15 VCAM-1 expression in MMP8
-/-
ApoE
-/-
 
mice compared MMP8
+/+
ApoE
-/-
 mice 
Mean levels of soluble VCAM-1 in plasma. Error 
bars in the column are standard error of the mean
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3.3.3.7. Measurement of plasma substance P and mesenteric substance P 
 
Plasma levels of substance P were measured, there was no significant difference 
between the two groups (p=0.382; fig 3.16 A); neither was there a significant difference 
in levels of substance P in the mesentery (p=0.888; fig 3.16 B).  
 
Figure 3.16. Substance P in MMP8
-/-
ApoE
-/-
 (n = 8) and MMP8
+/+
ApoE
-/-
 (n = 8) mice. (A) In 
plasma, (B) extracted from mesentery tissue (normalised by sample protein concentration. Error 
bars represent standard error of mean. 
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4.0 Discussion 
 
4.1 Genetic investigations into MMP1, MMP8 and disease 
 
4.1.1 Haplotype effects on MMP1 gene promoter activity in cancer cells 
 
The results from the study of variation in the MMP1 promoter establish that there is a 
haplotypic effect exerted by multiple polymorphisms on promoter activity in different 
cancer cell lines in vitro; the effect is larger than that caused solely by the rs1799750 
SNP; the 2G allele of which creates an Ets nuclear factor binding site leading to 
increased transcription (112). The results indicate that in most of the cell lines tested the 
rs1799750 SNP is the strongest individual driver of the haplotypic effect, but is not 
acting in isolation. In the melanoma cell line (A2058) all haplotypes containing the 2G 
allele of rs1799750 SNP had significantly higher promoter activity than those without. 
Evidence for the contribution of other SNPs towards overall haplotypic effects was 
given by the fact that there were significant differences between the promoter activities 
of the six 2G allele containing haplotypes in A2058 cells. Haplotype effects were also 
evident in the other melanoma cell line (A375), the breast cancer cell lines (MDA-MB-
231 and MCF7), and a lung cancer cell line (A549). In addition to the „2G‟ containing 
haplotypes high expression was conferred by most frequent haplotype (G-A-T-G-A-T-
T) in A375 and MD-MB-231 cells. The G-A-T-G-A-T-T haplotype was also amongst 
the higher expressing haplotypes in A549 cells; the GG-G-G-A-T-T-T haplotype, in 
these cells, had significantly higher expression than most of the other haplotypes. G-G-
T-A-A-C-T and GG-G-G-A-T-T-T haplotypes produced significantly higher expression 
than the others in MCF7 breast cancer cells, the top expressing haplotype (G-G-T-A-A-
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C-T) being only „1G‟ one with high expression. Detection of differences in between 
haplotypic expression was possibly confounded in H69, HT-29, and SW-620 cells by 
the relatively high expression of the empty pGL3-basic vector; this was not observed in 
the A5028, A375, MDA-MB-231, MCF7, and A549 where significant differences were 
obtained. Previously undertaken investigations show that null vectors such as pGL3-
basic can be trans-activated in some cell lines (204).  
 
As stated, the investigation into MMP1 promoter activity indicates an effect caused by 
the rs1799750 (-1607) SNP in combination with one or more of the other SNPs studied. 
Previous studies have also shown haplotypic effects on the transcription of other genes; 
the cooperation of two or more of four promoter variants effects influence the 
transcriptional regulation of the cytokine IL6 (22); the interaction of three SNPs in the 
CETP gene promoter alter its activity and CETP plasma levels (23). Investigations 
either published concurrently or subsequently to the data presented here (193) continue 
to provide a strong case for the analysis of haplotypes, over that of single 
polymorphisms, in relation to gene activity and phenotype, with the discovery of 
haplotypes effecting  O
6
-alkylguanine-DNA alkyltransferase (MGMT) and lung cancer 
susceptibility (205), eye colour (206), and Janus kinase 2 (JAK2) associated diseases 
(207). 
 
MMP gene regulation as covered in section 1.1.3.1 is partly dependent upon cis-
elements within their promoter regions; the cis-elements are small DNA sequences 
recognised and bound to by transcription factor proteins. The binding sites may be 
created, augmented or lost dependent upon the allele present if a SNP occurs within a 
cis-element sequence, a pertinent example the Ets-1 binding site created by the 
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rs1799750 2G allele (112). Functional haplotype effects can occur when more than one 
SNP is present within a cis-element or there are SNPs in more than one cis-element 
sometimes changing the interaction of more than one transcription factor (TF). It 
follows that the ability of haplotypes to affect promoter activity can depend upon the 
complement of transcription factors active within a particular cell or cell line; different 
breast cancer cell lines have been shown to have varied TF profiles (208). The divergent 
effects of MMP1 promoter haplotypes seen in the different cancer cell lines, and 
between cell lines of the same type of cancer may be caused by a different TF profiles; 
the amount of influence on promoter activity by SNPs has been seen to vary dependent 
on cell type in other genes such IL6, MMP2 and MMP8 (22, 50, 209). In silico 
examination of the MMP1 promoter using the Genomatix SNPinspector program places 
the studied polymorphisms within putative TF binding sites (Table 3.3), this supports 
the notion that these SNPs may regulate transcription via TF binding but functional 
investigations are needed to verify any interactions. The haplotypic effect of the MMP1 
promoter polymorphisms has already been established previously by colleagues, 
regarding risk of MI or promoter activity in THP1 cells (24); to date the majority of the 
genetic investigations into MMP1 and cancer have focussed solely upon the rs1799750 
1G>2G SNP (25, 27, 29, 113-116, 210, 211). This analysis of the haplotype effects in 
cancer cell lines provides functional data that gives credence to the notion that genetic 
epidemiological studies would be better served genotyping multiple SNPs/haplotypes 
rather than just single SNP analysis; it shows that this method gives a better coverage of 
the genetic variations that confer differences in promoter activity when studying 
MMP1. The conclusion that use of haplotype analysis provides a greater amount of 
information than the single marker approach is not particularly surprising. Haplotype 
analysis has previously been well discussed by de Bakker et al in 2005 (168) with 
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reference to the statistical power of genotyping strategies, they also mention that the 
power to detect causal variants is decreased in areas of low LD as you are in effect 
testing fewer putative alleles, this is relevant in this case as this study shows that the LD 
between MMP1 promoter SNPs is considerably low compared to some other genes e.g. 
MMP3 (212), probably due to recombination hotspot around the MMP1 SNPs (Fig 3.2). 
Recent studies into cutaneous malignant melanoma also support the notion that these 
seven polymorphisms and their haplotypes can influence risk of melanoma (213) and 
progression of melanoma (214). 
 
To summarise, this multi-marker analysis of MMP1 gene promoter SNPs shows that the 
MMP1 promoter polymorphisms exert haplotype effects on MMP1 promoter activity in 
cancer cells. The results show the advantage of examining haplotypes over single 
marker studies, in genetic investigations of the MMP1 gene and cancers. 
 
4.1.2 MMP1 gene variation in malignant melanoma and breast cancer  
 
Case control analysis of MMP1 gene SNPs and melanoma or breast cancer failed to find 
any significant association in the Polish study participants. This was despite the fact that 
the study encompassed five of the SNPs (rs498186, rs1144393, rs475007, rs514921, 
and rs494379) that were involved in the functional analysis of the promoter carried out 
earlier, shown to exert a haplotypic effect in A2058 and A375 melanoma cells lines, and 
MCF7 and MDA-MB-231 breast cancer cell lines. As always with this type of 
investigation, a small sample size and relatively low power means it is more difficult to 
uncover small or moderate effects and caveats should be provided for the negative 
interpretation.  The negative result not preclude associations being found in larger 
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studies, indeed a larger Texan melanoma study found a significant association with 
three of the above SNPs (rs1144393, rs475007, and rs494379) and susceptibility after 
adjustment for age, sex, family history and sun-exposure-related risk factors (213). The 
same group later found associations with MMP1 promoter SNPs and 
clinicopathological factors involved in melanoma progression (214).  
 
4.1.3 MMP8 gene variation and breast cancer  
 
The investigations on MMP8 gene variation in relation to breast cancer initially found 
an association with lymph node metastasis and four SNPs, rs11225395, rs1940475, 
rs1892886, and rs1276284, in patients in the Leuven breast cancer study. The most 
interesting discovery of reduced risk of lymph node metastasis conferred by the minor 
allele (T) of the rs11225395 SNP; a polymorphism purported to have an effect on 
MMP8 gene expression in earlier studies (50). This finding was supported by 
collaborators with further analysis of this SNP in patients from the Shanghai breast 
cancer study (Section: A4.1). They found the T allele to be associated with reduced 
cancer relapse and increased survival. Functional analysis of this polymorphism using 
luciferase reporter assays with the MDA-MB-231 breast cancer cell line showed the T 
allele to have higher promoter activity than that of the C allele. Further to this 
electrophoretic mobility shift experiments upon MDA-MB-231 nuclear extract showed 
protein interaction with the T allele and none with the C allele; suggesting a direct 
functional role for the rs11225395 SNP (Section A4.2). The above findings support the 
case for an inhibitory effect of MMP8 on breast cancer metastasis as put forward by 
Montel et al. (121), and Argarwal et al. (120). 
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A well established prognostic marker of breast cancer, lymph node status is probably 
the strongest independent predictor of disease free survival and overall survival (215); 
lymph node involvement at the primary diagnosis predicts a poor outcome after the first 
relapse independent of disease free survival or location (216). Often the first site of 
metastasis in breast cancer, the involvement of lymph nodes indicates that the 
associated primary tumour is of an aggressive metastatic phenotype (154, 216).  In the 
study presented here associations between lymph node metastasis and MMP8 SNPs 
were found, the strongest being with rs11225395. Additionally collaborators in an 
independent study observed that the less frequent T allele was associated with reduced 
cancer relapse and improved survival after breast cancer diagnosis in Chinese women 
(Tables A1 & A2, respectively). Although a trend was seen in all cases a significant 
association between the T allele and better prognosis was shown in Chinese women 
with early stage cancer (TMN stage 0-II) (Tables A1 & A2, Figure A2; see p174-176); 
the classification given when there is no involvement of other tissues or organs, any 
spread of cancer cells is restricted to lymph nodes only. These findings are in agreement 
with previous murine studies lymph node metastasis was much increased when MMP8 
was knocked down in animals with breast cancer cells orthoptically implanted, a much 
smaller effect was seen with metastasis to the lung, therefore it was posited that MMP8 
offers some protection against invasion via the lymphatic system, and less against 
invasion via the blood circulatory system (121). Also in agreement is a study that is 
subsequent to the publication of the data presented here (48); it was found that 
expression of MMP8 in humans correlated with a lower incidence of lymph metastasis 
and a better prognosis (217). 
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Luciferase reporter assays of rs11225395 revealed that the minor T allele had greater 
expression in breast cancer cells than the C allele. Additionally when the two alleles 
were subjected to electrophoretic mobility shift assay, no DNA-protein complexes were 
detected in conjunction with C allele. However three such complexes where seen with 
the T allele (Figure A3; see p180); the DNA-protein complexes may have been different 
nuclear proteins or three different fractions of the same protein. It is possible that the 
increased expression seen with the minor T allele is due to the nuclear proteins 
selectively binding to it acting as transcriptional enhancers. There were no good 
matches for consensus cis-elements with the rs11225395 T allele sequence when 
querying transcription factor binding databases but these are not yet exhaustive and so 
the nuclear protein may not be present within the databases. 
 
Collaborators in Shanghai examined only the rs11225395 SNP because within the 
Leuven study it was most significantly associated with lymph node metastasis; in LD 
with the other three SNPs associated with metastasis (i.e. rs1940475, rs1892886, and 
rs1276284; in Caucasian & Chinese populations) and had been suggested to have an 
effect on MMP8 gene expression in the literature (50). Also haplotype analysis of the 
nine SNPs in the Leuven study showed that the T allele of rs11225395 tagged the 
haplotypes associated with reduced lymph node metastasis (HAP 2, and HAP 4) whilst 
the C allele tagged haplotypes associated with higher metastasis risk (HAP 1, and HAP 
3).  
 
Whilst the minor alleles of rs11225395, rs1940475, rs1892886, and rs1276284 were 
associated with a reduced risk of lymph node metastasis; not all of the respective alleles 
need have a direct functional effect on the activity of the MMP8 promoter or enzyme, 
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associations may be indicative of LD between the alleles and true functional variants. 
The functional studies of the rs11225395 SNP presented in sections 3.2.5 & A4.2 
evidence a direct functional role for this promoter SNP aligning with the minor allele‟s 
association with reduced risk of lymph node metastasis and cancer relapse and 
improved survival. The rs1940475 variant is a plausible candidate for a functional role 
as it is a non-synonymous SNP occurring in exon 2 of the MMP8 gene. The SNP results 
in a glutamate to lysine substitution at amino acid residue 87 which is proximal to the 
cysteine residue that forms part of the „cysteine switch‟ motif and mechanism involved 
in conversion of the zymogen into the active enzyme. While at the time that the data 
discussed here was published (48) there had been no functional data for this SNP, 
subsequent functional analysis has shown the T allele to be less amenable to activation 
(Section A4.3.1.) and will be discussed in relation to atherosclerosis further on. The 
other two SNPs found to be associated with lymph node involvement, rs1892886 and 
rs1276284, are located in intron 4 and the 3‟ flanking region of the gene respectively, 
hence they are less likely candidates for functional role. Currently there is no functional 
data for these polymorphisms; none of the data, functional or otherwise precludes any 
or all of the four SNPs from tagging the effects SNPs not tested in this study. 
 
As mentioned in section 1.2.5 other MMP SNPS have been associated with cancer; 
Table 1.1 shows that most of the alleles leading to increased expression of the relevant 
MMP are associated with an increased susceptibility to cancer and/or metastasis; the 
data presented here shows a contrasting anti-tumourigenic effect of the higher 
expressing T allele of the rs11225395 MMP8 SNP; MMP12 is the best example of 
another MMP found to be beneficial by genetic studies in cancer; the lower expressing 
allele of rs2276109 is associated with poor prognosis in bladder cancer (55).  
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The small sample size of Leuven study gives some limitation to definitive conclusions 
regarding MMP8 variation and breast cancer, although this was somewhat remedied by 
the complementary findings by collaborators in a larger independent study with strong 
methodology (The Shanghai Breast Cancer Study). In common with all research any 
conclusions drawn can only be verified by replication and further work.  
 
Further investigations into MMP8 gene variation and breast cancer encompassed the 
genotyping of the „Strangeways‟ breast cancer cases (SEARCH) and controls (EPIC) 
(156), and genotyping cases and controls from a Polish study (162). This revealed that 
three of the four SNPs associated with lymph node metastasis in the Leuven study were 
significantly associated with increased susceptibility to breast cancer in the 
„Strangeways‟ population. The SNPs being rs11225395, rs1892886, and rs1276284, the 
minor alleles of each polymorphism were found to have higher frequencies in patients 
with breast cancer compared to controls. The promoter SNP rs11225395 was the only 
MMP8 variant to be investigated regarding breast cancer in the Polish study; unlike the 
Leuven and Strangeways studies, no significant association was found. Since the both 
the Strangeways study and the Polish study are case control studies of breast cancer 
involving Caucasians of European descent it was feasible to perform a meta-analysis 
combining the results for the rs11225395 SNP in the two studies. The meta-analysis 
showed an association between the minor allele (T) and the occurrence of breast cancer 
with no significant heterogeneity was detected.  
 
Despite significant associations involving the same SNPs in three studies, these results 
indicate diversity in the findings rather than replication and complementation. This is 
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best illustrated by focus on just the associations attributed to the minor (T) allele of 
rs11225395; in the Leuven study this allele confers a beneficial reduced risk of lymph 
node metastasis. The beneficial effect is supported by independent findings by 
collaborators, albeit in a non-Caucasian population (Chinese women). Contrary to these 
beneficial associations, the results from the Strangeways study and its meta-analysis 
with the Polish study indicate an increased risk of breast cancer conferred by the T 
allele. While Polish study is of a relatively small size, the Strangeways study consists of 
4550 individuals giving it a reasonable power to detect causal variants. It must be 
pointed out that, while apparently divergent, the end points are not the same pertaining 
to different stages of a complex disease (initiation & progression). Furthermore only 
patients were genotyped in the Leuven and Shanghai studies whereas the Polish and 
Strangeways study involved both patients and healthy controls. Possible explanations 
for this dichotomy are type 1 error, or even a potential „flip-flop‟ effect  (218) caused by 
the level of correlation with a true causal variant at another locus differing in different 
populations. However also presented here is reasonable evidence for the rs11225395 
polymorphism to be a functional SNP; luciferase assays in both the MDA-MB-231 and 
A2058 cancer cell lines, and EMSA results from MDA-MB-231 nuclear extract. Recent 
investigations into cardiovascular disease also show the T allele significantly associated 
with higher levels of serum MMP8 (219). The majority of published evidence regarding 
MMP8 and breast cancer points to a protective function (120, 121, 217); regarding other 
neoplastic pathologies there is also evidence to show a protective role against lung 
cancer (49). Mutational and cell analyses of MMP8 suggest a tumour suppressor 
function in melanoma (220). Finally, subsequent work by the Shanghai breast cancer 
study was able to replicate the initial finding (published in conjunction with the Leuven 
study) (48); genotyping an additional 5192 breast cancer patients; women homozygous 
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for the TT genotype had better overall survival than women with the CC genotype (HR: 
0.6, 95% CI: 0.4–0.9, p = 0.02) (221). 
 
The „flip-flop‟ between the Leuven and Strangeways studies was not limited to the 
rs11225395 SNP but included rs1892886, and rs1276284. Taken at face value these 
data demonstrate a complex relationship between MMP8 and breast cancer that may 
involve the promotion of breast cancer initiation but thereafter providing a protective 
role regarding metastasis lymph node metastasis and prognosis. A similar conclusion 
was drawn for an allele of promoter polymorphism of the chemokine RANTES “a risk 
factor for HIV transmission and as a protective factor for HIV progression” (222). Our 
findings combined with both prior and post studies build a strong argument the 
importance of MMP8 in cancers, particularly in a protective role. 
 
4.1.3 MMP8 gene variation and malignant melanoma 
 
Similar to the rs11225395 breast cancer results from the Strangeways study and its 
meta-analysis with the Polish study; the T allele of this MMP8 promoter SNP was 
significantly associated with an increased risk of malignant melanoma. Luciferase 
reporter assays show this allele has approximately a twofold higher activity than the 
major (C) allele in melanoma cells (A2058). Current literature favours a tumour 
suppressor role for MMP8 in melanoma; Palavalli et al (220) found it to be frequently 
mutated in melanoma, the wild type was able to inhibit human melanoma cell growth in 
vitro and suppress metastasis in vivo. A separate study showed that overexpression of 
MMP8 causes inhibition of invasion and transendothelial migration of murine 
melanoma cells in vitro, and is anti-metastatic in vivo (217). However the genotyping 
the exon 2 non-synonymous SNP (rs1940475) by different case control study revealed 
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no association with melanoma (223). Only one other study shows a potential negative 
role for this enzyme regarding melanoma; it found higher MMP8 serum levels to 
associated with melanoma ulceration vascular invasion (224). 
 
The results presented here indicate, as potentially with breast cancer, that MMP8 may 
increase susceptibly to this disease but play a suppressing role further down the line. 
 
4.1.4 MMP8 gene variation and atherosclerosis  
 
The study into MMP8 gene variation in CAD patients found association with the extent 
of coronary atherosclerosis. The same missense variation was also associated with the 
progression of carotid atherosclerosis and circulating levels of soluble VCAM-1 in the 
prospective Bruneck study. The rs1940475 SNP is situated in the pro-domain of MMP8, 
proximal to residues involved in the cysteine switch activation mechanism.  Western 
blot analysis (Section A4.3) showed the missense allele had an effect of reduced MMP8 
zymogen activation (Figure A4).  
 
Similar to investigations into cancer, most early efforts to elucidate the role of MMPs in 
cardiovascular diseases concentrated on their matrix remodelling properties and ability 
to degrade structural components of the ECM. Undoubtedly this aspect of MMP 
functionality is involved in part in the development and even acute episodes of CVD 
(69). It is emerging however that this is not the whole story, more recently other studies 
have begun to investigate various effects that MMPs can have through the processing of 
non-matrix molecules such as cell bound growth factors and receptors, adhesion 
molecules, cytokines and other MMP zymogens (6). The link seen in this study between 
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MMP8 gene variation and the extent of atherosclerosis and circulating levels of soluble 
VCAM-1 points to another potential route by which MMP8 can be involved in the 
pathogenesis of atherosclerosis. VCAM-1 is not the only atherogenic molecule that can 
be linked to MMP8, as it is able to generate Ang II from Ang I (194), The generation of 
Ang II by MMP8 provides a plausible mechanism for part of MMP8‟s role in 
atherosclerosis. Potential Ang II mediated pro-atherogenic effects include elevated 
blood pressure, production of ROS, activation of NF-kB and subsequently induced 
molecules that not only include VCAM-1, but also MCP-1 and ICAM-1 (225). 
Induction of adhesion factors such as VCAM-1 and ICAM-1 facilitate the recruitment 
of monocytes which are then attracted into lesions via MCP-1 chemokine gradients. 
Ang II has also been shown to induce ox-LDL-receptor LOX-1, known to play a 
prominent role in the activation of the endothelium (226). Unfortunately it was not 
possible to query the relative levels of Ang I or Ang II in the Southampton CAD 
patients or the Bruneck Study, in order to detect a potential link with MMP8 gene 
variation and these factors. Further exploration of a mechanism for the involvement of 
MMP8 with the pathogenesis of atherosclerosis is discussed in the section concerning 
biochemical and in vivo animal studies. 
4.2 Effects of Ang I cleavage products by MMP8 on the murine VCAM-1 
promoter 
 
Luciferase assays used to assess effects of Ang I cleavage by MMP8 on the murine 
VCAM-1 promoter confirmed that it has a functioning NF-kB response element; this is 
not in itself surprising as the human equivalent has previously been confirmed (185), 
added to this is that the murine and human genes share considerable homology (186). It 
was surprising that these assays failed to show significant differences in the effects of 
the aforementioned cleavage products on the promoter activity (see Fig 3.9); 
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particularly as Ang II is known to upregulate VCAM-1 (227), and as flow cytometry 
analysis performed concurrently by a colleague showed an increased VCAM-1 
expression.  A relatively small part of the proximal VCAM-1 promoter was assessed; it 
is possible that distal cis-elements for other transcription factors were required to work 
in conjunction NF-kB. Ultimately the results from the flow cytometry provided a closer 
model to in vivo physiological situations; as such this avenue was not pursued further.      
4.3 Information from biochemical and animal studies of MMP8 and 
atherosclerosis 
 
The following section discusses work in this study that was largely collaborative; as 
such a substantial proportion of the results were not directly generated by this 
investigator. Brief descriptions of the methods, along with those results are presented in 
the appendices (specifically Section A4.4 onwards). They are provided and discussed 
because they give context the data presented here and give a fuller story of the potential 
mechanism of MMP8 in the pathogenesis of atherosclerosis. 
 
As mentioned MMP8 has the ability to process Ang I into Ang II , the principal effector 
molecule in the Renin-Angiotensin system (RAS) (225), a finding confirmed in this 
study. It was also found that products of Ang I cleavage by MMP8 induced elevated 
expression of VCAM-1 in murine endothelial cells in vitro (Figure A6), previously 
shown to be induced by Ang II (227, 228).  
 
Prior to this study the loss of MMP8 had not been characterised using the ApoE 
deficient murine atherosclerosis model (195, 196). Here it was shown that the extent of 
the disease, induced by a high fat western diet, was much reduced in animals also 
deficient in MMP8 when compared with animals with the functional MMP8 wildtype. 
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There was a reduced amount of oil red O staining and fewer inflammatory cells were 
seen in the lesions of the MMP8 deficient mice, which also had higher collagen content 
(Figure A8).  In agreement with biochemical data on the generation of Ang II by MMP8 
there were lower levels of the vasoactive, pro-atherogenic molecule Ang II were seen in 
the double knock-out animals with concurrent higher levels of the precursor molecule 
Ang I. Consistent with the relative levels of Ang II in the two groups, blood pressure 
was found to be lower in the MMP8 deficient mice than the controls (Figure A9). This 
was in agreement with the finding that there were lower levels of VCAM-1 expression 
observed in the MMP8 KO mice compared with the controls (Figure A10). This 
correlates very well with the data provided by colleagues showing reduced leukocyte 
recruitment/rolling in the MMP8 deficient group of mice (Figure A11).  
 
The principle enzyme associated with the conversion of Ang I into Ang II is ACE, 
consequently many anti-hypertension therapeutics have been ACE inhibitors. ACE like 
MMP8 is a zinc dependent protease and belongs to the metallopeptidase superfamily 
(229, 230). An inherent feature of this superfamily is the considerable conservation seen 
in the sequence and structure of their catalytic domains (231), illustrated by coincident 
substrates and also the inhibition of MMPs by ACE inhibitors captopril, enalapril, 
lisinopril, and quinapril (232-237). Apart from ACE and MMP8, some cysteine and 
serine proteases have been shown to have the ability to perform the Ang I to Ang II 
conversion, these include chymases, and cathepsins (203). There were no significant 
differences in the levels of activity of ACE, chymases or cathepsins between the two 
groups of animals, enhancing the probability that MMP8 can cause RAS mediated 
effects, particularly in physiological or pathophysiological situations with a scarcity of 
the other enzymes. 
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Another potential avenue by which MMP8 may influence the progression of 
atherosclerosis is the inactivation of substance P (194). The MMP8 enzyme is able to 
cleave between  C terminus residues: Gly[9] and Leu[10], without the C-terminus 
residues substance P is unable to bind to tachykinin receptors (238). Similar to cleaving 
Ang I, the degradation of substance P by MMP8 can potentially lead to elevated blood 
pressure as it is generally a potent vasodilator, although when acting upon neurokinin-1 
receptors on SMCs substance P can have vasoconstrictor properties (239). Relevantly 
substance P may activate mast cells and induce intraplaque haemorrhage (240, 241). 
Measurement of plasma and mesenteric substance P did not show any significant 
differences between the two groups making it less likely that this in an avenue by which 
MMP8 can affect atherosclerosis. 
 
There have been several previous studies using murine atherosclerosis models showing 
the individual roles of MMPs (shown in Table 1.6) are complex, some appearing play a 
protective role while others appear to further the extent of disease. In an MMP1 mouse 
model, human MMP1 (hMMP1) was expressed in macrophages, as there is no murine 
homolog. The study found that lesion was size reduced in the hMMP1 transgenic 
animals but they also reduced collagen content, although there was no sign of plaque 
rupture (242). The third collagenase (MMP13) was seen to have a role in plaque 
collagen catabolism, knockout mice having increased content of interstitial collagen in 
their lesions (243). MMP2 (gelatinase-A) deficient mice were found to have reduced 
plaque and decreased SMCs, with no upregulation of MMP9 (gelatinase-B) (244). 
Conclusions on the role of MMP9 are not as clear; some studies indicate a detrimental 
effect, knockout animals having impaired SMC migration and smaller aortic lesion size 
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(137, 245, 246). Additionally an activated version of MMP9 when expressed from 
macrophages induced considerable plaque disruption (247). However another murine 
study focussing on lesions in the brachiocephalic artery showed that animals deficient in 
MMP9 had lesions that were much increased in size with an unstable phenotype. The 
same study concurrently investigating MMP12, showed that there were smaller lesions 
and a more stable phenotype in the double knockout group (142). Murine studies with 
MMP3 suggest a protective effect, enzyme deficiency causing increased lesion size and 
reduced SMC content (142, 248). MMP7 deficiency seemed to have a relatively neutral 
effect not causing any significant change in lesion development or stability, although 
lesions did show increased SMC compared to littermates only deficient for ApoE (142). 
MMP14 deficiency is lethal by 3 weeks, as such a study gave irradiated LDLR deficient 
mice either MMP14
-/-
 or MMP14
+/+
 bone marrow derived cells (BMDCs). There was 
more interstitial collagen within the lesions of the animals with MMP14
-/-
 BMDCs, 
although no other change in size or content (249). Along with MMP8 several MMP‟s 
(MMP1, MMP3, MMP13 and MMP14) were shown to reduce the collagen content of 
lesions, potentially reducing plaque stability. However, in these models, MMP8 is 
unique correlated to decreased collagen, more inflammatory cells, and larger lesions. 
 
This part of this study with regard to MMP8 and atherosclerosis has some limitations. 
Only the aorta was studied as a site of lesion formation, Johnson and colleagues showed 
studying the brachiocephalic site can sometimes give different results (142). The data 
was collected for only the 12 week time point on a western diet. It would be interesting 
to compare shorter and longer time points in order to gain more information to its role 
in the initiation and progression of the disease. Furthermore it would have been 
advantageous to investigate for evidence of plaque rupture (250). The animal study has 
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highlighted a potential route for MMP8 to affect atherosclerosis via the conversion from 
angiotensin I to angiotensin II. It would have been pertinent to investigate any 
correlation between MMP8 genotype and Ang II levels in the human studies 
(Southampton CAD patients and Bruneck), unfortunately these data are unavailable. 
 
In summary both human and murine studies pointed to an important role for MMP8 in 
atherosclerosis. In combination with prior associations between its plaque levels and 
unstable phenotype (149-151) there is a compelling case for a significant role for 
MMP8 in this disease. 
 
  
153 
 
References 
1. Ala-aho R, Kähäri V. Collagenases in cancer. Biochimie. 2005 2005 Mar-
Apr;87(3-4):273-86. 
2. Tallant C, Marrero A, Xavier Gomis-Ruth F. Matrix metalloproteinases: Fold 
and function of their catalytic domains. Biochimica Et Biophysica Acta-Molecular Cell 
Research. 2010 Jan;1803(1). 
3. Fanjul-Fernandez M, Folgueras AR, Cabrera S, Lopez-Otin C. Matrix 
metalloproteinases: Evolution, gene regulation and functional analysis in mouse models. 
Biochimica Et Biophysica Acta-Molecular Cell Research. 2010 Jan;1803(1):3-19. 
4. Stocker W, Bode W. Structural features of a superfamily of zinc-endopeptidases 
- the metzincins. Current Opinion in Structural Biology. 1995 Jun;5(3):383-90. 
5. Yan C, Boyd D. Regulation of matrix metalloproteinase gene expression. J Cell 
Physiol. 2007 Apr;211(1):19-26. 
6. Clark IA, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix 
metalloproteinases and their inhibitors. International Journal of Biochemistry & Cell 
Biology. 2008;40(6-7):1362-78. 
7. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of 
metalloproteinases - Structure, function, and biochemistry. Circulation Research. 2003 
May;92(8):827-39. 
8. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as 
modulators of inflammation and innate immunity. Nature Reviews Immunology. 2004 
Aug;4(8):617-29. 
9. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. 
Trends in Genetics. 1990 Apr;6(4):121-5. 
10. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. 
Trends in Biochemical Sciences. 2006 Feb;31(2):89-97. 
11. Chicoine E, Esteve PO, Robledo O, Van Themsche C, Potworowski EF, St-
Pierre Y. Evidence for the role of promoter methylation in the regulation of MMP-9 
gene expression. Biochemical and Biophysical Research Communications. 2002 
Oct;297(4):765-72. 
12. Couillard J, Demers M, Lavoie G, St-Pierre Y. The role of DNA 
hypomethylation in the control of stromelysin gene expression. Biochemical and 
Biophysical Research Communications. 2006 Apr;342(4):1233-9. 
13. Reunanen N, Li SP, Ahonen M, Foschi M, Han JH, Kahari VM. Activation of 
p38 alpha MAPK enhances collagenase-1 (Matrix metalloproteinase (MMP)-1) and 
stromelysin-1 (MMP-3) expression by mRNA stabilization. Journal of Biological 
Chemistry. 2002 Aug;277(35):32360-8. 
14. Xia HP, Qi YT, Ng SS, Chen XN, Li D, Chen S, et al. microRNA-146b inhibits 
glioma cell migration and invasion by targeting MMPs. Brain Research. 2009 
May;1269:158-65. 
15. Vanwart HE, Birkedalhansen H. The cysteine switch - a principle of regulation 
of metalloproteinase activity with potential applicability to the entire matrix 
metalloproteinase gene family. Proceedings of the National Academy of Sciences of the 
United States of America. 1990 Jul;87(14):5578-82. 
16. Owen CA, Hu ZM, Lopez-Otin C, Shapiro SD. Membrane-bound matrix 
metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of 
metalloproteinase-resistant collagenase and serpinase. Journal of Immunology. 2004 
Jun 15;172(12):7791-803. 
154 
 
17. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in 
regulation of gene expression and susceptibility of various diseases. Matrix Biology. 
2000 Dec;19(7):623-9. 
18. Goldstein DB, Weale ME. Population genomics: Linkage disequilibrium holds 
the key. Current Biology. 2001 Jul 24;11(14):R576-R9. 
19. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary-report - 
genetic-variation in the human stromelysin promoter is associated with progression of 
coronary atherosclerosis. British Heart Journal. 1995 Mar;73(3):209-15. 
20. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. 
Progression of coronary atherosclerosis is associated with a common genetic variant of 
the human stromelysin-1 promoter which results in reduced gene expression. Journal of 
Biological Chemistry. 1996 May;271(22):13055-60. 
21. Souslova V, Townsend PA, Mann J, van der Loos CM, Motterle A, D'Acquisto 
F, et al. Allele-Specific Regulation of Matrix Metalloproteinase-3 Gene by 
Transcription Factor NF kappa B. Plos One. 2010 Mar;5(3). 
22. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic 
polymorphisms on interleukin 6 transcriptional regulation. Journal of Biological 
Chemistry. [Article]. 2000 Jun;275(24):18138-44. 
23. Frisdal E, Klerkx A, Le Goff W, Tanck MWT, Lagarde JP, Jukema JW, et al. 
Functional interaction between-629C/A,-971G/A and-1337C/T polymorphisms in the 
CETP gene is a major determinant of promoter activity and plasma CETP concentration 
in the REGRESS Study. Human Molecular Genetics. [Article]. 2005 Sep;14(18):2607-
18. 
24. Pearce E, Tregouet DA, Samnegard A, Morgan AR, Cox C, Hamsten A, et al. 
Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial 
infarction. Circulation Research. 2005 Nov;97(10):1070-6. 
25. Zhu Y, Spitz MR, Lei L, Mills GB, Wu XF. A single nucleotide polymorphism 
in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer 
Research. 2001 Nov;61(21):7825-9. 
26. Woo M, Park K, Nam J, Kim JC. Clinical implications of matrix 
metalloproteinase-1,-3,-7,-9,-12, and plasminogen activator inhibitor-1 gene 
polymorphisms in colorectal cancer. Journal of Gastroenterology and Hepatology. 
[Article]. 2007 Jul;22(7):1064-70. 
27. Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, et 
al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 
and MMP-9 in breast cancer. Breast Cancer Research and Treatment. 2006;95(1):65-72. 
28. Six L, Grimm C, Leodolter S, Tempfer C, Zeillinger R, Sliutz G, et al. A 
polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the 
prognosis of patients with ovarian cancer. Gynecologic Oncology. [Article]. 2006 
Mar;100(3):506-10. 
29. Ye S, Dhillon S, Turner SJ, Bateman AC, Theaker JM, Pickering RM, et al. 
Invasiveness of cutaneous malignant melanoma is influenced by Matrix 
Metalloproteinase 1 gene polymorphism. Cancer Research. 2001 Feb;61(4):1296-8. 
30. Checa M, Ruiz V, Montano M, Velazquez-Cruz R, Selman M, Pardo A. MMP-1 
polymorphisms and the risk of idiopathic pulmonary fibrosis. Human Genetics. 2008 
Dec;124(5):465-72. 
31. Okamoto K, Mimura K, Murawaki Y, Yuasa I. Association of functional gene 
polymorphisms of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-9 with the 
progression of chronic liver disease. Journal of Gastroenterology and Hepatology. 2005 
Jul;20(7):1102-8. 
155 
 
32. Harendza S, Lovett DH, Panzer U, Lukacs Z, Kuhnl P, Stahl RAK. Linked 
common polymorphisms in the gelatinase A promoter are associated with diminished 
transcriptional response to estrogen and genetic fitness. Journal of Biological 
Chemistry. 2003 Jun;278(23):20490-9. 
33. Yu CY, Zhou YF, Miao XP, Xiong P, Tan W, Lin DX. Functional haplotypes in 
the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis 
of esophageal cancer. Cancer Research. 2004 Oct;64(20):7622-8. 
34. Zhou YF, Yu CY, Miao XP, Wang YG, Tan W, Sun T, et al. Functional 
haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. 
Carcinogenesis. 2005 Jun;26(6):1117-21. 
35. Miao XP, Yu CY, Tan W, Xiong P, Liang G, Lu WF, et al. A functional 
polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is 
associated with risk of development but not metastasis of gastric cardia 
adenocarcinomal. Cancer Research. [Article]. 2003 Jul;63(14):3987-90. 
36. Lin SC, Lo SS, Liu CJ, Chung MY, Huang JW, Chang KW. Functional 
genotype in matrix metalloproteinases-2 promoter is a risk factor for oral 
carcinogenesis. Journal of Oral Pathology & Medicine. [Article]. 2004 Aug;33(7):405-
9. 
37. Dong DM, Yao M, Liu B, Sun CY, Jiang YQ, Wang YS. Association between 
the-1306C/T polymorphism of matrix metalloproteinase-2 gene and lumbar disc disease 
in Chinese young adults. European Spine Journal. 2007 Nov;16(11):1958-61. 
38. Fang SM, Jin X, Wang R, Li Y, Guo W, Wang N, et al. Polymorphisms in the 
MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. 
Carcinogenesis. 2005 Feb;26(2):481-6. 
39. Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, et al. A 
single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances 
breast cancer susceptibility. Clinical Cancer Research. 2002 Dec;8(12):3820-3. 
40. Vairaktaris E, Yapijakis C, Vasiliou S, Derka S, Nkenke E, Serefoglou Z, et al. 
Association of-1171 promoter polymorphism of matrix metalloproteinase-3 with 
increased risk for oral cancer. Anticancer Research. 2007 Nov-Dec;27(6B):4095-100. 
41. Djuric T, Zivkovic M, Radak D, Jekic D, Radak S, Stojkovic L, et al. 
Association of MMP-3 5A/6A gene polymorphism with susceptibility to carotid 
atherosclerosis. Clinical Biochemistry. 2008 Nov;41(16-17):1326-9. 
42. Mattey DL, Nixon NB, Dawes PT, Ollier WER, Hajeer AH. Association of 
matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid 
arthritis. Genes and Immunity. 2004 Mar;5(2):147-9. 
43. Kubben F, Sier CFM, Meijer MJW, van den Berg M, van der Reijden JJ, 
Griffioen G, et al. Clinical impact of MMP and TIMP gene polymorphisms in gastric 
cancer. British Journal of Cancer. 2006 Sep;95(6):744-51. 
44. Singh H, Jain M, Mittal B. MMP-7 (-181A > G) promoter polymorphisms and 
risk for cervical cancer. Gynecologic Oncology. 2008 Jul;110(1):71-5. 
45. Vairaktaris E, Serefoglou Z, Yapijakis C, Vylliotis A, Nkenke E, Derka S, et al. 
High gene expression of matrix metalloproteinase-7 is associated with early stages of 
oral cancer. Anticancer Research. 2007 Jul-Aug;27(4B):2493-8. 
46. Zhang JH, Jin X, Fang SM, Wang R, Li Y, Wang N, et al. The functional 
polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to 
esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small 
cell lung carcinoma. Carcinogenesis. 2005 Oct;26(10):1748-53. 
47. Jormsjo S, Whatling C, Walter DH, Zeiher AM, Hamsten A, Eriksson P. Allele-
specific regulation of matrix metalloproteinase-7 promoter activity is associated with 
156 
 
coronary artery luminal dimensions among hypercholesterolemic patients. 
Arteriosclerosis Thrombosis and Vascular Biology. 2001 Nov;21(11):1834-9. 
48. Decock J, Ji-Rong L, Laxton RC, Shu XO, Hodgkinson C, Hendrickx W, et al. 
Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. 
Cancer Research. 2007 Nov;67(21):10214-21. 
49. Gonzalez-Arriaga P, Lopez-Cima MF, Fernandez-Somoano A, Pascual T, 
Marron MG, Puente XS, et al. Polymorphism+17 C/G in Matrix Metalloprotease 
MMP8 decreases lung cancer risk. Bmc Cancer. 2008 Dec;8. 
50. Wang H, Parry S, Macones G, Sammel MD, Ferrand PE, Kuivaniemi H, et al. 
Functionally significant SNP MMP8 promoter haplotypes and preterm premature 
rupture of membranes (PPROM). Human Molecular Genetics. 2004 Nov;13(21):2659-
69. 
51. Vairaktaris E, Vassiliou S, Nkenke E, Serefoglou Z, Derka S, Tsigris C, et al. A 
metalloproteinase-9 polymorphism which affects its expression is associated with 
increased risk for oral squamous cell carcinoma. Ejso. 2008 Apr;34(4):450-5. 
52. Morgan AR, Zhang BP, Tapper W, Collins A, Ye S. Haplotypic analysis of the 
MMP-9 gene in relation to coronary artery disease. Journal of Molecular Medicine-
Jmm. 2003 May;81(5):321-6. 
53. Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA. Matrix 
metalloproteinase-9 genotype influences large artery stiffness through effects on aortic 
gene and protein expression. Arteriosclerosis Thrombosis and Vascular Biology. 2004 
Aug;24(8):1479-84. 
54. Jones GT, Phillips VL, Harris EL, Rossaak JI, van Rij AM. Functional matrix 
metalloproteinase-9 polymorphism (C-1562T) associated with abdominal aortic 
aneurysm. Journal of Vascular Surgery. 2003 Dec;38(6):1363-7. 
55. Kader A, Liu J, Shao L, Dinney C, Lin J, Wang Y, et al. Matrix 
metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin 
Cancer Res. 2007 May;13(9):2614-20. 
56. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas 
of the mouse and human protein-encoding transcriptomes. Proceedings of the National 
Academy of Sciences of the United States of America. 2004 Apr;101(16):6062-7. 
57. Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S, et al. BioGPS: an 
extensible and customizable portal for querying and organizing gene annotation 
resources. Genome Biology. 2009;10(11). 
58. Huxley-Jones J, Clarke TK, Beck C, Toubaris G, Robertson DL, Boot-Handford 
RP. The evolution of the vertebrate metzincins; insights from Ciona intestinalis and 
Danio rerio. Bmc Evolutionary Biology. 2007 Apr;7. 
59. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. 
Annual Review of Cell and Developmental Biology. 2001;17:463-516. 
60. Murphy G, Knauper V. Relating matrix metalloproteinase structure to function: 
Why the ''hemopexin'' domain? Matrix Biology. 1997 Mar;15(8-9):511-8. 
61. Hasty KA, Jeffrey JJ, Hibbs MS, Welgus HG. The collagen substrate-specificity 
of human neutrophil collagenase. Journal of Biological Chemistry. [Article]. 1987 
Jul;262(21):10048-52. 
62. Mallya SK, Mookhtiar KA, Gao Y, Brew K, Dioszegi M, Birkedalhansen H, et 
al. Characterization of 58-kilodalton human neutrophil collagenase - comparison with 
human fibroblast collagenase. Biochemistry. [Article]. 1990 Nov;29(47):10628-34. 
63. Smith GN, Mickler EA, Hasty KA, Brandt KD. Specificity of inhibition of 
matrix metalloproteinase activity by doxycycline - Relationship to structure of the 
enzyme. Arthritis and Rheumatism. 1999 Jun;42(6):1140-6. 
157 
 
64. Van Lint P, Libert C. Matrix metalloproteinase-8: Cleavage can be decisive. 
Cytokine & Growth Factor Reviews. 2006 Aug;17(4):217-23. 
65. McGowan KA, Bauer EA, Smith LT. Localization of type-I human skin 
collagenase in developing embryonic and fetal skin. Journal of Investigative 
Dermatology. [Article]. 1994 Jun;102(6):951-7. 
66. Saarialhokere UK, Chang ES, Welgus HG, Parks WC. Distinct localization of 
collagenase and tissue inhibitor of metalloproteinases expression in wound-healing 
associated with ulcerative pyogenic granuloma. Journal of Clinical Investigation. 
[Article]. 1992 Nov;90(5):1952-7. 
67. Hasty KA, Hibbs MS, Kang AH, Mainardi CL. Secreted forms of human 
neutrophil collagenase. Journal of Biological Chemistry. 1986 Apr;261(12):5645-50. 
68. Cole AA, Chubinskaya S, Schumacher B, Huch K, CsSzabo G, Yao J, et al. 
Chondrocyte matrix metalloproteinase-8 - Human articular chondrocytes express 
neutrophil collagenase. Journal of Biological Chemistry. 1996 May;271(18):11023-6. 
69. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix 
metalloproteinases and matrix-degrading activity in vulnerable regions of human 
atherosclerotic plaques. Journal of Clinical Investigation. [Article]. 1994 
Dec;94(6):2493-503. 
70. Nikkari ST, Obrien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, et 
al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis 
Circulation. 1995 Sep;92(6):1393-8. 
71. Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, 
et al. Evidence for increased collagenolysis by interstitial collagenases-1 and-3 in 
vulnerable human atheromatous plaques. Circulation. 1999 May;99(19):2503-9. 
72. Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Murray T, et al. Cancer statistics, 
2008. Ca-a Cancer Journal for Clinicians. 2008 Mar-Apr;58(2):71-96. 
73. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, et al. Global 
cancer facts & figures 2007. Atlanta, GA: American Cancer Society. 2007:25-6. 
74. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. 
75. Fedi P, Tronick SR, Aaronson SA. Growth factors. In: Holland JF, Bast RC, 
Morton DL, Frei E, Kufe DW, Weichselbaum RR, editors. Cancer Medicine. Baltimore, 
MD: Williams and Wilkins; 1997. p. 41-64. 
76. Fynan TM, Reiss M. Resistance to inhibition of cell-growth by transforming 
growth-factor-beta and its role in oncogenesis. Critical Reviews in Oncogenesis. 
[Review]. 1993;4(5):493-540. 
77. Miyashita T, Reed JC. Tumor-suppressor p53 is a direct transcriptional activator 
of the human bax gene. Cell. [Article]. 1995 Jan;80(2):293-9. 
78. Bryan TM, Cech TR. Telomerase and the maintenance of chromosome ends. 
Current Opinion in Cell Biology. [Article]. 1999 Jun;11(3):318-24. 
79. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in 
fibroblasts by p53 regulation of thrombospondin-1. Science. 1994 Sep 9;265(5178). 
80. Gupta GP, Massague J. Cancer metastasis: Building a framework. Cell. 
[Review]. 2006 Nov;127(4):679-95. 
81. Fidler IJ. Timeline - The pathogenesis of cancer metastasis: the 'seed and soil' 
hypothesis revisited. Nature Reviews Cancer. 2003 Jun;3(6):453-8. 
82. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nature 
Reviews Cancer. 2003 Dec;3(12):921-30. 
83. Beral V, Bull D, Doll R, Peto R, Reeves G, Collaborative Group on Hormonal 
Factors in Breast C. Familial breast cancer: collaborative reanalysis of individual data 
158 
 
from 52 epidemiological studies including 58 209 women with breast cancer and 101 
986 women without the disease. Lancet. 2001 Oct;358(9291):1389-99. 
84. Houlston RS, Peto J. The search for low-penetrance cancer susceptibility alleles. 
Oncogene. 2004;23(38):6471-6. 
85. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: Markers and 
models. Nature Reviews Cancer. 2005;5(8):591-602. 
86. Miller AJ, Mihm MC, Jr. Mechanisms of disease - Melanoma. New England 
Journal of Medicine. 2006 Jul 6;355(1):51-65. 
87. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, 
Chanmugam A. Cutaneous malignant melanoma. Mayo Clinic Proceedings. 2006 
Apr;81(4):500-7. 
88. Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, et 
al. Final Version of 2009 AJCC Melanoma Staging and Classification. Journal of 
Clinical Oncology. 2009 Dec 20;27(36):6199-206. 
89. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted 
therapy. Nature. 2007 Feb 22;445(7130):851-7. 
90. Blackburn JS, Liu I, Coon CI, Brinckerhoff CE. A matrix metalloproteinase-
1/protease activated receptor-1 signaling axis promotes melanoma invasion and 
metastasis. Oncogene. [Article]. 2009 Dec;28(48):4237-48. 
91. Durko M, Brodt P. Suppression of type I collagenase expression by antisense 
RNA in melanoma cells results in reduced synthesis of the urokinase-type plasminogen 
activator receptor. Biochemical and Biophysical Research Communications. [Article]. 
1998 Jun;247(2):342-8. 
92. Ntayi C, Lorimier S, Berthier-Vergnes O, Hornebeck W, Bernard P. Cumulative 
influence of matrix metalloproteinase-1 and -2 in the migration of melanoma cells 
within three-dimensional type I collagen lattices. Experimental Cell Research. [Article]. 
2001 Oct;270(1):110-8. 
93. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: New Insights and 
New Therapies. Journal of Investigative Dermatology. [Review]. 2012 Mar;132(3):854-
63. 
94. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations 
of the BRAF gene in human cancer. Nature. [Article]. 2002 Jun;417(6892):949-54. 
95. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between 
NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. Journal of 
Investigative Dermatology. [Article]. 2004 Feb;122(2):337-41. 
96. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, et 
al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer 
Research. [Article]. 2004 Oct;64(19):7002-10. 
97. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene. [; 
Review]. 2003 2003 May;22(20):3092-8. 
98. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene. 
[Article]. 2003 May;22(20):3113-22. 
99. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, et al. 
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. [Article]. 
2001 Jan;409(6817):207-11. 
100. Straume O, Akslen LA. Alterations and prognostic significance of p16 and p53 
protein expression in subgroups of cutaneous melanoma. International Journal of 
Cancer. [Article]. 1997 Oct;74(5):535-9. 
159 
 
101. Sauter ER, Yeo UC, von Stemm A, Zhu WZ, Litwin S, Tichansky DS, et al. 
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Research. [Article]. 
2002 Jun;62(11):3200-6. 
102. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: 
Innovations for the post-trial era. Nature Reviews Cancer. 2002 Sep;2(9):657-72. 
103. Lopez-Otin C, Matrisian LM. Tumour micro environment - Opinion - Emerging 
roles of proteases in tumour suppression. Nature Reviews Cancer. 2007 Oct;7(10):800-
8. 
104. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell 
surface provides a mechanism for CD44-mediated tumor invasion. Genes & 
Development. 1999 Jan 1;13(1). 
105. Pozzi A, LeVine WF, Gardner HA. Low plasma levels of matrix 
metalloproteinase 9 permit increased tumor angiogenesis. Oncogene. 2002 
Jan;21(2):272-81. 
106. Gorrin-Rivas MJ, Arii S, Furutani M, Mizumoto M, Mori A, Hanaki K, et al. 
Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses 
primary tumor growth by halting angiogenesis. Clinical Cancer Research. 2000 
May;6(5):1647-54. 
107. Murray GI, Duncan ME, Oneil P, Melvin WT, Fothergill JE. Matrix 
metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature 
Medicine. [Article]. 1996 Apr;2(4):461-2. 
108. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. 
Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. 
Journal of Pathology. 1998 Jul;185(3):256-61. 
109. Ito T, Ito M, Shiozawa J, Naito S, Kanematsu T, Sekine I. Expression of the 
MMP-1 in human pancreatic carcinoma: Relationship with prognostic factor. Modern 
Pathology. [Article]. 1999 Jul;12(7):669-74. 
110. Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J, Leffall LD. 
Identification of MMP-1 as a putative breast cancer predictive marker by global gene 
expression analysis. Nature Medicine. [Article]. 2005 May;11(5):481-3. 
111. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen 
S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter 
disease-free survival in human metastatic melanoma. International Journal of Cancer. 
[Article]. 2002 Feb;97(4):432-8. 
112. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, et al. A 
single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an 
Ets binding site and augments transcription. Cancer Research. 1998 Dec;58(23):5321-5. 
113. Su L, Zhou W, Park S, Wain JC, Lynch TJ, Liu G, et al. Matrix 
metalloproteinase-1 promoter polymorphism and lung cancer risk. Cancer 
Epidemiology Biomarkers & Prevention. [Article]. 2005 Mar;14(3):567-70. 
114. Ghilardi G, Biondi ML, Mangoni J, Leviti S, DeMonti M, Guagnellini E, et al. 
Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal 
cancer invasiveness. Clinical Cancer Research. 2001 Aug;7(8):2344-6. 
115. Zinzindohoue F, Lecomte T, Ferraz JM, Houllier AM, Cugnenc PH, Berger A, 
et al. Prognostic significance of MMP-1 and MMP-3 functional promoter 
polymorphisms in colorectal cancer. Clinical Cancer Research. 2005 Jan;11(2):594-9. 
116. Przybylowska K, Zielinska J, Zadrozny M, Krawczyk T, Kulig A, Wozniak P, et 
al. An association between the matrix metalloproteinase 1 promoter gene polymorphism 
and lymphnode metastasis in breast cancer. Journal of Experimental & Clinical Cancer 
Research. [Article]. 2004 Mar;23(1):121-5. 
160 
 
117. Moilanen M, Pirila E, Grenman R, Sorsa T, Salo T. Expression and regulation of 
collagenase-2 (MMP-8) in head and neck squamous cell carcinomas. Journal of 
Pathology. 2002;197(1):72-81. 
118. Stadlmann S, Pollheimer J, Moser PL, Raggi A, Amberger A, Margreiter R, et 
al. Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the 
progression of ovarian cancer. European Journal of Cancer. 2003;39(17):2499-505. 
119. Stenman M, Paju A, Hanemaaijer R, Tervahartiala T, Leminen A, Stenman UH, 
et al. Collagenases (MMP-1,-8 and-13) and trypsinogen-2 in fluid from benign and 
malignant ovarian cysts. Tumor Biology. [Article]. 2003 Jan-Feb;24(1):9-12. 
120. Agarwal D, Goodison S, Nicholson B, Tarin D, Urquidi V. Expression of matrix 
metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with 
the absence of metastasis in an isogenic human breast cancer model. Differentiation. 
2003 Mar;71(2):114-25. 
121. Montel V, Kleeman J, Agarwal D, Spinella D, Kawai K, Tarin D. Altered 
metastatic behavior of human breast cancer cells after experimental manipulation of 
matrix metalloproteinase 8 gene expression. Cancer Research. 2004 Mar;64(5):1687-94. 
122. Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A, et al. Loss 
of collagenase-2 confers increased skin tumor susceptibility to male mice. Nature 
Genetics. 2003 Nov;35(3):252-7. 
123. Libby P. Inflammation in atherosclerosis. Nature. 2002 Dec;420(6917):868-74. 
124. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. Chronic diseases 1 
- The burden and costs of chronic diseases in low-income and middle-income countries. 
Lancet. 2007 Dec;370(9603):1929-38. 
125. Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo-Fernandez R, et 
al. European cardiovascular disease statistics. Brussels: European Heart Network. 2008. 
126. Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical 
coronary stenosis - instantaneous flow response and regional distribution during 
coronary hyperemia as measures of coronary flow reserve. American Journal of 
Cardiology. 1974;33(1):87-94. 
127. Fuster V, Badimon L, Badimon JJ, Chesebro JH. Mechanisms of disease - the 
pathogenesis of coronary-artery disease and the acute coronary syndromes .1. New 
England Journal of Medicine. 1992 Jan;326(4):242-50. 
128. Grech ED, Ramsdale DR. ABC of interventional cardiology - Acute coronary 
syndrome: unstable angina and non-ST segment elevation myocardial infarction. British 
Medical Journal. 2003 Jun;326(7401):1259-61. 
129. Alpert JS, Antman E, Apple F, Armstrong PW, Bassand JP, de Luna AB, et al. 
Myocardial infarction redefined - A consensus Document of the Joint European Society 
of Cardiology/American College of Cardiology Committee for the Redefinition of 
Myocardial Infarction. Journal of the American College of Cardiology. 2000 
Sep;36(3):959-69. 
130. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart 
disease and stroke statistics - 2008 update - A report from the American Heart 
Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 
[Review]. 2008 Jan;117(4):E25-E146. 
131. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an 
integrated view. Trends in Neurosciences. [Review]. 1999 Sep;22(9):391-7. 
132. Lusis AJ. Atherosclerosis. Nature. 2000 Sep;407(6801):233-41. 
133. VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis - Site-
selective responses to atherosclerotic modulators. Arteriosclerosis Thrombosis and 
Vascular Biology. 2004;24(1):12-22. 
161 
 
134. Gimbrone MA. Vascular endothelium, hemodynamic forces, and atherogenesis. 
American Journal of Pathology. 1999;155(1):1-5. 
135. Dai GH, Kaazempur-Mofrad MR, Natarajan S, Zhang YZ, Vaughn S, Blackman 
BR, et al. Distinct endothelial phenotypes evoked by arterial waveforms derived from 
atherosclerosis-susceptible and -resistant regions of human vasculature. Proceedings of 
the National Academy of Sciences of the United States of America. 
2004;101(41):14871-6. 
136. Ross R. Mechanisms of disease - Atherosclerosis - An inflammatory disease. 
New England Journal of Medicine. 1999 Jan;340(2):115-26. 
137. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and 
atherogenesis - The good, the bad, and the ugly. Circulation Research. 2002 
Feb;90(3):251-62. 
138. Cybulsky MI, Iiyama K, Li HM, Zhu SN, Chen M, Iiyama M, et al. A major role 
for VCAM-1, but not ICAM-1, in early atherosclerosis. Journal of Clinical 
Investigation. 2001;107(10):1255-62. 
139. Ye S, Gale CR, Martyn CN. Variation in the matrix metalloproteinase-1 gene 
and risk of coronary heart disease. European Heart Journal. 2003 Sep;24(18):1668-71. 
140. Ghilardi G, Biondi ML, DeMonti M, Turri O, Guagnellini E, Scorza R. Matrix 
metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are 
associated with carotid artery stenosis. Stroke. 2002 Oct;33(10):2408-12. 
141. Back M, Ketelhuth DFJ, Agewall S. Matrix Metalloproteinases in 
Atherothrombosis. Progress in Cardiovascular Diseases. 2010 Mar-Apr;52(5):410-28. 
142. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix 
metalloproteinase-3, metalloproteinase-7, metalloproteinase-9, and metalloproteinase-
12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proceedings of 
the National Academy of Sciences of the United States of America. 2005 
Oct;102(43):15575-80. 
143. Choi ET, Collins ET, Marine LA, Uberti MG, Uchida H, Leidenfrost JE, et al. 
Matrix metalloproteinase-9 modulation by resident arterial cells is responsible for 
injury-induced accelerated atherosclerotic plaque development in apolipoprotein E-
deficient mice. Arteriosclerosis Thrombosis and Vascular Biology. 2005 
May;25(5):1020-5. 
144. Smith E. The influence of age and atherosclerosis on the chemistry of aortic 
intima:: Part 2. Collagen and mucopolysaccharides. Journal of Atherosclerosis 
Research. 1965;5(2):241-8. 
145. Glass CK, Witztum JL. Atherosclerosis: The road ahead. Cell. 2001 
Feb;104(4):503-16. 
146. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, et al. 
Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma - 
A novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 
2001;104(16):1899-904. 
147. Tuomainen AM, Nyyssoenen K, Laukkanen JA, Tervahartiala T, Tuomainen 
TP, Salonen JT, et al. Serum matrix metalloproteinase-8 concentrations are associated 
with cardiovascular outcome in men. Arteriosclerosis Thrombosis and Vascular 
Biology. [Article]. 2007 Dec;27(12):2722-8. 
148. Kato R, Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F. Plasma 
matrix metalloproteinase-8 concentrations are associated with the presence and severity 
of coronary artery disease. Circulation Journal. [Article]. 2005 Sep;69(9):1035-40. 
149. Sluijter JPG, Pulskens WPC, Schoneveld AH, Velema E, Strijder CF, Moll F, et 
al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 
162 
 
and 9 with vulnerable carotid atherosclerotic lesions - A study in human endarterectomy 
specimen pointing to a role for different extracellular matrix metalloproteinase inducer 
glycosylation forms. Stroke. 2006 Jan;37(1):235-9. 
150. Turu MM, Krupinski J, Catena E, Rosell A, Montaner J, Rubio F, et al. 
Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque 
progression on ultrasound. Atherosclerosis. 2006;187(1):161-9. 
151. Molloy KJ, Thompson MM, Jones JL, Schwalbe EC, Bell PRF, Naylor AR, et 
al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. 
Circulation. 2004 Jul;110(3):337-43. 
152. Ye S, Dunleavey L, Bannister W, Day LB, Tapper W, Collins AR, et al. 
Independent effects of the -219 G > T and epsilon 2/epsilon 3/epsilon 4 polymorphisms 
in the apolipoprotein E gene on coronary artery disease: The Southampton 
Atherosclerosis Study. European Journal of Human Genetics. 2003 Jun;11(6):437-43. 
153. Elston CW, Ellis IO. Method for grading breast-cancer. Journal of Clinical 
Pathology. 1993;46(2):189-90. 
154. Singletary SE, Connolly JL. Breast cancer staging: Working with the sixth 
edition of the AJCC Cancer Staging Manual. Ca-a Cancer Journal for Clinicians. 2006 
Jan-Feb;56(1):37-47. 
155. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, et al. EPIC-
Norfolk: study design and characteristics of the cohort. British Journal of Cancer. 
[Article; Proceedings Paper]. 1999 Jul;80:95-103. 
156. Pooley KA, Baynes C, Driver KE, Tyrer J, Azzato EM, Pharoah PDP, et al. 
Common Single-Nucleotide Polymorphisms in DNA Double-Strand Break Repair 
Genes and Breast Cancer Risk. Cancer Epidemiology Biomarkers & Prevention. 2008 
Dec;17(12):3482-9. 
157. Azzato EM, Driver KE, Lesueur F, Shah M, Greenberg D, Easton DF, et al. 
Effects of common germline genetic variation in cell cycle control genes on breast 
cancer survival: results from a population-based cohort. Breast Cancer Research. 2008 
2008;10(3). 
158. Kiechl S, Willeit J, Bruneck Study G. The natural course of atherosclerosis - 
Part I: Incidence and progression. Arteriosclerosis Thrombosis and Vascular Biology. 
1999;19(6):1484-90. 
159. Kiechl S, Willeit J, Bruneck Study G. The natural course of atherosclerosis - 
Part II: Vascular remodeling. Arteriosclerosis Thrombosis and Vascular Biology. 
1999;19(6):1491-8. 
160. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et 
al. Toll-like receptor 4 polymorphisms and atherogenesis. New England Journal of 
Medicine. 2002;347(3):185-92. 
161. Ye S, Willeit J, Kronenberg F, Xu QB, Kiechl S. Association of genetic 
variation on chromosome 9p21 with susceptibility and progression of atherosclerosis - 
A population-based, prospective study. Journal of the American College of Cardiology. 
2008 Jul;52(5):378-84. 
162. Debniak T, Jakubowska A, Serrano-Fernandez P, Kurzawski G, Cybulski C, 
Chauhan SR, et al. Association of MMP8 gene variation with an increased risk of 
malignant melanoma. Melanoma Research. 2011;21(5):464-8. 
163. Debniak T, Gorski B, Scott RJ, Cybulski C, Medrek K, Zlowocka E, et al. 
Germline mutation and large deletion analysis of the CDKN2A and ARF genes in 
families with multiple melanoma or an aggregation of malignant melanoma and breast 
cancer. International Journal of Cancer. 2004 Jul 1;110(4):558-62. 
163 
 
164. Auranen A, Song HL, Waterfall C, DiCioccio RA, Kuschel B, Kjaer SK, et al. 
Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. International 
Journal of Cancer. 2005 Nov 20;117(4):611-8. 
165. Gao YT, Shu XO, Dai Q, Potter JD, Brinton LA, Wen WQ, et al. Association of 
menstrual and reproductive factors with breast cancer risk: Results from the Shanghai 
Breast Cancer Study. International Journal of Cancer. 2000 Jul;87(2):295-300. 
166. Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting 
DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb;16(3):1215. 
167. Ahn SJ, Costa J, Emanuel JR. PicoGreen quantitation of DNA: Effective 
evaluation of samples pre- or post-PCR. Nucleic Acids Research. 1996 Jul;24(13):2623-
5. 
168. de Bakker PIW, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. 
Efficiency and power in genetic association studies. Nature Genetics. 2005 
Nov;37(11):1217-23. 
169. Eberle MA, Kruglyak L. An analysis of strategies for discovery of single-
nucleotide polymorphisms. Genetic Epidemiology. 2000 2000;19:S29-S35. 
170. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist 
programmers. Methods in molecular biology (Clifton, NJ). 2000 2000;132:365-86. 
171. Birney E, Andrews D, Caccamo M, Chen Y, Clarke L, Coates G, et al. Ensembl 
2006. Nucleic Acids Research. 2006 Jan 1;34:D556-D61. 
172. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, et al. 
Enzymatic amplification of beta-globin genomic sequences and restriction site analysis 
for diagnosis of sickle-cell anemia. Science. 1985;230(4732):1350-4. 
173. Livak KJ. Allelic discrimination using fluorogenic probes and the 5 ' nuclease 
assay. Genetic Analysis-Biomolecular Engineering. 1999;14(5-6):143-9. 
174. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of 
LD and haplotype maps. Bioinformatics. 2005;21(2):263-5. 
175. Qin ZHS, Niu TH, Liu JS. Partition-ligation-expectation-maximization 
algorithm for haplotype inference with single-nucleotide polymorphisms. American 
Journal of Human Genetics. [Letter]. 2002 Nov;71(5):1242-7. 
176. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL. A new algorithm for 
haplotype-based association analysis: the stochastic-EM algorithm. Annals of Human 
Genetics. 2004 Mar;68:165-77. 
177. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype 
reconstruction from population data. American Journal of Human Genetics. 2001 
Apr;68(4):978-89. 
178. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype 
reconstruction from population genotype data. American Journal of Human Genetics. 
2003 Nov;73(5):1162-9. 
179. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, et al. 
Matlnspector and beyond: promoter analysis based on transcription factor binding sites. 
Bioinformatics. 2005 Jul;21(13):2933-42. 
180. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. 
PLINK: A tool set for whole-genome association and population-based linkage 
analyses. American Journal of Human Genetics. 2007 Sep;81(3):559-75. 
181. Cochran WG. The combination of estimates from different experiments. 
Biometrics. 1954 1954;10(1):101-29. 
182. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. 
Statistics in Medicine. 2002 Jun 15;21(11):1539-58. 
164 
 
183. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the 
eigenvalues of a correlation matrix. Heredity. 2005;95(3):221-7. 
184. Nyholt DR. A simple correction for multiple testing for single-nucleotide 
polymorphisms in linkage disequilibrium with each other. American Journal of Human 
Genetics. 2004;74(4):765-9. 
185. Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T. Functional-analysis 
of the human vascular cell-adhesion molecule-1 promoter. Journal of Experimental 
Medicine. 1992 Dec;176(6):1583-93. 
186. Cybulsky MI, Allanmotamed M, Collins T. Structure of the murine VCAM1 
gene. Genomics. 1993 Nov;18(2):387-91. 
187. Scott S, Teh A, Peng C, Lavin M. One-step site-directed mutagenesis of ATM 
cDNA in large (20kb) plasmid constructs. Hum Mutat. 2002 Oct;20(4):323. 
188. Weiner MP, Costa GL, Schoettlin W, Cline J, Mathur E, Bauer JC. Site-directed 
mutagenesis of double-stranded dna by the polymerase chain-reaction. Gene. 1994 
Dec;151(1-2):119-23. 
189. Montesano R, Pepper MS, Mohlesteinlein U, Risau W, Wagner EF, Orci L. 
Increased proteolytic activity is responsible for the aberrant morphogenetic behaviour of 
endothelial-cells expressing the middle t-oncogene. Cell. 1990 Aug 10;62(3):435-45. 
190. Behr JP. Gene-transfer with synthetic cationic amphiphiles - prospects for gene-
therapy. Bioconjugate Chemistry. 1994 Sep-Oct;5(5):382-9. 
191. Jacobsen LB, Calvin SA, Colvin KE, Wright M. FuGENE 6 transfection 
reagent: the gentle power. Methods. 2004 Jun;33(2):104-12. 
192. Arnold AS, Laporte V, Dumont S, Appert-Collin A, Erbacher P, Coupin G, et al. 
Comparing reagents for efficient transfection of human primary myoblasts: FuGENE 6, 
Effectene and ExGen 500. Fundamental & Clinical Pharmacology. 2006;20(1):81-9. 
193. Pearce EG, Laxton RC, Pereira AC, Ye S. Haplotype effects on matrix 
metalloproteinase-1 gene promoter activity in cancer cells. Molecular Cancer Research. 
2007 Mar;5(3):221-7. 
194. Diekmann O, Tschesche H. Degradation of kinins, angiotensins and substance-p 
by polymorphonuclear matrix metalloproteinases MMP-8 and MMP-9. Brazilian 
Journal of Medical and Biological Research. 1994 Aug;27(8):1865-76. 
195. Plump AS, Smith JD, Hayek T, Aaltosetala K, Walsh A, Verstuyft JG, et al. 
Severe hypercholesterolemia and atherosclerosis in apolipoprotein-e-deficient mice 
created by homologous recombination in ES cells. Cell. 1992 Oct;71(2):343-53. 
196. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous 
hypercholesterolemia and arterial lesions in mice lacking apolipoprotein-E. Science. 
1992 Oct;258(5081):468-71. 
197. Balcells E, Meng QC, Johnson WH, Oparil S, Dell'Italia LJ. Angiotensin II 
formation from ACE and chymase in human and animal hearts: methods and species 
considerations. American Journal of Physiology-Heart and Circulatory Physiology. 
1997 Oct;273(4):H1769-H74. 
198. Bradford MM. Rapid and sensitive method for quantitation of microgram 
quantities of protein utilizing principle of protein-dye binding. Analytical Biochemistry. 
1976;72(1-2):248-54. 
199. Foteinos G, Hu YH, Xiao QZ, Metzler B, Xu QB. Rapid endothelial turnover in 
atherosclerosis-prone areas coincides with stem cell repair in apolipoprotein E-deficient 
mice. Circulation. 2008 Apr;117(14):1856-63. 
200. Sidak Z. On multivariate normal probabilities of rectangles - their dependence 
on correlations. Annals of Mathematical Statistics. [Article]. 1968;39(5):1425-&. 
165 
 
201. Brasier AR, Recinos A, Eledrisi MS. Vascular inflammation and the renin-
angiotensin system. Arteriosclerosis Thrombosis and Vascular Biology. 2002 
Aug;22(8):1257-66. 
202. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes 
atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. Journal of 
Clinical Investigation. [Article]. 2000 Jun;105(11):1605-12. 
203. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW. Renin-angiotensin 
system and cardiovascular risk. Lancet. 2007;369(9568):1208-19. 
204. Dougherty DC, Sanders MM. Comparison of the responsiveness of the pGL3 
and pGL4 luciferase reporter vectors to steroid hormones. Biotechniques. 2005 
Aug;39(2):203-7. 
205. Hu ZB, Wang HF, Shao MH, Jin GF, Sun WW, Wang Y, et al. Genetic variants 
in MGMT and risk of lung cancer in southeastern Chinese: A haplotype based analysis. 
Human Mutation. 2007 May;28(5):431-40. 
206. Duffy DL, Montgomery GW, Chen W, Zhao ZZ, Le L, James MR, et al. A 
three-single-nucleotide polymorphism haplotype in intron 1 of OCA2 explains most 
human eye-color variation. American Journal of Human Genetics. 2007 Feb;80(2):241-
52. 
207. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 
haplotype is a major risk factor for the development of myeloproliferative neoplasms. 
Nature Genetics. 2009 Apr;41(4):446-9. 
208. Jiang X, Roth L, Lai CF, Li XQ. Profiling activities of transcription factors in 
breast cancer cell lines. Assay and Drug Development Technologies. 2006 
Jun;4(3):293-305. 
209. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic 
variants in the human matrix metalloproteinase-2 gene - Role of Sp1 in allele-specific 
transcriptional regulation. Journal of Biological Chemistry. 2001 Mar;276(10):7549-58. 
210. Hinoda Y, Okayama N, Takano N, Fujimura K, Suehiro Y, Hamanaka Y, et al. 
Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and 
MMP-3 genes with colorectal cancer. International Journal of Cancer. 2002 
Dec;102(5):526-9. 
211. Wenham RM, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, et al. 
Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. 
Journal of the Society for Gynecologic Investigation. 2003 Sep;10(6):381-7. 
212. Beyzade S, Zhang SL, Wong YK, Day INM, Eriksson P, Ye S. Influences of 
matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk 
of myocardial infarction. Journal of the American College of Cardiology. 2003 
Jun;41(12):2130-7. 
213. Wang L-E, Huang Y-j, Yin M, Gershenwald JE, Prieto VG, Lee JE, et al. 
Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. 
European Journal of Cancer. 2011 Jan;47(1):107-15. 
214. Liu H, Wei Q, Gershenwald JE, Prieto VG, Lee JE, Duvic M, et al. Influence of 
single nucleotide polymorphisms in the MMP1 promoter region on cutaneous 
melanoma progression. Melanoma Research. 2012 Apr;22(2):169-75. 
215. Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, 
et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and 
its inhibitor PAI-1 8377 breast cancer patients. Journal of the National Cancer Institute. 
2002;94(2):116-28. 
216. Rack B, Janni W, Gerber B, Strobl B, Schindlbeck C, Klanner E, et al. Patients 
with recurrent breast cancer: does the primary axillary lymph node status predict more 
166 
 
aggressive tumor progression? Breast Cancer Research and Treatment. 2003 
Nov;82(2):83-92. 
217. Gutiérrez-Fernández A, Fueyo A, Folgueras A, Garabaya C, Pennington C, 
Pilgrim S, et al. Matrix metalloproteinase-8 functions as a metastasis suppressor through 
modulation of tumor cell adhesion and invasion. Cancer Res. 2008 Apr;68(8):2755-63. 
218. Lin PI, Vance JM, Pericak-Vance MA, Martin ER. No gene is an island: The 
flip-flop phenomenon. American Journal of Human Genetics. [Article]. 2007 
Mar;80(3):531-8. 
219. Pradhan-Palikhe P, Pussinen PJ, Vikatmaa P, Palikhe A, Kivimaki AS, 
Lepantalo M, et al. Single nucleotide polymorphism -799C/T in matrix 
metalloproteinase-8 promoter region in arterial disease. Innate Immunity. 2012 2012 
(Epub 2011 Oct;18(3):511-7. 
220. Palavalli LH, Prickett TD, Wunderlich JR, Wei XM, Burrell AS, Porter-Gill P, 
et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often 
mutated in melanoma. Nature Genetics. 2009 May;41(5):518-20. 
221. Beeghly-Fadiel A, Zheng W, Lu W, Long JR, Zheng Y, Cai H, et al. Replication 
study for reported SNP associations with breast cancer survival. J Cancer Res Clin 
Oncol. [Article]. 2012 Jun;138(6):1019-26. 
222. McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif EM, Ollier WER, 
Zimmerman PA, et al. Chemokine RANTES promoter polymorphism affects risk of 
both HIV infection and disease progression in the Multicenter AIDS Cohort Study. 
Aids. 2000 Dec 1;14(17):2671-8. 
223. Nan H, Niu T, Hunter DJ, Han J. Missense Polymorphisms in Matrix 
Metalloproteinase Genes and Skin Cancer Risk. Cancer Epidemiology Biomarkers & 
Prevention. 2008 Dec;17(12):3551-7. 
224. Vihinen P, Koskivuo I, Syrjänen K, Tervahartiala T, Sorsa T, Pyrhönen S. 
Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of 
malignant melanoma. Melanoma Research. 2008 Aug;18(4):268-73. 
225. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and 
pathological effects in the cardiovascular system. American Journal of Physiology-Cell 
Physiology. 2007 Jan;292(1):C82-C97. 
226. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL. Upregulation of 
endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human 
coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circulation 
Research. [Article]. 1999 May;84(9):1043-9. 
227. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. 
Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear 
factor-kappa B activation induced by intracellular oxidative stress. Arteriosclerosis 
Thrombosis and Vascular Biology. 2000;20(3):645-51. 
228. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, 
et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat 
vasculature - A potential link between the renin-angiotensin system and atherosclerosis. 
Circulation. 1999;100(11):1223-9. 
229. Corvol P, Williams TA, Soubrier F. Peptidyl dipeptidase A - angiotensin-I-
converting-enzyme. Methods Enzymol. [Review]. 1995;248:283-305. 
230. Sturrock ED, Natesh R, van Rooyen JM, Acharya KR. Structure of angiotensin 
I-converting enzyme. Cellular and Molecular Life Sciences. [Review]. 2004 
Nov;61(21):2677-86. 
231. Soubrier F, Alhencgelas F, Hubert C, Allegrini J, John M, Tregear G, et al. 2 
putative active-centers in human angiotensin-I-converting enzyme revealed by 
167 
 
molecular-cloning. Proceedings of the National Academy of Sciences of the United 
States of America. [Article]. 1988 Dec;85(24):9386-90. 
232. Yamamoto D, Takai S, Jin D, Inagaki S, Tanaka K, Miyazaki M. Molecular 
mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. Journal 
of Molecular and Cellular Cardiology. [Article]. 2007 Dec;43(6):670-6. 
233. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, et al. 
Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. 
Journal of Clinical Investigation. [Article]. 1996 Aug;98(3):671-9. 
234. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR. Cardiac 
remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) 
irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE 
inhibitors on MMP. Heart. [Article]. 2002 Nov;88(5):525-30. 
235. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M, et al. 
Activation of matrix metalloproteinases precedes left ventricular remodeling in 
hypertensive heart failure rats its inhibition as a primary effect of angiotensin-
converting enzyme inhibitor. Circulation. [Article]. 2004 May;109(17):2143-9. 
236. Brower GL, Levick SP, Janicki JS. Inhibition of matrix metalloproteinase 
activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart 
failure. American Journal of Physiology-Heart and Circulatory Physiology. [Article]. 
2007 Jun;292(6):H3057-H64. 
237. Yamamoto D, Takai S, Miyazaki M. Prediction of interaction mode between a 
typical ACE inhibitor and MMP-9 active site. Biochemical and Biophysical Research 
Communications. [Article]. 2007 Mar;354(4):981-4. 
238. Harrison S, Geppetti P. Substance P. International Journal of Biochemistry & 
Cell Biology. 2001 Jun;33(6):555-76. 
239. Scotland RS, Chauhan S, Davis C, De Felipe C, Hunt S, Kabir J, et al. Vanilloid 
receptor TRPV1, sensory C-fibers, and vascular autoregulation - A novel mechanism 
involved in myogenic constriction. Circulation Research. [Article]. 2004 
Nov;95(10):1027-34. 
240. Bot I, de Jager SCA, Zernecke A, Lindstedt KA, van Berkel TJC, Weber C, et 
al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in 
apolipoprotein E-deficient mice. Circulation. 2007 May 15;115(19):2516-25. 
241. Bot I, de Jager SCA, Bot M, van Heiningen SH, de Groot P, Veldhuizen RW, et 
al. The Neuropeptide Substance P Mediates Adventitial Mast Cell Activation and 
Induces Intraplaque Hemorrhage in Advanced Atherosclerosis. Circulation Research. 
[Article]. 2010 Jan;106(1):89-U145. 
242. Lemaitre V, O'Byrne TK, Borczuk AC, Okada Y, Tall AR, D'Armiento J. ApoE 
knockout mice expressing human matrix metalloproteinase-1 in macrophages have less 
advanced atherosclerosis. Journal of Clinical Investigation. 2001 May;107(10):1227-34. 
243. Deguchi JO, Aikawa E, Libby P, Vachon JR, Inada M, Krane SM, et al., editors. 
MMP-13/collagenase-3 deletion promotes collagen accumulation and organization in 
mouse atherosclerotic plaques. 78th Annual Scientific Session of the American-Heart-
Association; 2005 Nov 13-16; Dallas, TX. 
244. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A. Effect of 
MMP-2 deficiency on atherosclerotic lesion formation in ApoE-deficient mice. 
Arteriosclerosis Thrombosis and Vascular Biology. 2006 May;26(5):1120-5. 
245. Johnson C, Galis ZS. Matrix metalloproteinase-2 and-9 differentially regulate 
smooth muscle cell migration and cell-mediated collagen organization. Arteriosclerosis 
Thrombosis and Vascular Biology. 2004 Jan;24(1):54-60. 
168 
 
246. Luttun A, Lutgens E, Manderveld A, Maris K, Collen D, Carmeliet P, et al. Loss 
of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-
deficient mice against atherosclerotic media destruction but differentially affects plaque 
growth. Circulation. 2004 Mar;109(11):1408-14. 
247. Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active 
MMP-9 induces acute plaque disruption in apoE-deficient mice. Journal of Clinical 
Investigation. 2006 Jan;116(1):59-69. 
248. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque 
but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene 
inactivation. Arteriosclerosis Thrombosis and Vascular Biology. 2001 Sep;21(9):1440-
5. 
249. Schneider F, Sukhova GK, Aikawa M, Canner J, Gerdes N, Tang SMT, et al. 
Matrix metalloproteinase-14 deficiency in bone marrow-derived cells promotes collagen 
accumulation in mouse atherosclerotic plaques. Circulation. 2008 Feb;117(7):931-9. 
250. Johnson J, Carson K, Williams H, Karanam S, Newby A, Angelini G, et al. 
Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse 
- Model characterization and effects of pravastatin treatment. Circulation. 2005 Mar 
22;111(11):1422-30. 
251. Shu XO, Gao YT, Cai QY, Pierce L, Cai H, Ruan ZX, et al. Genetic 
polymorphisms in the TGF-beta 1 gene and breast cancer survival: A report from the 
Shanghai Breast Cancer Study. Cancer Research. 2004 Feb;64(3):836-9. 
252. Long JR, Kataoka N, Shu XO, Wen WQ, Gao YT, Cai QY, et al. Genetic 
polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer Epidemiology 
Biomarkers & Prevention. 2006 Nov;15(11):2115-22. 
253. Wart HEV, Birkedal-Hansen H. The cysteine switch: a principle of regulation of 
metalloproteinase activity with potential applicability to the entire matrix 
metalloproteinase gene family. Proceedings of the National Academy of Sciences. 
1990;87(14):5578-82. 
254. Zhang LP, Cheng JZ, Ma YW, Thomas W, Zhang JQ, Du J. Dual pathways for 
nuclear factor kappa B activation by angiotensin II in vascular smooth muscle - 
Phosphorylation of p65 by I kappa B kinase and ribosomal kinase. Circulation 
Research. 2005;97(10):975-82. 
255. Ramos CL, Huo YQ, Jung US, Ghosh S, Manka DR, Sarembock IJ, et al. Direct 
demonstration of P-selectin- and VCAM-1-dependent mononuclear cell rolling in early 
atherosclerotic lesions of apolipoprotein E-deficient mice. Circulation Research. 
1999;84(11):1237-44. 
256. Huo YQ, Hafezi-Moghadam A, Ley K. Role of vascular cell adhesion molecule-
1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early 
atherosclerotic lesions. Circulation Research. 2000;87(2):153-9. 
 
 
 
  
169 
 
Appendices  
 
Appendix 1: Reagents, buffers and solutions 
 
 
500 ml 10X ELB (erythrocyte lysis buffer) - 1X is to be autoclaved  
5.05g   Potassium bicarbonate 
41g  Ammonium chloride 
2 ml  0.5M EDTA (pH 8) 
To volume H2O 
 
500 ml NLB (nucleic lysis buffer) 
 5 ml  1M Tris (pH 8) 
 40 ml  5M NaCl 
 2 ml  0.5M EDTA (pH 8) 
 To volume H2O 
 
1 L 50X TAE (Tris-acetate-EDTA) 
 242g   Tris base 
 57.1 ml   Glacial acetic acid 
100 ml  0.5M EDTA (pH 8) 
To volume H2O 
 
1 L 5X TBE (Tris-borate-EDTA) 
 54g  Tris base 
 27.5g  Boric acid 
 20 ml  0.5M EDTA (pH 8) 
 To volume H2O 
 
LB (Luria-Bertani) medium 
 1%  Tryptone 
 0.5%  Yeast extract 
 1%  NaCl 
 97.5%  H2O 
 
LB (Luria-Bertani) agar 
 1%  Tryptone 
 0.5%  Yeast extract 
 1%  NaCl 
 1.5%   Agar 
 96%  H2O 
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Appendix 2: MMP1 amplification primers and enzymes used for 
restriction fragment length polymorphism analysis 
 
 
 Genotyping 
  
 
-1607 GG>G (rs1799750) TCGTGAGAATGTCTTCCCATT (PCR forward primer) 
 
TCTTGGATTGATTTGAGATAAGTGAAATC (PCR reverse primer, mismatched nucleotide in bold) 
 
-839 G>A (rs473509) CCCATGATAATGATGGGCAAGGGGTGGG (PCR forward primer) 
 
GCTTGAGTGCAGCGGCACAATCACAGCT (PCR reverse primer, mismatched nucleotide in bold) 
 
-755 G>T (rs498186) TGATCCTCCCACCTCAGCCTCTTCCG (PCR forward primer, mismatched 
nucleotide in bold) 
 
CCCAGAATTTCAGGAGGCCGAGGCAG (PCR reverse primer) 
 
-519 A>G (rs1144393) TATAGGCTTGAGCCACCATG (PCR forward primer) 
  
CACAGGTCAAAGAGTACTCC (PCR reverse primer) 
 
-422 T>A (rs475007) TATAGGCTTGAGCCACCATG (PCR forward primer) 
 
CACAGGTCAAAGAGTACTCC (PCR reverse primer) 
 
-340 T>C (rs514921) AAAAAGACTGGTTCTGATGGTCTTAA (PCR forward primer, mismatched 
nucleotide in bold) 
 
GAACTTCAGTCAGTACAGGTGCC (PCR reverse primer) 
 
-320 T>C (rs494379) TTATGACCATCAGAACCGG (PCR forward primer, mismatched nucleotide in bold) 
 
CACACTCTGCCATGTAAACAGTGG (PCR reverse primer) 
 
Restriction endonuclease that specifically cleaved 1 of the 2 alleles. The restriction 
endonucleases used were XmnI (for -1607GG>G), HindIII (for -839G>A), MspI (for -
755G>T), KpnI (for -519A>G), BanI (for -422T>A), AflII (for -340T>C), and HaeIII 
(for -320T>C)  
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Appendix 3: MMP8 amplification and sequencing primers 
 
Exon1F: 5‟ GTTGCTTCATATTCCTGATGC 3‟ 
Exon1R 5‟ AACAAGAGAAAACAACCCACA 3‟ 
Exon2F: 5‟ GGGTTGCAAAATGACCAGA 3‟ 
Exon2R: 5‟ TCCCAAGAACAGTGTCTGTCAT 3‟ 
Exons3_4F: 5‟ GGTAGCACACCATGATGCAA 3‟ 
Exons3_4R: 5‟ CAAATGATCACTTTTTGTGAGTTTG 3‟ 
Exon5F: 5‟ CAGCTTTTCTGGGTTCTAAGA 3‟ 
Exon5R: 5‟ GGGAGTGTTCGCCTATTC 3‟ 
Exon6F: 5‟ TGAGAAGTCTCTGATGTACCCAAG 3‟ 
Exon6R: 5‟ GGAAAAGGTGACTAACGTGTGA 3‟ 
Exon7F: 5‟ CTCCCAGCAATCCTACAAGG 3‟ 
Exon7R: 5‟ GGCCCAACCCTAGTCTTCTG 3‟ 
Exon8F: 5‟ TGTGCAAGACCAAGAAGTGG 3‟ 
Exon8R: 5‟ TCAAAAGCCATGGTAACATCA 3‟ 
Exon9F: 5‟ TTGGTGTTAAATCGGATAAC 3‟ 
Exon9R: 5‟ TTGACACTAACCTGGTCAGCA 3‟ 
Exon10F: 5‟ TGGGATTACAGGCATTAGCC 3‟ 
Exon10R: 5‟ GCAGGACACAATGTAACGAAAA 3‟ 
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Appendix 4: Supporting data from collaborators/colleagues 
 
A4.1 The Shanghai Breast Cancer Study 
 
A cohort of 1455 Chinese breast cancer patients recruited between 1996 and 1998 as 
part of a population based case control study, the Shanghai Breast Cancer Study (165, 
251), there was a median follow up time of 7.1 years (252).   
A4.1.1 Genotyping of the Shanghai Breast Cancer Study 
 
Shanghai Breast Cancer subjects were genotyped for the rs11225395 SNP, also using 
the Applied Biosystems Taqman SNP Genotyping System (C___1366493_10). 
A4.1.2 Evaluation of the rs11225395 SNP in the Shanghai Breast Cancer Study cohort 
 
The rs11225395 SNP was chosen as the most suitable candidate for further evaluation 
by collaborators in America in the Shanghai Breast Cancer Study. The reasons being 
that this SNP, in the Leuven breast cancer study, showed the strongest association with 
lymph node metastasis, and is in linkage disequilibrium with the other 3 associated 
SNPs (rs1940475, rs1892886, and rs1276284, Fig A1). It also tags the four major 
haplotypes with C allele tagging haplotypes 1 and 3, which carry an increased risk of 
metastasis, and the T allele tagging haplotypes 2 and 4 which carry a reduced risk of 
metastasis.  
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Figure A1. LD plot, showing the LD patterns of the MMP8 SNPs in Caucasian and 
Chinese populations 
 
The results of their analysis of the rs11225395 SNP within the Shanghai study 
population are presented in tables A1 and A2, the genotypes stratified by TMN stage 
and cancer relapse status are shown in table A1. In all patients there was a trend towards 
a reduced rate of relapse for carriers of the T allele, though it was not significant. 
Patients with early-stage cancer (TNM stage 0-II) carrying the minor allele (T) had a 
lower rate of relapse versus those homozygous for the C allele in patients with early-
stage cancer (p = 0.04, Table A1).  
 
Caucasians
Chinese
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Table A1. MMP8 SNP rs11225395 in relation to TNM stage and breast cancer relapse in the Shanghai Breast 
Cancer Study 
 
Genotype 
TNM stage 
Cancer relapse  Cancer relapse  
in all patients in early stage (0-II) patients  
0-I IIa IIb III-IV  
No 
relapse Relapse P 
No 
relapse Relapse P 
 N (%) N (%) N (%) N (%) P N (%) N (%)  N (%) N (%)  
CC 
100 
(36.0) 
145 
(37.3) 
94 
(39.3) 
47 
(38.8)  
303 
(73.9) 
107 
(26.1)  
256 
(76.4) 
79 
(23.6)  
CT + TT 
178 
(64.0) 
244 
(62.7) 
145 
(60.7) 
74 
(61.2) 0.87* 
514 
(78.1) 
144 
(21.9) 0.11* 
451 
(82.2) 
98 
(17.9) 0.04* 
CT 
143 
(51.4) 
195 
(50.1) 
108 
(45.2) 
54 
(44.6) 0.69† 
408 
(79.2) 
107 
(20.8) 0.13† 
357 
(82.3) 
77 
(17.7) 0.12† 
TT 
35 
(12.6) 
49 
(12.6) 
37 
(15.5) 
20 
(16.5)   
106 
(74.1) 
37 
(25.9)   
94 
(81.7) 
21 
(18.3)   
* P value for the comparison of CT + TT versus CC 
† P value for trend test comparing CC, CT and TT 
 
 
The genotype distribution in relation to survival is shown in table A2. Survival rates 
were higher in T allele carriers versus C homozygotes; this was again more evident 
amongst patients with an early-stage cancer (TNM stage 0-II). The adjusted hazard 
ratios (HR) for T allele carriers were 0.7 (95% CI, 0.5–1.0; P = 0.02) for overall 
survival and 0.7 (95% CI, 0.5–0.9; P = 0.02) for disease-free (cancer 
recurrence/metastasis free) survival.  
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Table A2. MMP8 SNP rs11225395 in relation to survival among breast cancer patients in the Shanghai Breast 
Cancer Study 
 
Population Genotype  Overall survival  Disease-free survival 
 cases events HR (95% CI) P  cas
es 
even
ts 
HR (95% CI) P 
All women            
 CC  415 98 1.0 
(reference) 
  410 127 1.0 
(reference) 
 
 CT + TT  681 139 0.9 (0.7,1.1) 0.23*  658 172 0.8 (0.7,1.0) 0.09* 
 CT  530 109 0.9 (0.7,1.1) 0.25†  515 131 0.8 (0.6,1.0) 0.24† 
 TT  151 30 0.8 (0.5,1.2)   143 41 0.9 (0.6,1.3)  
            
TNM 0-II            
 CC  339 70 1.0 
(reference) 
  335 93 1.0 
(reference) 
 
 CT + TT  567 83 0.7 (0.5,1.0) 0.02*  549 115 0.7 (0.5,0.9) 0.02* 
 CT  446 69 0.7 (0.5,1.0) 0.01†  434 91 0.7 (0.5,1.0) 0.03† 
 TT  121 14 0.5 (0.3,1.0)   115 24 0.7 (0.5,1.1)  
            
TNM III-IV            
 CC  47 19 1.0 
(reference) 
  46 24 1.0 
(reference) 
 
 CT + TT  74 40 1.5 (0.9,2.6) 0.14*  70 42 1.3 (0.8,2.2) 0.31* 
 CT  54 30 1.6 (0.9,2.8) 0.26†  52 30 1.2 (0.7,2.1) 0.22† 
 TT  20 10 1.4 (0.6,3.0)   18 12 1.5 (0.8,3.1)  
* P value for the comparison of CT + TT versus CC 
† P value for trend test comparing CC, CT, and TT 
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A graphical representation of survival over time, the Kaplan-Meier survival curves (Fig. 
A2) show a slight increase in overall and disease free survival in carriers of the T allele 
(48). 
 
Figure A2. Overall and disease-free survival of breast cancer patients after diagnosis stratified 
by genotypes of SNP rs11225395. (A), overall survival among all women; (B), overall survival 
among women at TNM stages of 0 to II; (C), disease-free survival among all women; (D), 
disease-free survival among women at TNM stages of 0 to II. 
  
Figure 3A Overall survival among all patients Figure 3B Overall survival among patients with 
TNM stages of 0-II
Figure 3C Disease-free survival among all patients Figure 3D Disease-free survival among patients with 
TNM stages of 0-II
(A) (B)
(C) (D)
All patients Patients at TNM stages of 0-II
All patients Patients at TNM stages of 0-II
 era l survival among all patients  era l survival among patients with 
 f 0
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A4.2 MMP8 promoter SNP rs11225395 EMSA using nuclear protein extract 
from cancer cells 
 
Electrophoretic Mobility Shift Assay (EMSA); double stranded biotin labelled 
oligonucleotide probes were used for each rs11225395 allele (C: 5‟-
CCATGCAGAGCCTATAGTAGCTCC-3‟ and T: 5-CCATGCAGAGCTTATAGGTAGCTCC-3‟). The 
probes were incubated MDA-MB-231 cell nuclear protein extract, the resulting protein 
DNA complexes were separated using poly-acrylamide gel electrophoresis (PAGE); 
detection was with a LightShift Chemiluminescent EMSA kit (Pierce Biotechnology). 
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A4.2.1 EMSA Results 
 
One of the principal mechanisms by which SNPs in the promoter region of genes can 
functionally effect expression is via interaction with nuclear proteins. The C allele probe 
did not form any detectable DNA-protein complexes (Fig A3 lane 2). There were 3 
DNA-protein complexes detected by incubation of nuclear extract with the probe 
corresponding to the T allele (Fig A3 lane 9). Large amounts of unlabelled T 
oligonucleotide probe, acting as a competitor, caused the DNA-protein complex bands 
to be diminished (Fig. A3, lanes 12 and 13).  The DNA-protein complex bands were 
unaffected by the presence of large amounts of an unlabelled C allele oligonucleotide 
(Fig. A3, lanes 10 and 11) or large amounts of a non-specific oligonucleotide 
competitor (Fig. A3, lane 14).  
 
Figure A3. Representative results of electrophoretic mobility shift assays. Nuclear protein extracts from MDA-MB-231 
breast cancer cells were incubated with biotin-labelled probes corresponding to the C allele (lanes 1–7) or the T allele 
(lanes 8–14) of the -799C>T SNP (rs11225395) in the absence or presence of competitors. Lanes 1 and 8, no nuclear 
protein extract; lane 2 and 9, no competitor; lanes 3 and 10, competitor C in 20-fold molar excess (+); lanes 4 and 11, 
competitor C in 50-fold molar excess (++); lanes 5 and 12, competitor T in 20-fold molar excess (+); lanes 6 and 13, 
competitor T in 50-fold molar excess (++); lanes 7 and 14, nonspecific competitor in 50-fold molar excess (++). 
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A4.3 Functional analysis of MMP8 non-synonymous SNP rs1940475 
 
A full length MMP8 cDNA sequence containing the C (Glu87) allele was purchased 
(OriGen, Rockville, MD). Site directed mutagenesis was then used to create a cDNA 
sequence containing the T (Lys87) allele. The cDNAs were cloned into a TOPO 
expression vector (Invitrogen). Glu87 and Lys87 forms of MMP8 Zymogens were 
synthesised using the TNT quick coupled transcription/translation system (Promega). 
Both the zymogens were incubated with or without 1.5 mM APMA for 1 hour at 37°C, 
before undergoing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS 
PAGE). Detection was with a monoclonal anti-MMP8 antibody (R&D Systems), and 
Western blot analysis. Band intensities of the latent form (60kDa and 70kDa) and active 
form (40kDa and 45kDa) were quantified with the use of Image-pro software. 
 
A4.3.1 The T allele of rs1940475 is less amenable to activation 
 
The rs1940475 polymorphism is a non-synonymous substitution effecting a change in 
the amino acid sequence of the protein from a glutamic acid residue to a lysine residue 
at position 87. This residue is in close proximity to the cysteine switch, within the 
propeptide domain, a crucial mechanism in the conversion of the latent MMP8 zymogen 
into its active lytic form (253). In vitro Western blot analysis was carried out to 
investigate whether this SNP has an effect on MMP8 activation. It was found that the 
MMP8 Lys87 zymogen, coded for by the T allele is less amenable to activation than the 
Glu87 zymogen (C allele) (Figure A4).  
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(A) 
Figure A4. Western blot analysis showing that MMP8 zymogen with Lys87 is less amenable to activation than MMP8 zymogen with Glu87 (A) Image 
of Western blot analysis. MMP8 zymogens with Glu87 or Lys87 were incubated in the presence or absence of the activator 4-aminophenylmercuric 
acetate (APMA) and then subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis, followed by Western blot analysis with the use of 
a monoclonal anti-MMP8 antibody that recognizes both active and latent MMP8. 
(B) and (C) Curves represent intensities of the bands of latent (60kDa, and 70kDa likely representing a glycosylation form) and active (40kDa, and 
45kDa likely representing a glycosylation form) MMP8 with Glu87 (red lines) or Lys87 (blue lines). (B) shows that in the absence of the activator 
APMA, the intensities of the 40kDa and 45kDa bands (active MMP8) are similar between MMP8 with Glu87 (red line, representing intensities of bands 
in lane 1 in Western blot image) and MMP8 Lys87 (blue line, representing intensities of bands in lane 2 in Western blot image). (C) shows that in the 
presence of APMA, the intensity of the 40kDa and 45kDa bands (active MMP8) produced by MMP8 with Lys87 
(blue line, representing intensities of bands in lane 4 in Western blot image) are lower than those produced by MMP8 with Glu87 (red line, 
representing intensities of bands in lane 4 in Western blot image), indicating that MMP8 zymogen with Lys87 is less amenable to activation than the 
zymogen with Glu87.  
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A4.4 Flow cytometry 
 
Mouse endothelial cells (C166) were incubated with Ang I that had been subjected to 
cleavage by MMP8 or uncleaved Ang I, in the absence or presence of the Ang II type 1 
receptor (AT1R) antagonist losartan and the Ang II type 2 receptor (AT2R) antagonist 
PD123319, and then subjected to flow cytometric analysis of VCAM-1 expression. 
A4.4.1. Angiotensin II induces VCAM-1 over a wide range of concentrations 
 
The atherogenic properties of Ang II can partly be ascribed its induction of adhesion 
molecules (201, 203); VCAM-1 in particular, expressed on the vascular endothelium, is 
known to play a role in the formation of atherosclerotic lesions (227, 228, 254-256).  In 
vitro and FACS experiments confirmed that VCAM-1 is induced by a wide range of 
Ang II concentrations in endothelial cells, Figure A5.  
 
  
  
Figure A5. Chart showing that Ang II in a wide range of 
concentration increases VCAM-1 expression in cultured endothelial 
cells. Shown in chart are mean fluorescence intensities (and SEM) 
in flow cytometric analysis. P-values shown are for comparison 
between Ang II treated cells and untreated cells. 
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A.4.4.2 Products of Ang I cleavage by MMP8 also induce VCAM-1 expression in endothelial cells 
 
It was also found also found that VCAM-1 expression was increased in endothelial cells 
when they were incubated with products of Ang I cleavage by MMP8 compared to 
endothelial cells treated with Ang I (p=0.002; fig A6 A and B). This increase was no 
longer seen on repeating the same experiments this time in the presence of angiotensin 
receptor I (AT1R) antagonist Losartan and angiotensin receptor II (AT2R) antagonist 
PD123319 (p=0.937; fig A6 C and D).  
 
 
  
Figure A6. Products of Ang I cleavage by MMP8 increase VCAM-1 expression in endothelial cells. Panels A and 
B: representative plot (A) and mean fluorescence intensity (B) in flow cytometric analyses of VCAM-1 expression 
on endothelial cells incubated with uncleaved Ang I or with products of Ang I cleavage by MMP8. Panels C and 
D: representative plot (C) and mean fluorescence intensity (D) in flow cytometric analyses of VCAM-1 expression 
on endothelial cells incubated with uncleaved Ang I or with products of Ang I cleavage by MMP8, in the presence 
of the AT1R antagonist losartan and the AT2R antagonist PD123319. Error bars in the column charts are standard 
error of mean. 
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A4.5 Real-time reverse-transcriptase-PCR in MMP8
-/-
 apoE
-/-
 mice & 
controls 
 
Real-time RT-PCR was used to quantify the expression of other murine MMPs in the 
two groups. RNA was extracted from aortas and reverse transcribed into cDNA. The 
MMPs quantified, in duplicate, were MMP2, MMP9, MMP13 and MMP14. GAPDH 
was used as the house keeping reference; detection was with Sybr Green on the ABI 
Prism 7900HT Sequence Detection System (Applied Biosystems). PCR primers used 
are shown in the Table A3. 
Table A3. Primers used to quantify expression of murine MMPs 
Gene Forward primer Reverse primer 
MMP2 5'-GTCGCCCCTAAAACAGACAA-3' 5'-GGTCTCGATGGTGTTCTGGT-3' 
MMP9 5'-CGTCGTGATCCCCACTTACT-3' 5'-AACACACAGGGTTTGCCTTC-3' 
MMP13 5'-GCCCTGATGTTTCCCATCTA-3' 5'-TTTTGGGATGCTTAGGGTTG-3' 
MMP14 5'-GGATACCCAATGCCCATTGGCCA-3' 5'-CCATTGGGCATCCAGAAGAGAGC-3' 
GAPDH 5'-TGACGTGCCGCCTGGAGAAAC-3' 5'-CCGGCATCGAAGGTGGAAGAGT-3'  
  
Gene expression data was calculated using the ΔΔCT method, standardised against 
GAPDH reference house-keeping gene values. 
  
184 
 
A.4.5.1 Expression levels of other murine MMPs 
 
There were no differences between the 2 groups when measuring the expression levels 
of other mouse MMPs including MMP2, MMP3, MMP13, and MMP14 (p=0.108, 
p=0.611, p=0.509, and p=0.318, respectively; Fig A7). 
 
 
 
 
A4.6 Immunohistochemical characterisation of atherosclerotic lesions in 
murine study 
 
Immunohistochemical analysis of Ang II in the atherosclerotic lesions was done 
utilising an immunoperoxidase system (Vectastain Elite ABC kit, Vector Laboratories) 
in conjunction with a rabbit anti-angiotensin II antibody (Phoenix Pharmaceuticals) and 
a rabbit IgG isotype negative control. Immunohistochemical analysis, with antibodies 
against the relevant markers for macrophages (Mac-1, BD Biosciences Pharmingen), 
smooth muscle cells (α-actin, Sigma-Aldrich), collagen type I (Abcam), and VCAM-1 
(BD Biosciences Pharmingen), was used to assess the other contents of atherosclerotic 
lesions in frozen aortic root sections.  
 
Figure  A7. RT-PCR analysis of MMP2, MMP9, MMP13 and MMP14 and GAPDH. Real-time 
RT-PCR data were analysed using the ΔΔCT method, standardized against GAPDH reference 
house-keeping gene values. Data shown in chart are mean MMP CT values after being 
subtracted by GAPDH CT values. Error bars represent standard error of mean. 
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A4.6.1 Immunohistochemical characterisation results 
 
There were reduced Ang II levels in the atherosclerotic lesions of MMP8-/-ApoE-/- 
mice compared the lesions of wild type MMP8 mice (p=0.002; fig A8 A). There was a 
70% reduction (p=0.002, Figure A8 B) of macrophages within the lesions of double 
knockout mice in comparison with the lesions of the controls. Oil red O staining showed 
that the atherosclerotic lesions in the double knockout mice had a lower lipid content 
(reduced by 47%, p=0.001, Figure A8 C). Fewer smooth muscle cells were observed in 
the lesions of the MMP8 deficient mice than lesions in the controls, although the 
difference did not reach statistical significance (p=0.057, Figure A8 D). Collagen 
content was higher in the lesions in the double knockouts than lesions in the controls 
(differing by 27%, p=0.034, Figure A8 E). 
  
A 
Figure A 8 (A) . Representative images of Ang II staining in atherosclerotic 
lesions in MMP 8 - / - apoE - / - mice and MMP 8 +/+ ApoE - / - mice, respectively, and 
column chart showing lower relative intensity of Ang II staining in lesions in 
MMP 8 - / - ApoE - / - mice than in MMP 8 +/+ ApoE - / - mice . Data presented as means 
and standard error of mean . 
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A8 continued. Reduced atherosclerosis in MMP8-/-apoE-/- mice. Panels B, C, D and E: 
representative images of immunostaining of macrophages (B), lipids (C), smooth muscle cells 
(D) and collagen (E) in aortic root atherosclerotic lesions of MMP8+/+apoE-/- and MMP8-/-
apoE-/- mice, and charts showing percentages of mean macrophage, lipid, smooth muscle 
cell, and collagen contents in the two groups of mice. Data presented are mean and standard 
error of mean. 
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A4.7 Murine Blood pressure measurement 
 
Blood pressure was measured in conscious mice using a volume pressure recording 
sensor and occlusion tail cuff (Coda2, Kent Scientific, USA). 
 
A.4.7.1 Lower blood pressure in double knockout mice 
 
Blood pressure was lower in knockout animals, this is consistent with their reduced 
levels of the potent vasoconstrictor Ang II (P=0.017 for systolic and P=0.023 for 
diastolic blood pressure; Figure A9). 
 
  
Figure A9. Reduced blood pressure in MMP8-/-
ApoE-/- mice. Chart showing lower systolic and 
diastolic blood pressure in MMP8-/-ApoE-/- mice 
than in MMP8+/+ApoE-/- mice. Data shown are 
means and ±SEM.  
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A4.7.2 Immunohistochemical analysis of VCAM-1 
 
Immunohistochemical analyses showed that VCAM-1 expression was much reduced in 
the lesions and endothelial cells of double knockout animals compared to the controls 
(p=0.015 and 0.005 respectively; fig A10 B, C).  
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Figure A10. Reduced VCAM-1 expression in MMP8
-/-
/apoE
-/-
 mice compared with MMP8
+/+
/apoE
-/-
 mice  
Panels A, B and C show results of immunohistochemical analyses of VCAM-1 in aortic atherosclerotic lesions, 
(A), representative images; (B), mean VCAM-1 staining in lesions; (C), mean VCAM-1 staining in the 
endothelial layer. Error bars in the column charts are standard error of mean. 
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A4.8 Intravital microscopy 
 
Mesenteries of anaesthetised mice were superfused with bicarbonate buffered solution 
at 37°C at a rate of 2 ml/min. Cell rolling was determined by counting the number of 
leukocytes rolling per minute in each vessel. Cell adhesion was quantified by counting, 
for each vessel, the number of adherent leukocytes in a 100 µm length. 
 
A4.8.1 Leukocyte rolling reduced in double knockout mice 
 
Leukocyte rolling and adhesion on the vascular endothelium was shown to be reduced 
by approximately 50% in double knockout mice compared to MMP8 wild type controls, 
as measured by intravital microscopy (p=0.049 and p=0.009 respectively; Figure A11). 
 
 
 
 
 
 
 
 
Figure A11. Reduced leukocyte recruitment in MMP8-/-apoE-/- mice. A, Intravital microscopic images 
showing leukocyte rolling (arrow point 1) and adhesion (arrow point 2) on mesenteric postcapillary 
venules in vivo. B and C, Diagrams showing that leukocyte rolling and adhesion is reduced in MMP8-
/-apoE-/- mice compared with MMP8+/+apoE-/-mice. Data are presented as the means and standard 
error of mean. 
